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 vii 
Summary 
The results obtained from the experiments presented in this study aimed to further explore 
the  role  of  cyclin  dependent  k inases  and  cyclins  in  the  protozoan  parasite Leishmania 
major. Cdks in kinetoplastids, CRKs, are the key regulators that allow cells to progress 
through different cell cycle phases and promote parasite proliferation during infection.  
In chapter 3 of this study, the results presented showed that L. major CYCA is capable of 
activating  CRK3  in  an in  vitro  kinase  assay  using  histone  H1   as  substrate.  The 
CRK3/CYCA active complex was then used to analyse the effect of the phosphorylation at 
the  CRK3  activation  threonine using  a  kinase  activating  kinase  (yeast  CAK  or  Civ-1). 
Phosphorylated  CRK3  activity  was  compared  to  non-phosphorylated  CRK3  and  it  was 
found  that  the  phosphorylation  promotes  a  5-fold  increase  in  kinase  activi ty  of  the 
complex. The accessory protein Cks1 was assayed in vitro with the active CRK3/CYCA 
complex  and  it  was  shown  that Cks1  might  have  an  inhibitory  effect  when  histone  H1 
substrate is used. The IC50 for two different kinase inhibitors (Flavopiridol and Indirubin) 
was  determined  for  the in  vitro  CRK3/CYCA  complex  and  compared  with  the  values 
found for the in vivo purified CRK3. Similar values were obtained suggesting that the in 
vivo complex is indeed represented by the recombinant complex.  
In  the  following  chapter  4,  ye ast  Civ-1  purified  from  E.  coli,  was  used  to  try  to 
phosphorylate, in a similar manner, the activation of threonine/serine residues from other 
L. major CRKs. The kinases assessed were CRK1, CRK2, CRK4, CRK6 and CRK7. None 
of these were phosphorylated by Civ-1 suggesting that the only CRK under this type of 
regulation is CRK3. L. major CRK1-4 and CRK6-8 were tested in kinase assays by mixing 
under  described  conditions  with  L.  major  CYC9  and  kinase  activities  tow ards  three 
different  substrates  were  assessed.  L.  major  CYC9  was  not  able  to  activate   the  above 
kinases and the kinase subunit that interacts with this cyclin could not be identified. viii 
 In chapter 5, the L. major CYCA was used to elucidate the characteristics of this cyclin in 
vivo. A gene disruption strategy aimed to replace the two genomic alleles of this protein 
gene by homologous recombination. Plasmids were developed with flanking regions of this 
gene placed in association with two different drug resistance genes, one for each of the 
allele’s  disruption.  These  constructs  were  not  able  to  produce the  first  allele  knock  out 
suggesting that not only this gene might be essential but the levels of expression may also 
be  important. Tagging L.  major  CYCA  was  also attempted in  vivo  using  two  different 
strategies  (i.e.  two  different tagging  systems).  The  first  tag  employed  was  the  TAP  tag 
syste. Although drug resistant transfected cell lines were obtained, no tag detection could 
be  observed  by  western  blot  using  different tag-specific  antibodies  (α-protein-A  and  α-
calmodulin antibodies).  The second tag employed was HA, the 9-amino acid  sequence 
YPYDVPDYA, derived from the human influenza hemagglutinin (HA) protein. Plasmids 
that contained C and N-terminal HA tagged L. major CYCA were used to transfect WT 
cells  and  cells  extracts  of  resistant  cell  lines  analysed  by  western  blot.  Both  C  and  N -
terminal  HA  tagged  CYCA  were  d etected  by  the  α-HA  antibody.  Following  the 
confirmation  of  the  presence  o f  the  tagged  CYCA  in  the  cell extracts  an  affinity 
purification using an HA affinity  matrix was attempted and the  matrix  binding  material 
was used  in in vitro kinase assays. The presence of kinase activity towards Histone H1 
confirmed that CYCA was being succesfully immunoprecipitated in complex with a kinase 
partner.  The  identity  of  the  co-eluted  CRK  could  be  confirmed using  specific  α-CRK3 
antibody that detected CRK3 in the eluted material.  
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Chapter 1 
General Introduction 
 
 
 
 
 
 
 
 
       2 
1.1 General introduction 
Kinetoplastids are a remarkable group of protists and sophisticated eukaryotic parasites. 
They  contain  a  range  of  ubiqui tous  free-living  species,  as  well  as  pat hogens  of 
invertebrates, vertebrates and plants. They  are unicellular organisms that have  mastered 
unique  solutions  to  the  problems  of  being  a  eukaryotic  cell.  Kinetoplastid  peculiarities 
include:  complex  and  energy -consuming  mitochondrial  RNA  ed iting;  a  unique 
mitochondrial DNA; the arrangement of genes into polycistronic units; trans-splicing of all 
mRNA transcripts; modifications of nucleotides; glycolysis in a separated organelle; use of 
diverse mechanisms to evade host immune response (Simpson et al., 2006). Kinetoplastids 
have  a  unique  mitochondrial  st ructure  called  the  kinetoplast ,  hence  the  name 
Kinetoplastids (El Sayed et al., 2005).  
Many important aspects of the biology of kinetoplastids are currently being addressed in 
many  laboratories.  These  aspects,  like  flagellum  biology,  chromosome  segregation,  cell 
cycle and differentiation to list some, represents areas that are informed by similar studies 
in many other cell systems (Gull, 2001). Cell cycle and differentiation are among other 
aspects relatively unexplored. Little is known about the molecular mechanisms governing 
the  cell  cycle  stages,  its  che ck  points  and  its  association with  differentiation.  Since 
parasitism  with  vicious  conseq uences  to  the  host  will  always   depend  upon  cell 
proliferation, survival and differentiation the understanding of the cell cycle machinery can 
provide interesting new drug targets fighting diseases caused by kinetoplastid parasites.  
At the present time, no entirely satisfactory treatment exists to intervene in almost all of the 
human and animal parasitic protozoan derived diseases. Prevention is also a problematic 
issue with vaccine development, which has proven inefficient. Current biomedical research 
has its focus on the search for newer intervention strategies, to control the public health 
impact of parasitic diseases. The dramatic advances of molecular and cellular biology in       3 
recent times have provided opportunities for discovering and evaluating molecular targets 
for drug design, which now form a rational basis for the development of improved anti-
parasitic  therapy.  Many  cell  p rocesses  including  cell  cycle,  differentiation  and  hence 
proliferation  depends  on  prote in  kinases.  The  importance  of protein  kinases  in  cell 
signaling  and  cell  cycle  control  has  led  to  detailed  structural  and  functional  studies  in 
various eukaryotes, and hence to the synthesis of specific chemical inhibitors for managing 
disease (Doerig et al., 2002;Scapin, 2006;Margutti and Laufer, 2007). 
Protein phosphorylation has been documented in protozoan parasites for a number of years 
(Hermoso et al., 1991;Doerig et al., 2005). An  increasing number of protein kinases of 
parasitic protozoa are being evaluated as drug targets, just as they had been in trials to treat 
a wide range of other diseases and syndromes, such as cancer, cardiovascular disease and 
Alzheimer’s  disease  (Johnson,  2007).  In  recent  years,  pharmaceuti cal  companies  have 
invested heavily in the development of new compounds directed against specific protein 
kinase targets, and there are a wide range of protein kinase  inhibitors that have entered 
clinical trials (Naula et al., 2005;Johnson, 2007). 
In  eukaryotic  organisms,  the  c ell  cycle  is  regulated  in  part   by  the  produc tion  and 
destruction  of  cyclins.  When  expressed,  cyclins  associate  with  specific  kinases  (cyclin 
dependent  kinases) (Cdk)  making  an  active  pair  that  dri ves  the  cell  cycle  through  its  
distinct phases. The Cdk family was found to be relatively large in trypanosomatids with 
11 members in Trypanosoma brucei (T. brucei) and Leishmania major (L. major) and 10 
in Trypanosoma cruzi (T. cruzi) (Naula et al., 2005;Parsons et al., 2005). This is similar to 
what  is observed  in  mammalians cells,  where a  large  number of CDKs and cyclins are 
present,  and  different  to  unicellular  yeast,  which  has  only  one  CDK.  Th e  complexity 
observed in kinetoplastids may reflect the problem of dividing a highly polarized cell with 
an elaborate cytoskeleton and a single mitochondrion, along with an integral link between 
cell cycle control and life cycle differentiation. Despite the existence of a large number       4 
cyclins and of CDK family members (named CRK for cdc2-related kinase), their role in 
the biology of these parasites is poorly understood.  
T. brucei CRK3 was shown to form a complex with CYC6 mitotic cyclin and CYC2 (van 
Hellemond et al., 2000;Hammarton et al., 2003a). While CYC2 (named also cyclin E1) is 
essential for G1/S phase progression (Li and Wang, 2003b) CYC6 and CRK3 have been 
associated with the G2/M phase (Tu and Wang, 2004). A screen for possible interactions 
among the five CRKs (CRK1-CRK4, CRK6) and seven cyclins genes from T. brucei using 
yeast  two-hybrid  assays  showed  that  CYC2   also  interacts  with  CRK1  and  CRK2  
(Gourguechon et al., 2007). In Leishmania donovani (L. donovani), CRK3 was shown to 
interact with CYCA in the G1 phase (Banerjee et al., 2006). In Leishmania mexicana (L. 
mexicana) CRK3 was shown to be regulating G2/M phase transition (Hassan et al., 2001). 
More  detailed  and  precise  functional  studies,  as  well  as  information  about  the  CRKs, 
cyclins,  substrates  and  activators  is  urgently  needed  to  establish  if  there  are  significant 
differences in cell cycle regulation between these parasites and its mammalian hosts, and 
hopefully, some of these differences will be exploitable in the future in order to develop 
new anti-parasitic drugs. 
1.2 Epidemiology of kinetoplastid parasites 
Kinetoplastid  species  are  the aetiologic  agents  of  a  broad  s pectrum  of  tropical  and 
subtropical  diseases  including  the  leishmaniases  (Leishmania  spp.),  African  sleeping 
sickness (T. brucei) and Chagas’ disease (T.cruzi).  
Trypanosoma  brucei  and  its  relatives  are  responsible  for  diseases  in  humans  (“sleeping 
sickness”)  and  livestock  cattl e  in  equatorial  Africa  (“nagan a”).  T.  brucei  undergoes 
complex cycles of differentiation and multiplication in two very different hosts, the tsetse 
vector and the vertebrate host. Two forms of human sleeping sickness are recognised, a       5 
chronic form found in West and Central Africa, caused by Trypanosoma gambiense, and a 
more acute disease found in East Africa caused by Trypanosoma rhodesiense. Both these 
trypanosomes have similar morphology and are transmitted by tsetse flies, characteristics 
shared with T. brucei (Gibson, 2001). 
T. cruzi is responsible for Chagas’ disease. It primarily affects rural South America but 
also  constitutes  a  potential  hazard  in  Mexico and  the  United  States,  primarily  through 
blood and organ donations. Chagas disease is the clinical condition triggered by infection
 
with the protozoan T.cruzi. The infection is transmitted
 by triatomine insects while blood 
feeding  on  a  human  host   (Teixeira  et  al.,  2006).  The  disease  was  described  in   the 
pioneering work of Dr Carlos Chagas,
 a Brazilian physician who worked at the Oswaldo 
Cruz Institute,
 Rio de Janeiro, in 1909 (Chagas, 1909). 
Leishmania parasites are named after W.B. Leishman, a Scot, who developed one of the 
earliest stains for Leishmania in 1901. Today, 30 species are known and approximately 20 
are pathogenic for humans (Murray et al., 2005a). Widespread in 22 countries in the New 
World and in 66 nations in the Old World and occurring in several forms, the disease is 
generally  recognized  for  its  cutaneous  form  which  causes  non-fatal,  disfiguring  lesions, 
although epidemics of the potentially fatal visceral form cause thousands of deaths. The 
species that infect  humans  cause  a  different  spectrum  of  symptoms.  These  range  from 
simple,  self-healing  skin  ulcers  (e.g.  due to  infection  with L.  major),  to  severe,  life-
threatening  disease  (e.g.  visceral  leishmaniasis  caused  by L.  donovani).  In  between, 
mucocutaneous  leishmaniasis,  due  to Leishmania  braziliensis  (L.  braziliensis) infection, 
begins  with  skin  ulcers  which spread,  causing  dreadful  and  massive  tissue  destruction, 
especially of the nose and mouth. Post-kala-azar dermal leishmaniasis is a complication of 
visceral leishmaniasis observed mainly in Sudan and India where it follows treated visceral 
leishmaniasis  in  sometimes  50%.  Diffuse  cutaneous  leishmaniasis,  although  rare,  is       6 
associated  with  the  absence  of   specific  cell-mediated  immunity  to  Leishmania.  This 
disease shares features with visceral leishmaniasis (WHO, http://www.who.int).  
1.2.1 General biology of the genus Leishmania 
Leishmania is transmitted by the bite of certain species of sand fly, including flies in the 
genus Lutzomyia in the New World and Phlebotomus in the Old World. Human infection is 
caused  by  about  20 of  30 species  that  infect  mammals.  These  include  the L.  donovani 
complex with three species, which are L. donovani, Leishmania infantum (L. infantum), 
and Leishmania chagasi (L. chagasi); the L. mexicana complex with 3 main species, which 
are L. mexicana, Leishmania amazonensis (L. amazonensis) and Leishmania venezuelensis 
(L. venezuelensis); L. tropica; L. major; Leishmania aethiopica (L. aethiopica); and the 
subgenus  Viannia    with  four  main  species,  which   are  L.  (V.)  braziliensis,  L.  (V.) 
guyanensis,  L.  (V.)  panamensis ,  and  L.  (V.)  peruviana).  The  different  species  are 
morphologically indistinguishable, and can only be differentiated by isoenzyme analysis, 
DNA  sequence  analysis  and  monoclonal  ant ibodies.  The  pathogenic  profil es  of  the 
diseases provoked by the species inside these groups are more distinguishable. L. major 
and the L. mexicana complex include subspecies that cause cutaneous leishmaniasis and 
diffuse  cutaneous  leishmaniasis. L.  donovani,  L.  infantum,  and L.  chagasi  from  the L. 
donovani complex cause visceral leishmaniasis. Mucocutaneous leishmaniasis is caused by 
L. (V) braziliensis. 
Leishmaniases are globally widespread diseases. The life-cycle starts when a parasitized 
female sandfly takes a blood meal from a human host (Figure 1.1). As the sandfly feeds, 
promastigote  forms  of  the  leishmanial  parasite  enter  the  human  host  via  the  proboscis. 
Within the human host, the promastigote forms of the parasite are ingested by macrophage 
where they  metamorphose  into amastigote forms and reproduce by binary  fission. After 
amastigote  multiplication  and  rupture  of  the  macrophage,  the   amastigotes  invade       7 
neighbouring  macrophages.  The life  cycle  is  complete  when  a phlebotomine  female  is 
infected while feeding on the blood of an infected host. The amastigotes released in the 
sand  fly's  intestine  change  in to  procyclic  promastigotes  before  migrating  towards  the 
pharynx and the proboscis (Banuls et al., 2007).  
Within  the  intermediate  host, Leishmania  develops  as  promastigote  form s,  elongated 
motile extracellular stages possessing a prominent free  flagellum.  A  variety of different 
promastigote  forms  have  been  distinguished  on  morphological grounds  (Banuls  et  al., 
2007).  At  least  five  distinct Leishmania  developmental in  vivo  forms  can  be  detected: 
procyclic  promastigotes,  necto monad  promastigotes,  haptomona d  promastigotes, 
paramastigotes and metacyclic promastigotes (Bates, 1994). The first developmental event 
after the blood meal is the passage from amastigote to procyclic promastigote. Proliferation 
of procyclic promastigotes occurs in the peritrophic  membrane of the  insect tract. After 
three days in the insect, differentiated nectomonad promastigotes make their move to the 
posterior midgut spreading the infection to the anterior midgut. Haptomonad promastigotes 
are found attached in the stomodeal valve. Five days after infection, highly motile, human 
infective  metacyclic  promastigotes  are  observed  in  the  lumen  of   midgut  and  foregut 
(Kamhawi,  2006).  Human  infective  insect  forms  invest  c onsiderable  resources  in  the 
biosynthesis  of  promastigote  secretory  gel  (PSG),  which  is  a   key  factor  in  promoting 
transmission (Bates, 2006). Also, just before infection, and still inside the insect, occurs the 
metacyclogenesis: the differentiation of non-dividing metacyclic promastigotes, the actual 
human infective form. As different kinds of promastigote occur in the sand fly phase of the 
life cycle, it is important to note that synthesis of PSG only occurs at stages that are human 
infective. Metacyclic promastigotes are pre-adapted for survival in the mammalian host, 
they  are  complement  resistant,  express  stage-specific  genes  and  are  biochemically  part-
way to becoming amastigotes. 
       8 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The Leishmania life cycle. As Leishmania parasites cycle through the mammalian 
host and the sand fly they encounter a variety of different environments to which they have 
to  adapt  and  survive.  They  alternate  between  dividing-non-dividing  forms,  intracellular-
extracellular forms, and nonflagellated-flagellated forms.         9 
1.2.1.1 Mechanisms of escape 
Leishmania are extremely  successful parasites and natural  infections are  found  in  many 
different  mammals,  including  dogs,  rodents,  marsupials,  humans  and  other  primates  
(Murray et al., 2005a). All these vertebrates are considered as potential reservoirs of the 
disease.  Inside  the  vertebrate   host,  the  parasite  evolves  in to  an  amastigote  form. 
Amastigotes are ovoid (2.5–5 µm diameter), nonmotile intracellular stages that are formed 
by  differentiation  after  being  internalized  by  macrophages. They  do  not  have  a  free 
flagellum  and  are  located  in  t he  parasitophorous  vacuoles  of  the  host's  macrophages. 
Leishmania is capable of successfully parasitize the macrophages that are the mammalian 
cells responsible for their killing.  
Leishmania developed a range of sophisticated mechanisms to subvert normal macrophage 
function. These include preventing the activation of deadly antimicrobial agents such as 
nitric  oxide  (NO)  and  also  inh ibition  of  many  of  the  cytokin e-inducible  macrophage 
functions  necessary  for  the  de velopment  of  an  effective  immu ne  response.  Contact 
between  the  parasite
 and  the  macrophage  prevents  the  macrophage  from  responding  to
 
subsequent  exposure  to  interferon  gamma  (IFN-γ),  interleukin-1  (IL-1)  and  tumour
 
necrosis factor alpha (TNF-α). These factors are also directly inhibited by the parasite. This 
enables  the  parasite  to  evade the  innate  immune  response  and   to  divide  within  the 
phagolysosome of the infected macrophage, from where it can spread and propagate the 
disease within the host (Olivier et al., 2005).  
One important surface molecule is the glycoprotein gp63 (promastigote surface protease). 
This is a zinc-dependent metalloprotease with a wide range of substrates, including casein, 
gelatin, albumin, hemoglobin, and fibrinogen (McMaster et al., 1994). While around 10-
fold  less  abundant  than  lipoph osphoglycan  (LPG),  gp63  is  sti ll  found  throughout  the 
promastigote surface (Pimenta et al., 1991;McConville et al., 1995). However, its shorter       10 
length means that it is essentially buried under LPG. Like LPG, gp63 is down-regulated in 
the amastigote form (Schneider et al., 1992). This reduced expression may be counteracted 
by the absence of LPG on the amastigote surface, meaning that gp63 is no longer masked 
and may therefore play an important role in amastigote survival and modulation of the host 
response (Yao et al., 2003). In L. major and L. amazonensis the gp63 membrane protease 
converts complement protein C3b into C3bi promoting opsonisation and internalization by 
macrophages. L. major  metacyclic promastigotes LPG are  longer that LPG  in procyclic 
metacyclic and shown to prevent complement system cellular lysis by avoiding the binding 
of C5b-C9. LPG can also interact with C-reactive protein (CRP), an early inflammatory 
product, and thus triggers phagocytosis via the CRP receptor. The gp63 surface molecule 
has optimal activity at the acidic pH found in phagolysosomes, supporting the suggestion 
that  it  targets  lysosomal  enzymes.  However,  i ts  role  is  questionable,  as  pa rasites  with 
mutations in the six gp63 genes are still capable of survival, differentiation, and replication 
within macrophages. One study of 245 macrophage genes showed that 37% were repressed 
at least twofold following in vitro infection with amastigotes (Buates and Matlashewski, 
2001) which could explain how parasites can survive without gp63 inside the macrophage. 
1.2.1.2 Immune response 
Since  many  individuals  remain asymptomatic,  it  is  obvious  th at  the  natural  immune 
response  of  humans  can  eliminate  or  control  the  parasites  to   a  certain  extent.  While 
neutrophils are the first cells to arrive at the site of infection macrophages are the cells to 
be parasitized by Leishmania. Neutrophils interact with macrophages and regulate L. major 
infection  by  activation  leshmanicidal  activity  in  macrophages  (Ribeiro-Gomes  et  al., 
2004). Macrophages are key cells in the host immune defense (Basu and Ray, 2005), as 
well as dendritic cells, that present the parasite antigens to T cell receptors, via the major 
histocompatibility complex (MHC)  molecules. Antibody production or cellular cytolytic 
immune response will be unleashed depending on the cytokine context, on the Leishmania       11 
peptides presented and which MHC class is being used (Banuls et al., 2007). However, 
Leishmania  parasites  have  evolved  mechan isms  to  evade  or  interfere  wit h  antigen 
presentation processes, making it possible to partially resist the T cell-mediated immune 
responses  (Antoine  et  al.,  2004).  These  escape  strategies  appear  complex  and  various 
since, in humans, different patterns of immunological response are observed according to 
the clinical manifestation and exposure to different Leishmania species. Different T cell 
responses are observed among the different cutaneous forms of leishmaniasis: an absence 
of  a  T-helper-1  (Th1)  response  (rather  than  presenc e  of  Th2)  in  diffuse  cuta neous 
leishmaniasis; a Th1 response with self-healing lesions (Kemp et al., 1994;Ajdary et al., 
2000);  and  a  mixed  Th1/Th2  response   with  high  IFN-γ  levels  with  mucocutaneous 
leishmaniasis (Melby et  al.,  1994;Louzir et  al.,  1998;Bacellar et  al.,  2002).  In  visceral 
leishmaniasis, a mixed Th1/Th2 response is observed with production of IFN-γ along with 
IL-10 (Ghalib et al., 1993;Kenney et al., 1998). However, individuals with asymptomatic 
or  subclinical  infections  of  visceralizing  species  of Leishmania  show  peripheral  blood 
mononuclear cell proliferation and production of IL-2, IFN-γ and IL-12; in cured patients, 
both  Th1  and  Th2  clones  producing  IFN-γ  and  IL-4  have  been  isolated (Kemp et  al., 
1993).  
1.2.1.3 Membrane 
Leishmania  parasites  can  be  distinguishe d  by  their  surface  molecule  co mposition. 
Procyclic  promastigotes  are  covered  by  a  7-nm-thick  glycocalyx.  The  glycocalyx  of 
metacyclic  promastigotes  is  17  nm.  It  is  almost  completely  a bsent  from  amastigotes 
(Pimenta  et  al.,  1991).  This  surface  comprises  glyco proteins  and  other  glycosylated 
groups,  which  are  anchored  to the  surface  membrane  by  a  dist inctive 
glycosylphosphatidylinositol  (GPI)  linkage  (Ferguson,  1997).  The  dominant  surface 
molecule  of  promastigotes  is  L PG.  The  structure  of  LPG  varie s  between Leishmania 
species, but it is composed principally of repetitive units consisting of a disaccharide and a       12 
phosphate, linked to the membrane by a GPI anchor. Leishmania species differ markedly 
by the presence of glycan side chains, as well as by their composition and positioning on 
the LPG core structure. LPG of L. major, for example, is highly branched, whereas that of 
L. donovani is  not (McConville et al., 1995). Furthermore, the structure of LPG differs 
between procyclic and metacyclic promastigotes, being significantly longer in the latter, 
and is almost completely absent from amastigotes (Naderer et al., 2004). 
The most abundant promastigote surface molecule is glycosylinositol phospholipid (GIPL), 
a class of GPI-linked glycolipids. These molecules are 10 times more abundant than LPG, 
but their small size keeps them close to the parasite membrane, so it is unclear what role 
they play in interaction with the host. Unlike LPG, which is continually shed, GIPL has a 
long  half-life  and  so  is  believed  to  pla y  a  protective  role  at  the  pro mastigote  surface 
(Proudfoot et al., 1995). 
1.2.1.4 Disease diagnostic 
Since  morphologic  differentiation  of  Leishmania  species  is  not  possible,  a  va riety  of 
diagnostic tests using biochemical, immunologic, or molecular tools were developed. Most 
diagnostic tests for Leishmania are genus specific but not species specific (Schwartz et al., 
2006a). Systemic treatment is recommended for L. viannia species but is not required for 
most cases of other cutaneous leishmaniasis. Necessary or unnecessary systemic therapy 
may  be  harmful,  since  it  can  b e  associated  with  toxic  adverse  effects (Schwartz  et  al., 
2006b). For that reason, it is important to have diagnostic tests that can distinguish between 
L.  viannia  and  other  leishmanias.  Several  PCR-based  assays  for  species  differentiation 
were  developed.  A  simple  metho d  was  described  using multiplex  PCR  that  al lows 
simultaneous detection of the Leishmania genus  and  identification of the L. braziliensis 
complex  (Belli  et  al.,  1998).  This  was  achieved  using kinetoplast  DNA  (kDNA) 
minicircles but a number of other methods using as the rRNA gene (van Eys et al., 1992),       13 
repetitive  sequences (Piarroux et  al.,  1995), the  gp63  gene  locus (Victoir et  al.,  1998), 
microsatellite DNA (Russell et al., 1999), internal transcribed spacer regions (Cupolillo et 
al., 1995;Eisenberger and Jaffe, 1999) and the tubulin gene (Luis et al., 1998) have also 
been described. 
1.2.1.5 Disease treatment 
At  the  present  moment,  treatment  of  cutaneous  leishmaniasis  aims  to  accelerate  cure, 
reduce scarring, and to attempt to prevent dissemination like mucosal disease or relapse. 
Resilient  and  older  than  6  mon ths  lesions  are  generally  treated.  Pentavalent  antimony, 
paromomycin,  miltefosine, pentamidine  are  some  drugs  used  against  the  parasites.  The 
other strategies are immunotherapeutic interventions.  
Immunotherapeutic interventions have been used as a form of treatment since endogenous 
host mechanisms can lead to tissue damage of the host itself. Prevention against these host 
mechanisms  is  called  immunointervention.  Healing  of  diffuse cutaneous  and  mucosal 
leishmaniasis  was  achieved  using  injections  of  attenuated  promastigotes (Convit  et  al., 
2004). Other approaches have also included use of activating cytokines, inhibition of TNF-
induced inflammation and  and topical immunomodulators (Murray et al., 2005c). In one 
study drug-refractory patients were successfully treated with a combination of Leishmania 
recombinant antigens (Badaro et al., 2001) 
Pentavalent  antimony  is  available  in  branded  (sodium  stibogluco nate  [Pentostam], 
meglumine  antimoniate  [Glucantime],  and  generic  form .  For  cutaneous  leishmaniasis 
antimony is administrated parenteral and intralesional. However, up to 20 daily injections 
of a moderately toxic drug causes as much morbity to patients as the disease itself (Murray 
et al., 2005a). Carefully tested, well tolerated, inexpensive oral agents are urgently needed. 
Furthermore, there is no consensus on optimum  treatment in cutaneous  leishmaniasis  in 
general, alternatives to systemic antimony are under active  investigation (Murray  et al.,       14 
2005b). The first oral anti-leishmanial drug, Miltefosine (hexadecylphosphocholine), was 
an oral anticancer agent that has shown to be effective against Leishmania (Croft et al., 
1987;Kuhlencord et al., 1992). Although it is an effective oral drug its teratogenicity makes 
Miltefosine still a drug of limited (Olliaro et al., 2005). 
1.2.2 General biology of the genus Trypanosoma 
Two more important species that causes disease in human and animals inside the genus 
Trypanosoma  are  the  American  trypanosome T.  cruzi  and  the  African  trypanosome  T. 
brucei. T. cruzi enters the human body though broken skin of the damage caused by the 
bite and bloodfeeding of bugs from the sub-family Triatominae. They emerge at night to 
bite and suck  blood. While  feeding these  bugs dispose their  faeces containing parasites 
which can enter the wound left after the bloodmeal, usually when it is scratched or rubbed 
(http://www.who.int/). T. brucei enters the bloodstream via the bite of bloodfeeding tsetse 
flies (Glossina spp).  Male and  female tsetse  flies transfer the parasites  from  human to 
human. Cattle and other wild mammals act as reservoir hosts of the parasites. Tsetse flies 
can  acquire  parasites  by  feeding  on  these  animals,  or on  an infected  person.  Inside  the 
human host, T. brucei multiply and invade most tissues. 
The natural immunity of humans to the cattle pathogen Trypanosoma brucei brucei, but 
not  to  the  human  pathogens T.  b.  gambiense  and T.  b.  rhodesiense,  is  a  result  of  the 
selective killing of T. b. brucei  by  normal  human  serum (Rickman and Robson, 1970). 
Normal  human  serum  contains  ap olipoprotein  L-I,  which  lyses  African  trypanosomes 
(Vanhamme  et  al.,  2003)  except  resistant  forms  such  as  T.  brucei  rhodesiense.  T.  b. 
rhodesiense  expresses  the  apoL -I-neutralizing  serum  resistance -associated  protein, 
endowing this parasite with the ability to infect humans and cause trypanosomiasis (Baral 
et al., 2006). African trypanosomes undergo a complex life cycle when they move from the 
bloodstream  of  their  mammalian  host  to  the  blood-feeding  insect  vector,  the  tsetse  fly       15 
(Glossina spp.). They encounter many different environments during their life cycle and 
respond to these by significant morphological and metabolic changes, including adaptation 
of  their  energy  metabolism  (van  Hellemond  et  al.,  2005) .  But  the  most  remarkable 
adaptation to survival developed by these parasites is the constant change in their surface 
proteins. Trypanosomes are coated with a variant surface glycoprotein (VSG) (McCulloch, 
2004)  that  is  so  densely  packed  tha t  it  physically  protects  under lying  proteins  from 
effectors of the host immune system (Marcello et al., 2007). When antibodies are produced 
to a specific VSG that is expressed by the population the parasite then switches to express 
a distinct VSG which, if antigenically novel, allows clonal proliferation of the switched 
cells,  generating  a  new  parasitaemia  peak.  Each  trypanosome  expresses  only  one  VSG 
gene but has the potential to switch to any of probably hundreds of others (Berriman et al., 
2005). 
1.3 Genomic organization of kinetoplastid parasites 
Trypanosomatids  have  a  unique  mitochondrion  containing  a  kinetoplast  (Lukes  et  al., 
2005). This organelle has a uniquely structured DNA content called kinetoplast DNA and, 
as  one  of  the  largest   existing  organellar  genomes, is  assembled  into  two  classes  of 
molecules: dozens of maxicircles and thousands of minicircles. Minicircles are circular but 
non-supercoiled molecules that are typically 1 Kb in size and linked together (catenated) 
into  a  network  that  resembles chain  mail  armour.  Maxicircles   encode  most  of  the 
mitochondrial  genetic  information  but  many  transcripts  are  extensively  e dited  by  the 
insertions  and/or  deletions  of   uridines:  a  process  controlle d  by  numerous  minicircle-
encoded guide RNAs (Simpson et al., 2003). 
Old World Leishmania (L. donovani and L. major groups) have
 36 chromosome pairs (0.28 
to  2.8  Mb),  whereas  New  Worl d
  species  have  34  or  35,  with  ch romosomes  8+29  and 
20+36 fused
 in the L. mexicana group and 20+34 in the L. braziliensis group (Ivens at al.,       16 
2005). Between L. major, T. brucei and T. cruzi a large-scale gene synteny over 200–500 
million  years  was  found (El  Sayed  et  al.,  2005).  However,  the  organization  of  t he 
chromosomes of Leishmania differ from those of the trypanosome species in not having 
extended subtelomeric regions containing species-specific genes (Peacock et al., 2007b) . 
The  genomes  of L.  infantum,  L.  brasiliensis  and L.  major  have  around  200  genes  or 
pseudogenes differences. There are also around 78 genes that are species specific (Peacock 
et al., 2007a) . The genomes of L. infantum and L. brasiliensis show significant differences 
to the genome of L. major. It was suggested that there are too few species specific genes. 
However,  these  genes  are  suggested  to  be  important  in  pathogenesis.  Furthermore,  the 
main source of variations may be gene copy number and the parasite genome plays only a 
small part in determining the clinical aspects of the disease (Peacock et al., 2007c).  
T.
  brucei  have  a  26-megabase  genome  contains  9068 predicted  genes,
  including  900 
pseudogenes  and  1700 T.  brucei–specific
 genes.  Large  subtelomeric  arrays  contain  an 
archive of 806 VSG genes used by the parasite to evade
 the mammalian immune system 
(Berriman et al., 2005;Barry et al., 2005). 
1.3.1 Regulation of gene expression 
It  is  generally  accepted  that the  genome  of  kinetoplastids  i s  organized  in  long, 
polycistronic  transcription  units,  with  batteries  of  genes oriented  in  the  same  direction 
(Gibson et al., 1988;Tschudi and Ullu, 1988;Myler et al., 1999). These genes are usually 
separated by only a few hundred base pairs and, with a few exceptions, they do not contain 
introns. The long polycistronic units seem to be permanently transcribed in proliferative 
stages of the parasite (Martinez-Calvillo et al., 2003). Cellular differentiation is controlled 
primarily at the level of individual mRNA maturation and stability (Clayton, 2002). The 
transcription units of the two major stage-specific antigens, surface glycoproteins like the       17 
VSG in T. brucei and procyclin of the procyclic form, are subject to an additional layer of 
control including RNA elongation and processing (Pays, 2005).  
1.3.1.1 Transcriptional 
In eukaryotic cells there are three distinct classes of nuclear RNA polymerase: RNAP I, II 
and III. Each class of polymerase  is responsible  for the synthesis of a different kind of 
RNA:  RNAP  I  is  involved  in  the   production  of  18S,  5.8S  and  2 8S  rRNAs;  RNAP  II 
participates  in  the  generation  of  mRNAs  and  most  of  the  smal l  nuclear  RNAs;  while 
RNAP III synthesizes small essential RNAs, such as tRNAs, 5S rRNA and some snRNAs 
(Martinez-Calvillo  et  al.,  2007) .  Transcription  in  the  kinetop lastid  protozoa  shows 
substantial  variation  from  other  eukaryotic  gene  expression  systems,  inclu ding 
polycistronic transcription, few RNA polymerase II promoters, no differential transcription 
initiation factors for most protein-coding genes, transcription of some protein-coding genes 
by  RNA  polymerase  I,  an  exclusive  su bnuclear  location  for  VSG  transcription,  the 
dependence of small nuclear RNA gene transcription on an upstream tRNA gene, and the 
synthesis of mitochondrial tRNAs in the nucleus (Campbell et al., 2003;Martinez-Calvillo 
et al., 2007). Promoters for RNA polymerase I (Pol I) have been extensively characterized 
in trypanosomatids (Rudenko et al., 1995;Yan et al., 1999), as have some Pol III promoters 
(Ben  Shlomo et  al.,  1997).    In  trypanosomatids,  the  lac k  of  transcriptional  regulation 
suggests  the  presence  of  distinct  posttranscriptional  mechanisms  to  control  differential 
gene expression. It was demonstrated that mRNA transcripts of four genes accumulate at 
the beginning of S-phase, and degrade rapidly after DNA replication is completed. All the 
genes showing this post-transcriptional cell cycle-dependent regulation encode for proteins 
that participate in DNA metabolism (Zick et al., 2005;Banerjee et al., 2006). In Leishmania 
the stability of S-phase specific mRNAs in these parasites is determined primarily by the 
presence of the octanucleotide sequence (C/A)AUAGAA(G/A) in the untranslated regions 
(UTRs) of the transcripts (Zick et al., 2005). The promoter for the spliced  leader RNA       18 
genes  recruits  RNA  polymerase II (Das  and  Bellofatto,  2003),  whereas  the  three  other 
known  promoters  recruit  RNA  polymerase  I,  including  the  protein  coding  genes  and 
promoters of the rDNA (Pays, 2005). Another evidence for RNA pol II transcription shows 
that this enzyme acts on the strand-switch region bidirectionally at a few sites along the 
chromosome and ends at the tRNA region (Martinez-Calvillo et al., 2004). 
1.3.1.2 Post-transcriptional 
The general organization of genes in polycistronic units means that all mRNAs must be 
trans-spliced to be capped and that post-transcriptional regulation of the mRNA level is 
important for changes of gene expression (Campbell et al., 2000). This regulation occurs 
through  sequence  elements  in  intergenic  UTRs  that  determine  stage -specific  mRNA 
abundance  (Drozdz  and  Clayton,  1999).  In  addition  to  that  the spliced  leader  RNA 
(SLRNA) that provides a 5' cap to the polycistronically transcribed mRNA and has been 
implicated in mRNA translation (Zeiner et al., 2003). Regulation of gene expression seems 
to happens mainly at the post-transcriptional level (Clayton and Shapira, 2007).  
Post-transcriptional regulation of gene expression in kinetoplastids may be explained when 
the  cell  experiences  a  major  s tress  that  probably  precludes the  activation  of  energy -
dependent  mechanisms.  Just  changing  the  choice  between  pre-existing  RNAs  would  be 
more  efficient  than  switching promoter  activity  through  the recruitment  of  specific 
silencers  and/or  activators  as  occurs  in  most  eukaryotes.  Ho wever,  this  requires  the 
permanent  degradation  of  an  important  fraction  of  the  transcriptome  and  costs  energy 
(Brems et al., 2005). The components of a RNA turnover machinery has being partially 
described as the T. brucei exosome (Estevez et al., 2001). Posttranscriptional processing 
and  degradation  of  RNAs  are  performed  by  enzymes  and  ribonucleoprotein  complexes 
regulated by trans-acting factors that bind the RNAs.       19 
Recently, strong influence of the pre-ATG triplet on the level of protein expression over a 
20-fold range was detected in L. tarentolae (Lukes et al., 2006). This study concluded that 
a  conserved  mechanism  of  translation  initiation  site  selection  exists  in  kinetoplastids, 
which is strongly influenced not only by the pre-ATG sequences but also by the coding 
region  of  the  gene (Lukes  et  al.,  2006).  Because  stable  and  structural  RNAs  must  be 
processed, modified, and assembled into ribonucleoprotein complexes posttranscriptional 
processing  and  degradation  of  RNAs  are   affected  by  enzymes  and  ribonuc leoprotein 
complexes and regulated by trans-acting factors that bind the RNAs. The mRNAs from 
Kinetoplastids  contain  AU-rich  elements  (AREs)  in  their 3′  UTRs  that  seems  to  be 
important for mRNA metabolism like in mammalian cells (De Gaudenzi et al., 2005). 
However, the most remarkable aspect of trypanosomatid RNA metabolism is the editing of 
kinetoplast  mRNA  transcripts  through  the  addition  and  deleti on  of  uridine  residues 
(Simpson et al., 2003). This trypanosome-specific processes and organization evolved by 
the  acquisition  of  a  large  num ber  of  foreign  genes,  which  en tered  a  trypanosomatid 
ancestor through lateral gene transfer. Many different organisms like viruses and bacteria, 
such as cyanobacterial endosymbionts and non-phototrophic bacteria were probable donors 
(Opperdoes and Michels, 2007). 
1.4 The eukaryotic cell cycle 
Many of the core components involved in the cell cycle are conserved across eukaryotes, 
both functionally and structurally (de Lichtenberg et al., 2007). The control is exerted at 
different  levels  like  transcriptional  regulation,  phosphorylation,  subcellular  translocation 
and  targeted  degradation (de  Lichtenberg et  al.,  2007). The  cell  cycle  and  progression 
through its phases (G1, S, G2 and M) is regulated by several means including microRNAs, 
which  target  transcripts  encoding  proteins  directly  or  indirectly  involved  in  cell  cycle 
progression and cellular proliferation (Carleton et al., 2007). Also by iron (Fe) that regulate       20 
and  control  molecules  like  p53 ,  p27  (Kip1),  cyclin  D 1  and  cdk2  (Yu  et  al.,  2007). 
However, genome-scale data showed poor conservation of both the transcriptional and the 
post-translational regulation of individual genes and proteins involved in the cell cycle (de 
Lichtenberg et al., 2007). 
The  cell  cycle  and  progression  through  its  phases  is  regulat ed  by  the  production  and 
destruction of cell cycle specific proteins called cyclins (Standart et al., 1987). Different 
classes of cyclins are synthesized in each cell cycle stage where they associate with CDKs 
activating the kinase (Pines and Hunter, 1991). The kinase activity is believed to be the 
driving force behind the cell cycle progression. CDKs are relatively small proteins (~34 
kDa) containing little more than a protein kinase catalytic domain (Pines, 1996). They are 
inactive as monomers, and activation requires not only association with positive regulatory 
cyclin  subunit  but  also  the  ph osphorylation  of  a  conserved  threonine  residue  (T161  in 
human CDK1 and T160 CDK2) by a separate protein kinase known as the CDK-activating 
kinase (Brown et al., 1999). In  mammalian cells the activating kinase  is  another cyclin 
dependent kinase, CDK7/CyclinH associated with a third protein called MAT-1 (“ménage 
à trois-1”). In yeast cells this activation is performed by a single protein kinase (CAK or 
Civ1) (Desai et al., 1995). CDK7 phosphorylates and regulates CRK1, CDK2, CRK4 and 
CDK6 (Lolli and Johnson, 2005).  
Cyclin  activated  kinases  drives  the  cell  to the  next  cell  cyc le  stage  where  the  cyclin  is 
targeted  to  destruction  in  the   cyclin  destruction  box  by  pro teasome  degradation  after 
ubiquitination. In human cells two CDKs are well understood, CDK1 is activated by cyclin 
B in the G2/M transition (Pines and Hunter, 1994) and is involved in induction of mitosis. 
CDK2, is activated late in G1 and remains active until the end of G2; its major partners are 
cyclin E and A (Koff et al., 1992;Dulic et al., 1992). CDK2-cyclin complexes appear to be 
involved in the control of G1 events and DNA replication (Cardoso et al., 1993;Pagano et 
al., 1993;van den and Harlow, 1993). Differently from mammalian cells, yeast cells have       21 
only one CDK (Schizosaccharomyces pombe cdc2 or Saccharomyces cerevisiae CDC28), 
which is responsible for transition through both G1/S and G2/M boundaries (Nurse and 
Bissett, 1981;Reed and Wittenberg, 1990). 
In summary, the eukaryotic cell cycle can described as follows. Progression through the 
G1, S, G2 and M phases of the cell division cycle are regulated by CDKs. In early–mid 
G1, extracellular signals modulate the activation of CDK4 and CDK6 associated with D-
type  cyclins.  These  complexes phosphorylates  and  inactivate the  retinoblastoma  protein 
(pRb), resulting in the release of the E2F and DP1 transcription factors, which control the 
expression  of  genes  required  for  G1/S  transition  and  S  phase  progression.  The  CDK2–
cyclin  E  complex  is  responsibl e  for  G1/S  transition  but  also   regulates  centrosome 
duplication. During S phase, CDK2–cyclin A phosphorylates various substrates allowing 
DNA  replication  and  the  inacti vation  of  G1  transcription  fac tors.  Around  the  S/G2 
transition, CDK1 associates with cyclin A. Later, CDK1–cyclin B appears and triggers the 
G2/M  transition  by  phosphorylating  a  large  set  of  substrates .  Phosphorylation  of  the 
‘anaphase promoting complex’  by CDK1–cyclin B results  in transition to anaphase  and 
completion of mitosis. These successive waves of CDK–cyclin assembly, activation and 
inactivation  are  regulated  tightly  by  post-translational  modifications  and  intracellular 
translocations,  and  are  coordinated  and  dependent  on  the  com pletion  of  previous  steps, 
through so-called ‘checkpoint’ controls (Knockaert et al., 2002). 
Certain CDKs, including CDK1 and CDK2, form tight complexes with a small (9-18kDa) 
protein known generically as the Cdc kinase subunit (Cks). These proteins are believed to 
be essential for CDK function and cell cycle but their precise function is poorly understood 
(Pines, 1996). Cks and cyclins physically interact simultaneously and independently with 
CDKs. Cks proteins do not act as inhibitors or activators in the classic sense, but seem to 
modulate substrate choice or the extent of phosphorylation (Harper, 2001). The association 
of a Cks protein, in its monomeric state, with the CDK1–Cyclin B complex permits the       22 
phosphorylation of the CDC25 phosphatase and the entry in mitosis (Patra et al., 1999). 
CDK1–Cyclin  B–CKS  complex  phosphorylates  the  sub-unit  CDC27  of  the  anaphase 
promoting  complex,  which  promotes  ubiquitination  of  cyclin  B  and  exit  from  mitosis 
(Patra  and  Dunphy,  1998) .  After  cyclin  B  is  ubiquitina te,  Cks1  interact  with  the 
proteasome to promote proteolysis of the cyclin (Kaiser et al., 1999). The human Cks1 
hCKS1 associates with SKP2, a subunit of the SCF-ubiquitin-ligase complex, and favours 
the ubiquitination of the CKI (cdk inhibitor) p27
Kip1 and thus the G1/S transition (Pines, 
1996;Nakayama et al., 2000). 
Previous  studies  have  suggested  that  the  affinity  of  the  interaction  between  CDKs  and 
cyclins  may  be  affected  by  pho sphorylation  at  the  activating  threonine.  According  to 
(Desai et al., 1995), certain CDK-cyclin complexes form readily in vitro in the absence of 
other  proteins  or  phosphorylation,  whereas  other  complexes  f orm  only  when  CDK 
phosphorylation is allowed to occur. It is also known that CDK2-cyclin A exhibits about 
0.2% of the activity of the fully activated phosphorylated binary complex (Brown et al., 
1999). The effect of the cyclin A bound to CDK2 is that this protein assumes a protein 
kinase fold with mostly -sheet structure on the N-terminal domain that contains one helix, 
the C-helix, and a predominantly - helical C terminal domain. The ATP binding site is 
situated at the domain-domain interface. There are no changes in cyclin A structure when 
bound  to  CDK2,  but  CDK2  changes  to  create  the  ATP  recognition  site (Brown et  al., 
1999;Lolli et  al.,  2005). Inactive  monomeric  CDK2  can  not  bind  ATP  but  because  the 
necessary  residues  are  not  pro perly  disposed  and  the  alignme nt  for  the  triphosphate 
catalysis is disabled. This inactive conformation is due to the C-helix, which contains the 
PSTAIRE motif and the activation segment (residues 145-147 and 170-172). Thr160 in the 
inactive  CDK2  is  not  correctly  located  (it  is  buried  in  the conserved  glycine-rich  loop) 
because of the loss of interaction between E51 (the E residue of the PSTAIRE sequence) 
and L33 (Desai et al., 1995;Russo et al., 1996).        23 
It is generally accepted that mammalian cells require Cdk1, Cdk2, Cdk3, Cdk4 and Cdk6, 
to  drive  cells  through  the  cell  cycle  (Figure  1.2).  However,  since  unicellular  organisms 
such  as  yeasts  require  a  singl e  cyclin-dependent  kinase,  experiments that  knocked  out 
several Cdks in mice embryonic cells, showed that mammalian cells require only Cdk1 to 
drive the cell cycle (Santamaria et al., 2007). Cdk4–CyclinD, Cdk6–CyclinD and Cdk3–
CyclinC complexes are believed to be involved in regulation of the G0–G1 transition and 
the early phases of G1 (in proliferating cells) by phosphorylating the pRb. Cdk2–CyclinE 
complexes have been also implicated in the G1–S transition. Cdk2 associates with Cyclin 
A  during  S  phase.  Cdk1  partici pates  in  the  S–G2  and  G2–M  transitions  by  sequential 
binding  to  Cyclin  A  and  Cyclin  B.  CA K,  as  already  mentioned,  phosphorylates,  and 
presumably activates, all cell-cycle Cdks. Cdk10 and Cdk11 may be involved in mitosis, 
but their roles is not known. Finally, Cyclin F is probably required for entry into G1 and 
Cyclin G is acts in the DNA damage response during the G2–M transition  (Figure 1.2) 
(Malumbres and Barbacid, 2005). 
Cdk7  to  Cdk11  are  related  to  the  cell-cycle  control through  activities  of  transcription. 
CAK, along with six additional subunits, forms the general transcription factor TFIIH that 
is  involved  in  promoter  clearance  and  progression  of  transcription.  Cdk8–CyclinC  and 
Cdk9–CyclinT  complexes  also  regulate  transcription  by  phosphorylating  the  C-terminal 
domain of the large subunit of RNA polymerase II. Cdk8–CyclinC complex is actually a 
component  of  the  RNA  polymerase  holoenzym e.  Cdk8–CyclinC  also  phosphorylates 
Cyclin H to inhibit CAK activity. Cdk9, by contrast, binds to Cyclin T and Cyclin K to 
form  the  P-TEFb  transcription  factor  implicated  in  transcript  elon gation  by  RNA 
polymerase II (Malumbres et al., 2005;Santamaria et al., 2007). 
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Figure 1.2 The role of CDKs in the cell cycle. Adapted from (Malumbres et al., 2005). From 
G0 to the restriction point R, where the cells commit to mitosis, 3 different kinases are 
involved,  Cdk3,  Cdk4  and  Cdk6  in  complex  with  Cyclin  C  (CycC)  and  CycD.  After  the 
restriction point R, G1 specific CycE and Cdk2 drive the cells to S-phase where they are still 
active together with Cdk2-CycA complex. In G2, mitotic Cdk1-CycA (possibly CycG as well) 
are active. At the end of G2 and in mitosis, Cdk1 forms a complex with CycB. Cdk11-CycL 
and Cdk11 have also a role in mitosis. Cak or Cdk7 complex phosphorylates most of the 
cyclin-kinase complexes through the cycle. 
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Cdk5  can  bind  to  two  different  activators,  p35  and  p39,  expressed  in  the  brain.  When 
complexed with Cyclin D or Cyclin E, Cdk5 does not appear to have known substrates. 
Cdk5–p35  and  Cdk5–p39  complexes  phosphorylate  numerous  substrates  involved  in 
several aspects of transcription and neuronal functions (Malumbres et al., 2005;Santamaria 
et al., 2007). 
Other protein kinases are involved in the cell cycle. Aurora kinases, like Aurora A, B and 
C, have their role as regulators of mammalian cell division. Aurora kinases are essential to 
ensure  error-free  cell  division  (Hassan  et  al.,  2001;Carmena  and  Earnshaw,  2 003). 
Mammalian Polo-like kinase family is also involved in the cell cycle. Plk1, the best studied 
polo, specifically localizes in the centrosomes, the spindle midzone and the post-mitotic 
bridge, and it acts in both mitotic entry and mitotic progression (Barr et al., 2004). Some 
family members of the NIMA family, such as Nek2, Nek6, Nek7 and Nek9, are involved 
in  mitotic  progression (Hayes  et  al.,  2006).  MOB  kinases,  a  small  family of  highly 
conserved, non-catalytic proteins that are found in all eukaryotes, play critical roles in cell-
cycle regulation and function chiefly by interacting with and activating the Dbf2-related 
protein kinases. The functional co-dependence of the Mob and Dbf2-like proteins is similar 
to that of how cyclins bind and regulate Cdks (Mrkobrada et al., 2006). 
1.5 Proteomics and the kinome of pathogenic trypanosomatids 
Six major groups of eukaryotic protein kinase have been defined on the basis of sequence 
similarity  of  the  catalytic  domains:  AGC,  CAMK,  CMGC,  TK,  TKL,  STE (Hanks  and 
Hunter, 1995). Approximately 2% of the L. major, T.  brucei and T. cruzi genomes codes 
for protein kinases. The analysis of these genomes (Parsons et al., 2005) revealed a total of 
176 protein kinases in T. brucei, 190 in T. cruzi and 199 in L. major, most of which are 
orthologous  across  the  three  species.  This  is  approximately 30%  of  the  number  in  the 
human host and double that of the malaria parasite, Plasmodium falciparum. Among the       26 
various groups of eukaryotic protein kinases identified, the CMGC, STE and NEK groups 
showed  an  evolutionary  expansi on  and  are  overrepresented  in  comparison  to  other 
organisms (Parsons et al., 2005). 
Protein kinases are classified into two superfamilies: serine/threonine kinases and protein 
tyrosine kinases. In trypanosomatids CMGC kinases include MAP kinases (MAPKs), dual 
specificity CLK and DYRK kinases and CRKs. While unicellular yeast has a single cyclin 
dependent kinase essential for the cell cycle (CDC28), the CRK family is relatively large 
in trypanosomatids with 11 members in T. brucei and L. major and 10 in T. cruzi. This 
complexity may reflect the problem of dividing a highly polarized cell with an elaborate 
cytoskeleton and a single  mitochondrion, along  with an  integral  link  between cell cycle 
control and life cycle differentiation. 
It was proposed that phosphorylation on tyrosine in trypanosomatids is likely to be due to 
the action of atypical tyrosine kinases such as Wee1 and dual-specificity kinases that can 
phosphorylate serine, threonine, and tyrosine (Parsons et al., 2005). Multiple members of 
the  dual  specificity  kinase  fa milies  (DYRKs,  CLKs,  and  STE7)   are  present  in  the 
trypanosomatid  genomes.  In  y east  and  higher  eukaryotes  Wee 1  phosphorylates  a 
conserved tyrosine residue in the ATP binding pocket of CDK1 (cdc2), inactivating the 
protein  kinase.  This  mechanism  is  likely  to  be  conserved  in the  three  trypanosomatids, 
since there are two Wee1 family members in L. major and T. cruzi and one in T. brucei. In 
addition, CRK3, the putative functional CDK1 homologue in trypanosomatids, contains a 
conserved tyrosine residue in the same subdomain as the human CDK1 regulatory tyrosine 
(Naula et al., 2005). 
A large number of MAPK-related genes are also present in trypanosomatids. The parasites 
undergo  substantial  changes  of   temperature,  pH,  nutrients,  and  stress es  during  their 
developmental cycle.  A phosphorylation signaling system that responds to those sudden       27 
changes may be a key strategy for this group of organisms (Parsons at al., 2005). MAPKs 
are activated by phosphorylation within the activation loop, typically both on a tyrosine 
and a threonine. MAP kinase kinases, which are members of the STE7 family, perform this 
activation. STE7 is one of the three major families of STE group kinases that are generally 
described  as  upstream regulators  of  MAP  kinase  cascades.  Some  of  the  MAPKs,  like 
Leishmania mexicana LmxPK4 have being studied and  found to have a role  in parasite 
differentiation (Kuhn and Wiese, 2005). Another, LmxMKK has a role in flagellar length 
(Wiese et al., 2003).  
Trypanosomatids lack receptor-linked tyrosine and tyrosine kinase-like kinases, although 
they do possess dual-specificity kinases. It was also shown that these parasites possess a 
large  number  of  unique  eukaryotic  protein  kinases  that  show no  strong  affinity  to  any 
known group. Few protein kinases with predicted transmembrane domains were identified, 
suggesting that receptor eukaryotic protein kinases are absent (Parsons et al., 2005).  
1.6 The trypanosomatid cell cycle 
Trypanosomes are flagellated protists that contain a single Golgi complex (He et al., 2004) 
as well as a large mitochondrion that hosts a single kinetoplast formed by a network of 
minicircle and maxicircle DNA molecules. A single flagellum connected to the kinetoplast 
at its basal body emerges from a flagellar pocket, an invagination of the plasma membrane 
(Gull, 2003). In model organisms, like yeast, the mechanisms that ensure cell division have 
been  studied  with  respect  to  the  control  of  cell  growth,  DNA   replication,  and  mitosis, 
including  the  establishment of  networks  of  interacting  molecules  expressed  at  different 
times of the cell cycle. However, much less is known about the relationship between the 
duplication and segregation of organelles and cell cycle progression in Kinetoplastids.  
All trypanosomatids
 contain  single-copy organelles, such
 as the  nucleus,  mitochondrion, 
kinetoplast (containing the mitochondrial
 genome), basal body and flagellum. In T. brucei,       28 
the morphological events occurring during the cell cycle were described (Woodward and 
Gull, 1990). Morphological alterations that occur during the cell cycle of other species of 
trypanosomes  are  different  as they  have  distinct  cell  shapes,  kinetoplast  position,  and 
flagellum insertion (Elias et al., 2007). Crithidia and Leishmania species, for instance, do 
not replicate their nuclear and kinetoplast DNA in the same order as T. brucei (Elias et al., 
2007). There is no migration of the basal body and kinetoplast segregation occurs close to 
the nuclear mitosis. In addition, although no detailed description has been provided, the 
new flagellum does not attach to the old one (Briggs et al., 2004). 
The investigations of the molecules that regulate the cell cycle of Leishmania have initially 
identified  two  cdc-2  related  protein  kinases,  CRK 1  and  a  CRK3 (Mottram  et  al., 
1993;Mottram and Grant, 1996a). The L. mexicana CRK3 gene that encodes for a cdc2-
related protein kinase with activity towards histone H1 at G2:M (Grant et al., 1998), is 
encoded  by  an  essential  gene  a nd  is  post  translationally  regulated  in  a  stage-specific 
manner,  being  active  in  dividing  cells  (promastigotes  and  amastigotes)  but  not  in  non-
dividing cells (metacyclic promastigotes) (Grant et al., 2004). 
The  data  already  published  about Leishmania  CRK3 (Grant et  al.,  1998;Hassan et  al., 
2001)  shows  that  CRK3  encodes  a  35. 6kDa  cdc-2  related  kinase  with  activity  towards 
histone H1 that is essential for the progression of L. mexicana cell cycle. It also has 54% 
sequence  identity  with  human  cyclin  dependent  kinase  cdk1  and  78%  identity  with T. 
brucei  CRK3.  The  trypanosomatid  CRK3  have  an  unusual,  poorly  conserved  19-amino 
acid N-terminal extension not present in human cdc2. CRK3 is a single copy, and there is a 
5-fold higher mRNA presence in the replicative promastigote life cycle stage than in non-
dividing metacyclic form or mammalian amastigote form. 
Despite the existence of a large number of CDK family members (named CRK for cdc2-
related kinase), only 2 have been shown to be essential for cell cycle progression. CRK3 in       29 
complex with the CYC6 mitotic cyclin is essential for G2/M phase progression and is the 
functional homologue of CDK1 (Hassan et al., 2001;Hammarton et al., 2003a;Tu et al., 
2004;Tu and Wang, 2005). CRK3 in complex with CYC2 is essential for G1 progression 
(Li et al., 2003b;Hammarton et al., 2004;Gourguechon et al., 2007). A CYC2 cyclin and a 
CYC6 cyclin control the cell cycle of the procyclic form of T. brucei (Li et al., 2003a), 
while TbCRK1  is  also  an  essential  gene  required  for  G1  phase  progression (Tu et  al., 
2004;Tu et al., 2005). However, the roles of CRKs  in the cell cycle are complex, with 
functional differences between bloodstream and procyclic form T. brucei as revealed by 
RNAi knockdown studies. 
CRK7 has the highest level of sequence identity to CDK7 of mammals. CDK7, in complex 
with cyclin H and MAT1, is a CDK-activating kinase (CAK) that phosphorylates the T-
residue of CDKs (e.g., T160 of human CDK1). No cyclin H or MAT1 orthologues can be 
identified in trypanosomatids based on sequence, so it remains to be determined if CRK7 is 
a  functional  cyclin-dependent  kinase  or  indeed  if it  has  CAK  activity.  However, many 
CRKs,  including  CRK1,  2,  3,  6,   7,  8,  9  and  12,  have  a  conser ved  T-loop  residue, 
suggesting that the CRKs might be activated in vivo by a CAK activity (Naula et al., 2005) 
Other protein kinases like polo kinases have been studied in trypanosomes. T. brucei polo-
like-kinase  (TbPLK)  can  complement  the  temperature -sensitive  S. cerevisiae  cdc5-1 
mutant. RNAi of PLK in procyclic T. brucei inhibited growth, indicating a role for PLK in 
the initiation of cytokinesis in this life cycle stage (Kumar and Wang, 2006). In another 
study,  downregulation  of  PLK  results  in  an  earlier  ce ll  cycle  defect  in  basal  body 
duplication and delay in kDNA replication preventing thus cytokinesis (Hammarton et al., 
2007).        30 
1.7 Kinase inhibitors 
Cyclin-dependent protein kinases are attractive targets for drug discovery and efforts have 
led to the identification of novel Cdk selective inhibitors in the development of treatments 
for  cancers,  neurological  disorders,  and  infectious  diseases.  CDKs  from parasites  have 
been  identified  and  several  are  considered  potential  drug  targets.  A  series
  of  chemical 
inhibitors,  which  display  various  de grees  of  CDK
  selectivity,  have  been  identif ied, 
including olomoucine (Havlicek et al., 1997),
 roscovitine (Meijer et al., 1997), purvalanol 
(Gray et al., 1998), flavopiridol (Losiewicz et al., 1994), butyrolactone (Kitagawa et al., 
1993), indirubins (Hoessel et al., 1999), and paullones (Zaharevitz et al., 1999).  All these 
inhibitors
 act by competing with ATP for binding at the catalytic site. About 70 different 
kinases  have  had  their  structu res  determined  and  these  datab ases  are  being  used  for 
developing  more  specific  inhibitors  with  some  limitations (Thaimattam  et  al.,  2007). 
Kinase  inhibitors  such  as dasatinib  are  currently  used  for  the  tr eatment  of cancer  and 
several of these kinase inhibitors are specific for tyrosine kinase (Thaimattam et al., 2007).  
As  cytotoxic  drugs,  Cdk  inhibitors  have  more  effect  on  tumor  cells,  which
 are  rapidly 
dividing,  than  on  normal  quies cent  cells.  Considering  kinetoplastid  parasites  as    the 
undesired proliferating cell instead of a tumor, the same effect could be obtained against 
parasitic  diseases  using  Cdk  i nhibitors  (Grant  et  al.,  2004).  It  has  been  shown  to  be 
possible to obtain Cdk specific inhibitors. This has been achieved through the development 
of inhibitors that are capable of differentially inhibit Cdk families. More studies are needed 
to discover, design,
 or develop inhibitors that are selective for parasite protein
 kinases of 
the CDK family. The Leishmania kinase CRK3 was studied as a novel antileishmanial
 drug 
target (Grant et al., 2004). In a kinase inhibitor screening, only 3 compounds had similar 
IC50  to  control  human  Cdk1-Cyclin  B.  All  other  tested  com pounds  showed  a  range  of 
variation  suggesting  that  it  i s  possible  to  specific  inhibit  cell  proliferation  with  Cdk 
inhibitors.         31 
1.8 Aims of the project 
Based on the above the aim of this project was to study cell cycle related proteins, cyclins 
and kinases from trypanosomatid parasites Leishmania and T. brucei in vitro and in vivo. 
Specifically: 
To generate an active CRK3 kinase from T. brucei and Leishmania in vitro 
To characterize biochemically the CRK3:CYCA complex 
To define the role of the phosphorylation of the Thr178 on the kinase activity of CRK3 
To study the role of Cks1 protein in the activity of CRK3:CYCA complex 
Try to generate a system to identify cyclin:kinase complexes 
To try to identify other CRK/cyclin pairs in L. major  
To tag CYCA and study its function in vivo 
To tag CRK6 and study its function in vivo 
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Chapter 2 
General Methods 
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2.1 Genomic DNA preparation from Leishmania 
10  ml of  log phase Leishmania culture was pelletted for 10 min at 1000g. Pellets were 
resuspended in lysis buffer from a gDNA extraction kit (Qiagen) and extraction procedures 
were  performed  according  to  manufacture’s  instructions.  The  gDNA  extracted  from L. 
mexicana and L. major was used for amplifying the genes of the proteins of interest. The 
same extraction procedure was also used for obtaining T. brucei gDNA. 
2.2 Cloning 
For the cloning of the following proteins, the same general procedure was used, which is 
described below. PCR reactions were set up in a final volume of 50µl using 10mM oligos, 
0.5  Unit  Thermozyme  (Invitroge n),  1µl  genomic  DNA,  10X  PCR  m ix  and  water. 
Thermocycling conditions consisted of 1min at 94C followed by 25 cycles at 94C for 30 
sec, 65C for 1 min and 72C for 90 sec and was completed with 10 min at 72C. PCR 
products (1µl) were checked by electrophoresis on 1% agarose gel stained with ethidium 
bromide. PCR product purification was then carried out using the Qiaquick Gel Extraction 
kit (Qiagen). The purified PCR products were again visualized on 1% agarose gel stained 
with  ethidium  bromide  to  confi rm  the  purification  quality  an d  ligated  into  PGEM-T 
plasmid  (Novagen).  Ligation  into  pGEM-T  and  subsequent  vectors  was  p erformed  as 
follows:  plasmid  and  DNA  insert  were  mixed  in  a  ratio  of  3:1   respectively  in  a  10µl 
reaction containing 1X T4 ligase  buffer and 1Unit of T4  ligase (New England Biolabs) 
overnight at room temperature. Ligation reactions were then used to transform DH5α E. 
coli cells by heat shock (30 min on ice/ 30 sec at 42
oC). Transformation reaction was then 
plated on L. agar plates containing the appropriate antibiotic necessary for selection of the 
clones. Positive clones were selected and analysed by restriction enzyme digestions.  
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2.2.1 L. major CYC3 (LmCYC3his) 
PCR amplification of CYC3 (LmjF30.0080) was performed using genomic DNA (gDNA) 
from  L.  major,  oligos  OL1765  and  OL1762  (Ta ble  2.1)  and  Invitrogen  Thermozyme 
polymerase.  The  PCR  product  was  gel  pu rified  and  ligated  in  the  pGEM -T  vector 
generating  pGL1266.  The  sequence  of  the  insert  was  confirmed   by  alignment  with 
LmjF30.0080.  The  PCR  product  w as  excised  from  pGL1266  using BamHI  and  NdeI 
restriction sites generated by the PCR oligos and subcloned in the expression vector pET-
15b+, which was pre-digested with BamHI and NdeI generating pGL1350. This plasmid 
was  used  to  express  LmCYC3his and  an  affinity  purification  of  this  protein  was  also 
attempted.  
 2.2.2 L. major CYC7 (LmCYC7his) 
PCR amplification of LmjF30.3630 was performed using gDNA from L. major, oligos OL 
1767 and OL 1768 (Table 2.1) and Invitrogen Thermozyme polymerase. The PCR product 
was gel purified and ligated in the pGEM-T vector generating pGL1267. The sequence of 
the insert was confirmed by alignment with LmjF30.0080. The PCR product was excised 
from pGL1267 using BamHI and NdeI restriction sites generated by the PCR oligos and 
subcloned  in the expression  vector pET-15b+, which was pre-digested with BamHI and 
NdeI  generating  pGL1335.  This  pla smid  was  used  to  express  and  a ffinity  purify 
LmCYC7his.  
2.2.3 L. major CYC9 (LmCYC9his) 
PCR  amplification  of  LmjF32.0760  was  performed  using  gDNA  from L.  major,  oligos 
OL1770 and 1771 (Table 2.1) and Invitrogen Thermozyme polymerase. The PCR product 
was gel purified and ligated in the pGEM-T vector generating pGL1253. The sequence of 
the insert was confirmed by alignment with LmjF32.0760. The PCR product was excised       35 
from pGL1253 using BamHI and NdeI restriction sites generated by the PCR oligos and 
subcloned  in the expression  vector pET-15b+, which was pre-digested with BamHI and 
NdeI  generating  pGL1336.  This  pla smid  was  used  to  express  and  a ffinity  purify 
LmCYC9his.  
2.2.4 L. major CYC10 (LmCYC10his) 
PCR  amplification  of  LmjF24.1890  was  performed  using  gDNA  from L.  major,  oligos 
OL1772  and  OL1773  (Table  2.1) and  Invitrogen  Thermozyme  polymerase.  The  PCR 
product  was  gel  purified  and  ligated  in  the  pGEM-T  vector  generating  pGL1268.  The 
sequence of the insert was confirmed by alignment with LmjF24.1890. The PCR product 
was excised from pGL1268 using BamHI and NdeI restriction sites generated by the PCR 
oligos  and  subcloned  in  the  expression  vector  pET-15b+,  which  was  pre-digested  with 
BamHI  and NdeI  generating  pGL1337.  This  plasmid  was  used  to  express  and   affinity 
purify this protein LmCYC10his.  
2.2.5 L. major CRK1 (LmCRK1his) 
PCR  amplification  of  LmjF21.1080  was  performed  using  gDNA  from L.  major,  oligos 
OL1783  and  OL1784  (Table  2.1) and  Invitrogen  Thermozyme  polymerase.  The  PCR 
product  was  gel  purified  and  ligated  in  the  pGEM-T  vector  generating  pGL1254.  The 
sequence of the insert was confirmed by alignment with LmjF21.1080. The PCR product 
was excised from pGL1254 using BamHI and NdeI restriction sites generated by the PCR 
oligos  and  subcloned  in  the  expression  vector  pET-15b+,  which  was  pre-digested  with 
BamHI  and NdeI  generating  pGL1338.  This  plasmid  was  used  to  express  and  a ffinity 
purify LmCRK1his.        36 
2.2.6 L. major CRK2 (LmCRK2his) 
PCR  amplification  of  LmjF05.0550  was  performed  using  gDNA  from L.  major,  oligos 
OL1785  and  OL1786  (Table  2.1) and  Invitrogen  Thermozyme  polymerase.  The  PCR 
product  was  gel  purified  and  ligated  in  the  pGEM-T  vector  generating  pGL1269.  The 
sequence of the insert was confirmed by alignment with LmjF05.0550. The PCR product 
was excised from pGL1269 using BamHI and NdeI restriction sites generated by the PCR 
oligos  and  subcloned  in  the  expression  vector  pET-15b+,  which  was  pre-digested  with 
BamHI  and NdeI  generating  pGL1339.  This  plasmid  was  used  to  express  and  affinity 
purify LmCRK2his.  
2.2.7 L. major CRK3 (LmCRK3his) 
PCR  amplification  of  LmjF36.0550  was  performed  using  gDNA  from L.  major,  oligos 
OL1787  and  OL1789  (Table  2.1) and  Invitrogen  Thermozyme  polymerase.  The  PCR 
product  was  gel  purified  and ligated  in  the  pGEM-T  vector  generating  pGL1255.  The 
sequence of the insert was confirmed by alignment with LmjF36.0550. The PCR product 
was excised from pGL1255 using BamHI and NdeI restriction sites generated by the PCR 
oligos  and  subcloned  in  the  expression  vector  pET-15b+,  which  was  pre-digested  with 
BamHI  and NdeI  generating  pGL1340.  This  plasmid  was  used  to  express  and  a ffinity 
purify LmCRK3his.  
2.2.8 L. major CRK4 (LmCRK4his) 
PCR  amplification  of LmjF16.0990  was  performed  using  gDNA  from  L.  major,  oligos 
OL1789  and  OL1790  (Table  2.1) and  Invitrogen  Thermozyme  polymerase.  The  PCR 
product  was  gel  purified  and  ligated  in  the  pGEM-T  vector  generating  pGL1270.  The 
sequence of the insert was confirmed by alignment with LmjF16.0990. The PCR product 
was excised from pGL1270 using BamHI and NdeI restriction sites generated by the PCR       37 
oligos  and  subcloned  in  the  ex pression  vector  pET15b+,  which  was  pre-digested  with 
BamHI  and NdeI  generating  pGL1616.  This  plasmid  was  used  to  express  and  a ffinity 
purify LmCRK4his.  
2.2.9 L. major CRK6 (LmCRK6his) 
PCR  amplification  of LmjF27.0560  was  performed  using  gDNA  from  L.  major,  oligos 
OL1791  and  OL1792  (Table  2.1) and  Invitrogen  Thermozyme  polymerase.  The  PCR 
product  was  gel  purified  and  ligated  in  the  pGEM-T  vector  generating  pGL1271.  The 
sequence of the insert was confirmed by alignment with LmjF27.0560. The PCR product 
was excised from pGL1271 using BamHI and NdeI restriction sites generated by the PCR 
oligos  and  subcloned  in  the  expression  vector  pET-15b+,  which  was  pre-digested  with 
BamHI  and NdeI  generating  pGL1341.  This  plasmid  was  used  to  express  and  a ffinity 
purify LmCRK6his.  
2.2.10 L. major CRK7 (LmCRK7his) 
PCR  amplification  of  LmjF26.0040  was  performed  using  gDNA  from L.  major,  oligos 
OL1793  and  OL1794  (Table  2.1)  and  Invitrogen  Thermozyme  polymerase.  The  PCR 
product  was  gel  purified  and  ligated  in  the  pGEM-T  vector  generating  pGL1256.  The 
sequence of the insert was confirmed by alignment with LmjF26.0040. The PCR product 
was excised from pGL1256 using BamHI and NdeI restriction sites generated by the PCR 
oligos  and  subcloned  in  the  expression  vector  pET-15b+,  which  was  pre-digested  with 
BamHI  and NdeI  generating  pGL1349.  This  plasmid  was  used  to  express  and  a ffinity 
purify LmCRK7his.        38 
2.2.11 L. major CRK8 (LmCRK8his) 
PCR  amplification  of  LmjF11.0110  was  performed  using  gDNA  from L.  major,  oligos 
OL1795  and  OL1796  (Table  2.1) and  Invitrogen  Thermozyme  polymerase.  The  PCR 
product  was  gel  purified  and  ligated  in  the  pGEM-T  vector  generating  pGL1272.  The 
sequence of the insert was confirmed by alignment with LmjF11.0110. The PCR product 
was excised from pGL1272 using BamHI and NdeI restriction sites generated by the PCR 
oligos  and  subcloned  in  the  expression  vector  pET-15b+,  which  was  pre-digested  with 
BamHI  and NdeI  generating  pGL1342.  This  plasmid  was  used  to  express  and  affin ity 
purify LmCRK8his.  
2.2.12 Non-tagged L. mexicana CRK3 (LmCRK3)  
L. mexicana CRK3  from pGL751 was excised using NdeI/BamH1 restrictions  sites and 
cloned into NdeI/BamHI of pET21a+ generating pGL1072. This plasmid expresses a non-
his-tagged version of CRK3 to be used in binding assays. 
2.2.13 T. brucei CYC6 box (TbCYC6boxGST) 
PCR amplification was performed using T. brucei Eatro 795 gDNA, oligos OL1413 and 
OL1414 (Table 2.1) and Invitrogen Thermozyme polymerase. The PCR product was gel 
purified and cloned in the pGEM-T vector generating pGL979. The sequence of the insert 
was  confirmed  by  alignment  with  Tb11.01.8460.  The  PCR  product  was  excised  from 
pGL979 using BamHI and SalI restriction sites generated by the PCR oligos and subcloned 
in  the  expression  vector  pGEX5 X-1,  which  was  pre-digested  with  BamHI  and  SalI 
generating  pGL980.  This  plasmid  was  used  to  express  and  affi nity  purify  TbCYC6box 
protein.       39 
2.2.14 T. brucei CRK3 (TbCRK3his) 
PCR amplification was performed using T. brucei Eatro 795 gDNA, oligos OL1412 and 
OL427 (Table 2.1) and Invitrogen Thermozyme  polymerase. The PCR product was gel 
purified and ligated in the pGEM-T vector generating pGL977. The sequence of the insert 
was  confirmed  by  alignment  with  Tb10.70.2210.  The PCR  product  was  excised  from 
pGL977  using  BamHI  and  NdeI  restriction  sites  generated by  the  PCR  oligos  and 
subcloned  in the expression  vector pET-15b+, which was pre-digested with BamHI and 
NdeI  generating  pGL1036.  This  pla smid  was  used  to  express  and  affi nity  purify 
TbCRK3his.  
2.2.15 T. brucei CKS1 (Tbp12
CKS1his) 
The T. brucei CKS1 (Tb11.01.8085), an accessory protein involved in the cyclin:kinase 
complex, was cloned into the pET15b with an N-terminal histidine tag. PCR amplification 
was  carried  out  using T.  brucei  gDNA,  oligos  OL1260  and  OL861   (Table  2.1)  and 
Invitrogen Thermozyme. The PCR product was gel purified and cloned into the pGEM-T 
vector creating pGL975. The sequence for Tbp12
CKS1his was confirmed by alignment with 
Tb11.01.8085. The PCR product contained XhoI and NdeI restriction sites that were used 
to remove the fragment from pGL975 and subcloned in the expression vector pET15b to 
give pGL976. This plasmid was used to express and purify Tbp12
CKS1his. 
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Table 2.1 Primer sequences  
Description  Primer  Primer sequence 5’ to 3’ 
TbCYC6 cyclin box sense primer for cloning into pGEX5X-1  OL1413  GAAAGGATCCCCGTAGGTACGGCAGGGAA 
TbCYC6 cyclin box antisense primer  for cloning into pGEX5X-1  OL1414  GTTTGTCGACTCACATTTGTGTCTGTTGAGA 
5’ flank of TbCYC6 locus sense primer (NotI)  OL1467  GCGGCCGCACGCCAGATGTCGAAATTCC 
5’ flank of TbCYC6 locus antisense primer (XbaI)  OL1468  TCTAGACGTTCGTTCGTAACTCCACT 
3’ flank of TbCYC6 locus sense primer (ApaI)  OL1469  GGGCCCTGATTGGTTTACTTCGTTAC 
3’ flank of TbCYC6 locus antisense primer (ApaI/EcoRV)  OL1470  GGGCCCGATATCCTTTGGAACTCCTCTTTCTC 
L.majorCYC6 sense primer for cloning into pET15b (Nde-I)  OL1515  GCATATGTTCGTGGAACGAGAGCGGCAGG 
L.majorCYC6 antisense primer for cloning into pET15b (Xho-I)  OL1516  GCTCGAGTCACAGCGCCGGCAGCTCGTTAGGC 
Sense primer for L.majorCYCA 5’flank (HindIII)  OL1750  GAAGCTTGGTTGGTGCGATTCATCCC 
Antisense primer for L.majorCYCA 5’flank (SalI)  OL1751  GGTCGACTTTGACCGCCGTGCTTCTA 
Sense primer for L.majorCYCA 3’flank (SmaI)  OL1752  GCCCGGGTTAGTGTCTGCTTTCGTGG 
Antisense primer for L.majorCYCA 3’flank (BglII)  OL1753  AGATCTACAGCATGGGCACAACGCC 
Sense primer for L.majorCYCA (NdeII) C-term TAP TAG  OL1754  GCATATGGCGGTCCCACTGCGAATG 
Antisense primer for L.majorCYCA (KpNI) N-term TAP TAG  OL1755  CGGTACCCGCAGAAGTTGAAATGAAAG 
Sense primer for L.majorCYC6 (NdeII) C-term TAP TAG  OL1756  TCATATGTTCGTGGAACGAGAGCGG 
Antisense primer for L.majorCYC6 (KpNI) N-term TAP TAG  OL1757  TGGTACCCAGCGCCGGCAGCTCGTTAG 
Sense primer for L.majorCYC3 (NdeI)  OL1765  GCATATGTCGACCGATCTCGCAATTGTGACGACGG 
Antisense primer for L.majorCYC3 (XhoI)  OL1766  GCTCGAGGGACAGTCTGCGATGAAAGCAGTAGCAC       41 
Sense primer for L.majorCYC7 (NdeI)  OL1767  CCATATGCCTTTGCGAGCTTGCGTATCCAGG 
Antisense primer for L.majorCYC7 (XhoI)  OL1768 
GCTCGAGTCAGACCTCTCCGGAGGGAAGTGAAAAA
G 
Sense primer for L.majorCYC9 (NdeI)  OL1770  CCATATGTCGTCAAGCCCATTGTCGCCGGTG 
Antisense primer for L.majorCYC9 (XhoI)  OL1771  GCTCGAGTCACTGCTCTGACATCTTCATGAGTGG 
Sense primer for L.majorCYC10 (NdeI)  OL1772  GCATATGCAGATTGGCTTAGCGGGGTGCAGCAG 
Antisense primer for L.majorCYC10 (XhoI)  OL1773 
GCTCGAGCTACACACGGGGCTGATCTGGAGGTGGA
GG 
Sense primer for L.majorCRK1 (NdeI)  OL1783 
CCATATGACCAGCCGGTACGAGCGGCAGGAGAAG
ATC 
Antisense primer for L.majorCRK1 (BamHI)  OL1784  CGGATCCCTAAAACTGGAGGCTAAAGTACGGGTG 
Sense primer for L.majorCRK2 (NdeI)  OL1785  CCATATGCGGAGCAGCGGCCCCACCCCAGCGC 
Antisense primer for L.majorCRK2 (BamHI)  OL1786  CGGATCCTTACGACTGCTGCTGCTGCTGCTGCTG 
Sense primer for L.majorCRK3 (NdeI)  OL1787  CCATATGTCTTCGTTTGGCCGTGTTACCGCCC 
Antisense primer for L.majorCRK3 (BamHI)  OL1788  CGGATCCCTACCAGCGAAGGTCACTGAACCACGGG 
Sense primer for L.majorCRK4 (NdeI)  OL1789  CCATATGTCGACGGCGGGTCGGTACAAGCACG 
Antisense primer for L.majorCRK4 (BamHI)  OL1790  CGGATCCTCATAGCAAGTGGCAGGCCTCCATCGTC 
Sense primer for L.majorCRK6 (NdeI)  OL1791  CCATATGTCCGCGTCAGTGAACGACTTGGATG 
Antisense primer for L.majorCRK6 (BamHI)  OL1792  CGGATCCCTACGCATCCTTCATAAAGGGGTGTTCC 
Sense primer for L.majorCRK7 (NdeI)  OL1793  CCATATGGACAAGTACGCGTTGGGGCCGGTTATC 
Antisense primer for L.majorCRK7 (BamHI)  OL1794  CGGATCCTCATGCACGCAGCAAGGTATCTGAGAG       42 
Sense primer for L.majorCRK8 NdeI)  OL1795  CCATATGGGAGGGGAACTGGATAACCAGAAC 
Antisense primer for L.majorCRK8 (BamHI)  OL1796  CGGATCCTCAATGCTCCAGCTCCTTCCGCTTGACC 
Sense primer for L.majorCYCA HA TAG amplification from pGL630  OL1896  GGGGATCCTCACTCGAGCGCAGAAGTTGAA 
Antisense for L.majorCYCA HA TAG amplification from pGL630  OL1897  GGCCCGGGATGTACCCCTACGACGTCCCGGACTAT
GCCATGGCGGTCCCACTGCGAATG 
Sense primer for L.mexicanaCYCA HA TAG (SmaI) C-terminal  OL1935  CCCCGGGATGGCGGTCCCACTGCGAATGAGGA 
Antisense primer for L.mexicanaCYCA HA TAG (BamI) C-terminal  OL1936  TGGATCCTCAGGCATAGTCCGGGACGTCGTAGGGG
TACGCAGAAGTTGAAATGAAAGGAAATTC 
Sense primer for L.mexicanaCYCA HA TAG (SmaI) N-terminal  OL1937  CCCCGGGATGTACCCCTACGACGTCCCGGACTATG
CCATGGCGGTCCCACTGCGAATG 
Antisense primer for L.mexicanaCYCA HA TAG (BamI) N-terminal  OL1938  GTGGATCCTCACGCAGAAGTTGAAATGAAAGG 
Sense primer for L.majorCRK6 HA TAG (SmaI) C-terminal  OL1939  CCCCGGGATGTCCGCGTCAGTGAACGAC 
Antisense primer for L.majorCRK6 HA TAG (BamI) C-terminal  OL1940  TGGATCCTCAGGCATAGTCCGGGACGTCGTAGGGG
TACGCATCCTTCATAAAGGGGTTG 
Sense primer for L.majorCRK6 HA TAG (SmaI) N-terminal  OL1941  CCCCGGGATGTACCCCTACGACGTCCCGGACTATG
CCATGTCCGCGTCAGTGAACGAC 
Antisense primer for L.majorCRK6 HA TAG (BamI) N-terminal  OL1942  TGGATCCCTACGCATCCTTCATAAAGGG 
Sense primer for L.mexicanaCYCA HA TAG (XhoI) N-terminal  OL1943  CCTCGAGATGGCGGTCCCACTGCGAATG 
Antisense primer for L.mexicanaCYCA HA TAG (NotI) N-terminal  OL1944  CGCGGCCGCTCAGGCATAGTCCGGGACGTCGTAG
GGGTACGCAGAAGTTGAAATGAAAG 
Sense primer for L.mexicanaCYCA HA TAG (XhoI) C-terminal  OL1945  CCTCGAGATGTACCCCTACGACGTCCCGGACTATG
CCATGGCGGTCCCACTGCGAATG 
Antisense primer for L.mexicanaCYCA HA TAG (NotI) C-terminal  OL1946  CGCGGCCGCTCACGCAGAAGTTGAAATGAAAGG 
Sense primer for L.majorCRK6 HA TAG (XhoI) N-terminal  OL1947  CCTCGAGATGTACCCCTACGACGTCCCGGACTATG
CCATGTCCGCGTCAGTGAACG 
Antisense primer for L.majorCRK6 HA TAG (NotI) N-terminal  OL1948  CGCGGCCGCCTACGCATCCTTCATAAAGGGG 
Sense primer for L.majorCRK6 HA TAG (XhoI) C-terminal  OL1949  CCTCGAGATGTCCGCGTCAGTGAACG       43 
Antisense primer for L.majorCRK6 HA TAG (NotI) C-terminal  OL1950  CGCGGCCGCTCAGGCATAGTCCGGGACGTCGTAG
GGGTACGCATCCTTCATAAAGGGG 
Sense primer for L.majorCYCA knockout 3’flank detection (pGL1249)  OL2058  GACTGTCGGGCGTAC 
Antisense  primer  for  L.majorCYCA  knockout  3’flank  detection  (CYCA 
knockout locus) 
OL2059  CAACGCGTCTATTTC 
Sense primer for L.majorCYCA knockout 5’flank detection (pGL1249)  OL2060  CTGCGTGTCAATGCC 
Antisense  primer  for  L.majorCYCA  knockout  5’flank  detection  (CYCA 
knockout locus) 
OL2061  GTCGCGGTGAGTTCAG 
Sense primer for pGL1250 mutagenesis  OL2132  CACTTGATGATGACGAACATATGGCGGTC 
Antisense primer for pGL1250 mutagenesis  OL2133  GACCGCCATATGTTCGTCATCATCAAGTG 
Sense primer for pGL955 mutagenesis  OL2134  CACTTGATGATGACGAACATATGGCGGTCC 
Antisense primer for pGL955 mutagenesis  OL2135  GGACCGCCATATGTTCGTCATCATCAAGTG 
Sense primer for L.mexicanaCYCA Adds NcoI site  OL2152  GATCCATGGATGGCGGTCCCACTGC 
Antisense primer for L.mexicanaCYCA Adds XhoI site  OL2153  GCTCGAGCGCAGAAGTTGAAATG 
Antisense primer for L.majorCYC6 HA TAG Adds XhoI site  OL2154 
CCGCGGCCGCTCAGGCATAGTCCGGGACGTCGTAG
G 
GGTACAGCGCCGGCAGCTCGTTAG 
Sense primer for L.majorCYC6 HA TAG Adds NotI site  OL2155  CCTCGAGATGTTCGTGGAACGAGAG 
Sense primer for L.majorCYC6 HA TAG Adds XhoI site  OL2156 
CCTCGAGATGTACCCCTACGACGTCCCGGACTATG
C 
CATGTTCGTGGAACGAGAGC 
Antisense primer for L.majorCYC6 HA TAG Adds NotI site  OL2157  CGCGGCCGCTCACAGCGCCGGCAG 
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2.3 Protein purification 
2.3.1 L. mexicana (LmeCRK3his) 
Plasmid  pET28a+  (pGL751)  containing  LmeCRK3his (Grant et  al.,  1998)  was  used  to 
express this protein in E. coli BL21 DE3 pLYS cells. This expression vector added a poly-
his tag to the C-terminal end of the protein and allows purification using Qiagen Ni-NTA 
agarose beads. For LmeCRK3his purification, BL21 DE3 E. coli cells were transformed 
with plasmid pGL751 and grown to 0.6 O.D. at 37
oC. Protein expression was induced at 
19
oC over night using 150µM IPTG. Cells were centrifuged and resuspended in 40 ml of 
ice cold PBS pH 7.4 incubated with DNAse-I (0.1mg/ml) and Lysozyme (0.1mg/ml) for 60 
min  on  ice  and  sonicated  5  x  1 5  sec  (1  sec  on/1  sec.  off).  T he  lysate  was  centrifuged 
15000g  for  20  min.  The  supernatant  was  called  "Soluble  aliquot"  and  pellet  "Insoluble 
aliquot". To the Soluble aliquot 200 µl of Ni-NTA-agarose beads was added and incubated 
mixing gently for 20 min at 4
oC temperature and centrifuged at 1000g for 5 min at 4
oC. 
The column was washed 2 x 40 ml ice cold PBS pH 7.4 imidazole 20mM and eluted in 100 
µl  fractions  with  100mM  NaPi  pH  7.4,  10mM  NaCl,  0.5M  imidazole.  10  µl  of  elution 
fraction was mixed to 10µL 2X Laemmli protein buffer and the total volume of 20 µl was 
loaded on a 12% SDS-PAGE gel. The gel was transferred to membrane and Western was 
performed using mouse his tag monoclonal antibody to detect and to confirm purification 
of the correct size protein.  
2.3.2 L. mexicana CYCA (LmeCYCAhis) 
For  LmeCYCAhis  purification,  BL21  DE3  pLYS E.  coli cells  were  transformed  with 
plasmid pGL630. Cells were grown to 0.6 O.D. at 37
oC and induced for protein expression 
at 19
oC over night using 5mM IPTG. The same procedure used for LmeCRK3his was also 
used for LmeCYCAhis.       45 
2.3.3 S. pombe (Civ1-GST) 
Yeast Civ1-GST was obtained from a pGEX construct (pGL716) (Brown et al., 1999). For 
protein expression of Civ1 BL21 DE3 pLys E. coli strain was used for transformation with 
plasmid  pGL716.  Cell  culture  was  grown  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression at 21
oC over night using 0.4mM IPTG. Cells were centrifuged and resuspended 
in ice cold PBS pH 7.4 incubated with DNAse-I (0.1mg/ml) and Lysozyme (0.1mg/ml) for 
60 min. on ice and sonicated 5 x 15sec (1sec. on/1sec. off). Lysate was centrifuged 15000g 
for  20  min,  supernatant  was  called  Soluble  aliquot  and  pellet  Insoluble  aliquot.  To the 
Soluble aliquot was added 200 µl of glutatione-Sepharose column and incubated mixing 
gently for 30 min at 4
oC to allow binding. Lysates were then centrifuged at 1000g for 5 
min and resin column was washed 2 times with PBS 7.4 and eluted in 100 µl fractions of 
elution solution, 50mM Tris-Cl pH 8.0, 20mM glutathione. 10 µl of elution fraction was 
mixed with10 µl Laemmli protein buffer 2x and the total volume of 20 µl was loaded on a 
12% SDS-PAGE gel. 
2.3.4 L. major CYC3 (LmCYC3his) 
For  LmCYC3his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1350.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  5mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCYC3his. 
2.3.5 L. major CYC7 (LmCYC7his)  
For  LmCYC7his  purification,  BL21  DE3  pLYS E.  coli  cells  were  transformed  with 
plasmid  pGL1335.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  5mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCYC7his.       46 
2.3.6 L. major CYC9 (LmCYC9his) 
For  LmCYC9his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1336.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  1mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCYC9his. 
2.3.7 L. major CYC10 (LmCYC10his) 
For  LmCYC10his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1337.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  usin g  5mM  IPTG.  The  same  procedure   used  for 
LmeCRK3his was also used for LmCYC10his. 
2.3.8 L. major CRK1 (LmCRK1his) 
For  LmCRK1his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1338.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  1mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCRK1his. 
2.3.9 L. major CRK2 (LmCRK2his) 
For  LmCRK2his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1339.  Cells  were  grown  to  0.6  O.D.  at 37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  1mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCRK2his.       47 
2.3.10 L. major CRK3 (LmCRK3his) 
For  LmCRK3his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1340.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  1mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCRK3his. 
2.3.11 L. major CRK4 (LmCRK4his) 
For  LmCRK4his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1616.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  1mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCRK4his. 
2.3.12 L. major CRK6 (LmCRK6his) 
For  LmCRK6his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1341.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  1mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCRK6his. 
2.3.13 L. major CRK7 (LmCRK7his) 
For  LmCRK7his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1349.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  1mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCRK7his.       48 
2.3.14 L. major CRK8 (LmCRK8his) 
For  LmCRK8his  purification,  BL21  DE3  pLYS  E.  coli  cells  were  transformed  with 
plasmid  pGL1342.  Cells  were  gr own  to  0.6  O.D.  at  37
oC  and  induced  for  protein 
expression  at  19
oC  over  night  using  1mM  IPTG.  T he  same  procedure  used  for 
LmeCRK3his was also used for LmCRK8his. 
2.3.15 L. mexicana CRK3/CYC6his complex 
The expression of non-tagged CRK3 from pGL1072 was done when BL21 DE3 pLys cells 
were grown to 0.6 O.D. at 37
oC and  induced  for protein expression at 19
oC over night 
using IPTG at 2.5mM. The expression of L. major CYC6 was made from pGL1218 (Rod 
Walker PhD thesis) to transform E. coli BL21 DE3 pLYS and grow to 0.6 O.D at 37
oC and 
induced for protein expression at 19
oC overnight using IPTG at 5mM. Around 500 ml of E. 
coli culture of each different culture was centrifuged and mixed just prior to sonication in 
Sonication Buffer (SB, 50mM NaH2PO4 + 300mM NaCl pH 8.0). The sonication product 
was  centrifuged  at  20.000g  for  15  minutes,  fi ltered  at  0.22µm  and  loaded  in   pre-
equilibrated  POROS  MC  Column  (Ni2+  charged)  for  His-tagged  protein  purifications. 
Column was washed in SB + 50mM Imidazole and eluted in SB + 500mM Imidazole. The 
elutions  containing  the  proteins  were  pooled  together  and re-purified  by  Ion-Exchange 
Chromatography. The pooled fractions are first passed through a desalting column (PD10, 
Biorad), eluted in 3.5ml of Buffer A (Tris/Cl + 5mM EDTA pH 8.0). This elution is then 
loaded  into  Ion-Exchange  column  (BIORAD,  UNO -Q1).  The  purified  complex  is 
recovered in the flow through and analysed on Coomassie gel.        49 
2.3.16 T. brucei CRK3 (TbCRK3his) 
For  TbCRK3his  purification,  BL21  DE3  E.  coli  cells  were  transformed  with  pl asmid 
pGL1074 (were grown to 0.6 O.D. at 37
oC and  induced  for protein expression at 19
oC 
overnight using IPTG at 2.5mM following the same procedure used for LmeCRK3his. 
2.3.17 T. brucei CKS1 (Tbp12
CKS1his) 
For  Tbp12
CKS1his  (CKS1  yeast  homologue)  purification,  BL21  DE3 E.  coli cells  were 
transformed  with  plasmid  pGL976  (were  grown  to  0.6  O.D.  at  37
oC  and  induced  for 
protein expression at 19
oC over night using IPTG at 2.5mM following the same procedure 
used for LmeCRK3his. 
2.4 Protein quantification 
Protein elution was quantified using PIERCE BCA
TM Protein Assay Kit. Standard protein 
BSA was used to plot concentration curves according to manufacture’s instructions for all 
the proteins quantified.  
2.5 Protein kinase assays 
Protein kinase assays were performed using 50mM MOPS pH 7.2, 20mM MgCl2, 10mM 
EGTA, 2mM DTT, 4μM ATP, γ-P
32ATP and 2.5µg histone H1 as substrate. Reactions are 
incubated at 30
oC for 30 min. Final volume of each reaction was 20 µl and at the end of the 
30  min  incubation  20  µl  of  2  x   Laemmli  protein  loading  buffer  was  added  to stop the 
reaction, samples then were incubated at 100
oC for 5 min and loaded on 12% acrylamide 
gel. The gel was dried and exposed to KODAK sensitive film overnight. Alternatively to 
histone H1, 2.5 μg of β-casein or Myelin Basic Protein (MBP) was used.        50 
Table 2.2 List of constructs generated for protein expression 
 
Plasmid number 
 
Gene  Solubility  Expression level 
pGL1218  LmCYC6  Soluble 
Low levels of 
expression 
pGL1334  LmCYCA  Soluble 
Low levels of 
expression 
pGL1335  LmCYC7  Insoluble 
Low levels of 
expression 
pGL1336  LmCYC9  Soluble 
High levels of 
expression 
pGL1337  LmCYC10  Insoluble 
Low levels of 
expression 
pGL1350  LmCYC3  Insoluble 
Low levels of 
expression 
pGL1338  LmCRK1  Soluble 
High levels of 
expression 
pGL1339  LmCRK2  Soluble 
High levels of 
expression 
pGL1340  LmCRK3  Soluble 
High levels of 
expression 
pGL1341  LmCRK6  Soluble 
Low levels of 
expression 
pGL1342  LmCRK8  Soluble 
Low levels of 
expression 
pGL1349  LmCRK7  Soluble 
High levels of 
expression 
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2.6 Binding assay 
To assess whether CRK3 can bind CYCA in vitro, a non his-tag LmCRK3 was subcloned 
into  expression  vector  pET21a (pGL1071).  This  construction  w as  used  to  express 
LmCRK3 in E. coli BL21 competent cells and the cell extract was used in a binding assay. 
A lysate was made at 50 ml of an overnight induced cell culture, incubated with lysozyme 
and  sonicated  so  that  this  extract  could  be  used  in  the  binding  assay  using  an  affinity 
column  with  LmeCYCAhis. BL21  DE3  E.  coli  cells  were  transformed  with  pl asmid 
pGL630 and were grown to 0.6 O.D. at 37
oC and induced for protein expression at 19
oC 
over  night  using  IPTG  at 5mM.  Cells  were  centrifuged  an d  resuspended  in  PBS  7.4 
incubated  with  DNAse-I  (0.1mg/ml)  and  Lysozyme  (0.1mg/ml)  for  60  min  on  ice  and 
sonicated 5 x 15sec (1sec on/1sec off).  The lysate was centrifuged 15000g for 20 min. The 
supernatant  was  incubated  with  200   µl  of  Ni-NTA  agarose  bead  for  5  min at  room 
temperature and centrifuged for 5 min at 2100g. This column of Ni-NTA + CYCAhis was 
washed 2 x with PBS 7.4 and incubated with the soluble bacteria lysate containing non 
taggedCRK3  for  30  min,  mixing  at  room  temperature to  permit  the  binding  of  the  two 
proteins. The beads were then centrifuged at 1000g for 5 min. The column was washed 2X 
with PBS 7.4 and eluted in 100 µl fractions with phosphate buffer consisting of 100mM 
NaPi 7.4, 10mM NaCl and 0.5M imidazole (pH 8.0). 10 µl of elution fraction was mixed to 
10 µl Laemmli protein buffer 2 x and the total volume of 20 µl was loaded on a 12% SDS-
PAGE gel. The proteins on the gel were transferred to a PVDF membrane and a western 
blot  was  performed  using  α -CRK3  antibodies  diluted  1:2000   in  PBS.  The  α -rabbit 
peroxidase  conjugate  was  used at  1:5000  dilution.  The  membrane  was  developed  using 
PIERCE Quimioluminescense kit.        52 
2.7 Transfection of Leishmania 
Leishmania was grown to middle log-phase. Cells were pelletted at 1300g for 10 min and 
washed  in  half of the original  volume of cytomix electroporation  buffer  (120mM  KCl, 
0.15mM CaCl2, 10mM K2HPO4, 25mM HEPES, 2mM EDTA and 2mM MgCl2; pH 7.6) 
(Robinson and Beverley, 2003). The cells were pelletted again at 1300g for 10 min. The 
pellet was resuspended in cytomix buffer to a final concentration of 2 x 10
8 ml
-1. 10 µg of 
DNA solution was mixed with 500 µl of cell suspension kept on ice and electroporated 
twice  at  25  µF,  1500  volts  (3. 75  kV  cm
-1)  pausing  10  sec  between  pulses.   The 
electroporated cuvettes were then stored on ice for 10 min. The cells were placed in a flask 
with medium (Homem + 20% FCS) and the flask was incubated overnight at 25
oC on its 
side to increase aeration of the medium. The appropriate antibiotic for selection was added 
in the following day. For selection of transfected cell lines, the following concentrations of 
drugs  were  used:  50µgml
-1  neomycin,  10µgml
-1  puromycin,  50µgml
-1  hygromycin  and 
10µgml
-1 blastocydin.  
2.8 Preparation of stabilate 
DMSO  (as  a  cryopreservative)  w as  used  to  a  final  concentrati on  of  5%.  0.5  ml  of 
Leishmania (log-phase) was mixed with 0.5 ml of pre-chilled Homem with 20 % FCS and 
10% DMSO per cryovial. The tubes were stored overnight at -20
oC, transferred to -80
oC 
where were left overnight and then transferred to the liquid nitrogen storage tanks for long 
term storage.  
2.9 Silver staining for acrylamide protein gels 
Milli-Q water was used for all steps. The gels were soaked in water as a primary wash to 
remove running buffer residues. After the gels were fixed with 50% methanol, 5% acetic       53 
acid, 45% water for 20 min under gentle agitation, they were washed in 50% methanol in 
water. After this wash, gels were washed with water only for 10 min (gels could be left 
overnight at this  stage). A solution containing 0.02% sodium thiosulphate  in water was 
used to sensitize the gels for 1 min. The gels were then washed twice in water for 1 min 
and were stained with 0.1% silver nitrate (ice cold solution) in water for 20 min at 4
oC. If 
silver nitrate precipitation was observed, the solution was replaced with a fresh one during 
the  staining.  After  staining, gels  were  washed  twice  in  water  for  1  min  and  we re  then 
developed with 0.04% formaldehyde in 2% sodium carbonate. If the developing solution 
turned yellow, a fresh solution was used immediately. 5% acetic acid was used to stop the 
reaction and the storage of the gels was possible in 1% acetic acid solution. 
2.10 Preparation of Leishmanial cell lysates 
100 ml of mid log-phase Leishmania promastigotes were centrifuged at 1300 g for 10 min. 
The  cell  pellet  was  washed  in 50  ml  of  sterile  PBS  and  centr ifuged  again  at  the 
aforementioned  speed.  The  washed  cells  were  then  resuspended  in  1  ml   of Leishmania 
lysis  buffer  (10%  glycerol,  50mM  MOPS  pH  7.2,  100mM  NaCl,  1m M  EDTA,  1mM 
EGTA,  1%  Triton  X -100)  and  a  protease  inhibitor mixture  was  added  to  a  final 
concentration of 2.5mM 1,10 phenanthroline, 100µgml
-1 Leupeptin, 5µgml
-1 Pepstatin A, 
500µgml
-1 Pefabloc SC, 0.5mM EGTA and 0.5mM EDTA. After the addition of protease 
inhibitors, the cells were vortexed, left on ice for 30 min and centrifuged at 100,000g at 
4
oC  for  45  min.  The  supernatant (S-100)  contained  the  soluble  protein  ly sate  of 
Leishmania, which was used for western blot analysis and protein purification. 
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Table 2.3 Summary of protein expression conditions 
 
Protein/tag  Plasmid  E. coli  Temperature  of 
expression 
IPTG 
concentration 
LmeCRK3his 
  pGL751  BL21 DE3 pLYS  19
oC  150µM 
LmeCYCAhis 
  pGL630  BL21 DE3 pLYS  19
oC  5mM 
Civ1-GST 
  pGL716  BL21 DE3 pLYS  21
oC  0.4mM 
LmCYC3his 
  pGL1350  BL21 DE3 pLYS  19
oC  5mM 
LmCYC7his 
  pGL1335  BL21 DE3 pLYS  19
oC  5mM 
LmCYC9his 
  pGL1336  BL21 DE3 pLYS  19
oC  1mM 
LmCYC10his 
  pGL1337  BL21 DE3 pLYS  19
oC  5mM 
LmCRK1his 
  pGL1338  BL21 DE3 pLYS  19
oC  1mM 
LmCRK2his 
  pGL1339  BL21 DE3 pLYS  19
oC  1mM 
LmCRK3his 
  pGL1340  BL21 DE3 pLYS  19
oC  1mM 
LmCRK4his 
  pGL1616  BL21 DE3 pLYS  19
oC  1mM 
LmCRK6his 
  pGL1341  BL21 DE3 pLYS  19
oC  1mM 
LmCRK7his 
  pGL1349  BL21 DE3 pLYS  19
oC  1mM 
LmCRK8his 
  pGL1342  BL21 DE3 pLYS  19
oC  1mM 
TbCRK3his 
  pGL1074  BL21 DE3 pLYS  19
oC  2.5mM 
Tbp12
CKS1his 
  pGL976  BL21 DE3 pLYS  19
oC  2.5mM 
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2.11 Western blot  
Protein  samples  were  transferred  from  the  gel  to  nitrocellul ose  membrane  by  using 
BIORAD  semi-dry  blotting  system  for  30  min .  After  transferring,  the  membrane  was 
blocked for 1 hour in PBS/Tween 20 (0.1%)/milk 3.5% and washed 5 times for 5 min with 
PBS/Tween 20 (0.1%) between and after the antibodies incubation. After washing, the first 
antibody was diluted at the appropriate concentration in PBS/Tween 20 (0.1%)/milk 3.5% 
and  incubated  with  the  membrane  mixing  gently  for  1  hour.  Th e  membrane  was  then 
washed again 5 times  for 5  min with PBS/Tween 20 (0.1%). The second antibody was 
diluted at the appropriate concentration in PBS/Tween 20 (0.1%)/milk 3.5% and incubated 
with the membrane mixing gently for 1 hour. After washing the membrane 5 times for 5 
min with PBS/Tween 20 (0.1%), the membrane was developed with undiluted West-Pico 
Quimioluminescense kit (Perbio). 
For western blots to detect histidine tagged proteins, the following antibody dilutions were 
used: α-his antibody diluted at 1 in 5,000 as primary antibody and α-mouse IgG diluted at 
1 in 5,000 for HRP monoclonal (200 µgml
-1) as secondary. 
For western  blots to detect GST tagged proteins, the  following  antibody dilutions  were 
used: Sigma rabbit α-GST antibody diluted at 1 in 2,000 as primary antibody and α-rabbit 
HPR conjugated antibody as secondary, diluted at 1 in 5,000. 
For western blots to detect CRK3, a specific polyclonal antibody was developed against 
CRK3 in rabbit and the serum was used diluted at 1 in 500. As a secondary antibody α-
rabbit HPR conjugated antibody diluted at 1 in 5,000 was used.    
For  western  blots  to  detect  ph osphorylated  CRK3,  a  specific monoclonal  antibody 
(Calbiochem  anti-phosphothreonine  mouse  monoclonal  antibody,  14B3)  diluted  at  1  in       56 
1,000  was  used.  The  second  ant ibody  used  was  α-mouse  HRP  monoclonal  antibody 
(SIGMA) diluted at 1 in 5,000. 
Antibody  13  was  developed  agai nst  L.  mexicana  CYCA  unique  peptide  sequence  for 
western blot. Antibody 13 diluted at 1 in 1,000 was used as a primary antibody and anti-
mouse antibody conjugated with HRP diluted at 1 in 5,000 was used as a secondary.  
For western blots to detect HA tagged proteins, Roche monoclonal mouse HRP conjugated 
antibody was used diluted at 1 in 500. Since this antibody was already conjugated to HRP, 
no secondary antibody was necessary. 
2.12 Immunofluorescence Assays 
2.12.1 Fixation 
Leishmania was washed twice in PBS before fixation in 200 µl of 1% formaldehyde/ PBS 
for 30 min at room temperature. The cells were then permeabilised by addition of 20 µl of 
1% Triton X-100/PBS for 10 min. 20 µl of 1M glycine/ PBS were added to neutralise the 
free  adelhyde  bounds  resulting  for  the  formaldehyde  fixation,  in  order  to  diminish  any 
background  fluorescence. The cells were  incubated a further 10  min. In the  meanwhile, 
glass  slides  were  washed  with 70%  ethanol  and  air  dried.  The  treated  cells  were  then 
pipetted on the clean slides and left to sediment and adhere to the surface until completely 
dried.   
2.12.2 Immunofluorescence 
The primary antibody was diluted 1 in 500 in 0.1% Triton X-100, 0.1% BSA and added to 
the top of the slide to incubate for 1 hour at room temperature or alternatively overnight at 
4
oC. The cells were then washed 3 times with 1 ml of PBS. The secondary antibody was       57 
diluted at 1 in 1,000 in 0.1% Triton X-100, 0.1% BSA , added to the cells and incubated in 
the dark for 1 hour at room temperature. The slides were then washed 3 times with PBS to 
remove  the  excess  of  antibody and  left  drying  (but  not  compl etely)  before  adding  a 
mounting  solution  (2.5%  DABCO in  50%  glycerol  containing  0.5µgml
-1  of  DAPI.  The 
primary antibody used was Roche monoclonal mouse antibody diluted at 1 in 200 and the 
secondary antibody was α-mouse FITC conjugated diluted at 1 in 1,000. 
2.13 Immunopreciptation (IP)  
L. major friedlin strain was transfected with pGL1388 and pGL1389 generating cell lines 
that  would  overexpress  LmCYCA containing  N-terminal  (stabilate  No.  8105)  and  C-
terminal (stabilate No. 8106) HA tag respectively. HA tagged proteins can be purified with 
Anti-HA  3F10  antibody  that  recogniz es  the  9-amino  acid  sequence  YPYDVPDYA, 
derived from the human influenza hemagglutinin (HA) protein. The antibody recognizes its 
antigenic  determinant  even  when  the  HA  peptide  epitope  is  in troduced  into  unrelated 
recombinant  proteins  by  a  tech nique  known  as  “epitope  taggin g.”  This  antibody  is 
immobilized into an affinity matrix by Roche in an Anti-HA Affinity Matrix. 
These cell lines were grown to mid log phase and 50ml of culture was pelletted at 1000g 
for 10 min at 4
oC.  The cell pellet was then washed twice in cold PBS and resuspended in 
1ml of IP lysis buffer containing protease inhibitors. To this lysis suspension, 50 µl of HA 
affinity purification  matrix (Roche) was added and an overnight incubation at 4
oC with 
agitation  was  done.  The  matrix   was  then  washed  3X  with  1ml  o f  lysis  buffer  and 
resuspended in 50 µl of lysis buffer. 10 µl was loaded in an SDS-PAGE gel, which was 
used in western blot or silver stained, while 5 µl was used in a kinase assay using H1 as 
substrate.       58 
The IP procedure described above for LmCYCA was also used for LmCRK6 HA tagged. 
Transfected  cell  lines  (stabilate  No.  7653  and  7654 )  were  obtained  using plasmids 
pGL1394 and pGL1392. For pGL1392 transfected cell lines (7653) a C-terminal HA tag is 
added to LmCRK6  for overexpression. For pGL1394 transfected cell  lines a C-terminal 
HA tagged LmCRK6 is expressed by integration of the construct in the rDNA locus.  
2.17 Cloning of untagged CRKs 
L. major CRKs were excised from their plasmids using restriction sites BamHI and XhoI. 
DNA fragments corresponding to the correct sizes were gel purified and ligated into dual 
expression vector pACYC Duet. This plasmid, conferring Chlorophenicol resistance to the 
cells,  was  previously  digested  with BamHI  and  XhoI  and  gel  purified.  pACYC  Duet  
plasmids containing the L. major CRKs were named as pGL1338  (LmCRK1), pGL1339 
(LmCRK2), pGL1340 (LmCRK3), pGL1616 (LmCRK4), pGL1341 (LmCRK6), pGL1349 
(LmCRK7), pGL1342 (LmCRK8) and pGL1072 (TbCRK3). 
2.18 Bacterial Co-transformation  
pET15b-derived  pGLs  containing  cyclin   genes  (LmCYCA,  LmeCYCA,  LmCYC 6, 
LmCYC7, LmCYC9, LmCYC10 and LmCYC11) were transformed into competent BL21 
E. coli and selected with ampicillin. The cells were co-transformed with a second plasmid 
(pACYCA Duet, Chlorophenicol resistant) containing the CRK genes to generate a double 
resistant E. coli strain capable of expressing one His-tagged CYC protein and one non-His-
tagged CRK. The CRK genes of interest were LmCRK1, LmCRK2, LmCRK3, LmCRK4, 
LmCRK6, LmCRK7 and LmCRK8. In total, 49 different strains were generated and some 
of them were used in expression and co-purification assays (Tables 2.3 and 2.4). 
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Table 2.4 Co-expression of cyclin-kinase pairs in E. coli 
 
  pGL1334  pGL1218  pGL1335  pGL1336  pGL1337  pGL1350  pGL630 
pGL1338  CYCA 
his/CRK1 
CYC6 
his/CRK1 
CYC7 
his/CRK1 
CYC9 
his/CRK1 
CYC10 
his/CRK1 
CYC3 
his/CRK1 
MexCYCA 
his/CRK1 
pGL1339  CYCA 
his/CRK2 
CYC6 
his/CRK2 
CYC7 
his/CRK2 
CYC9 
his/CRK2 
CYC10 
his/CRK2 
CYC3 
his/CRK2 
MexCYCA 
his/CRK2 
pGL1340  CYCA 
his/CRK3 
CYC6 
his/CRK3 
CYC7 
his/CRK3 
CYC9 
his/CRK3 
CYC10 
his/CRK3 
CYC3 
his/CRK3 
MexCYCA 
his/CRK3 
pGL1616  CYCA 
his/CRK4 
CYC6 
his/CRK4 
CYC7 
his/CRK4 
CYC9 
his/CRK4 
CYC10 
his/CRK4 
CYC3 
his/CRK4 
MexCYCA 
his/CRK4 
pGL1341  CYCA 
his/CRK6 
CYC6 
his/CRK6 
CYC7 
his/CRK6 
CYC9 
his/CRK6 
CYC10 
his/CRK6 
CYC3 
his/CRK6 
MexCYCA 
his/CRK6 
pGL1349  CYCA 
his/CRK7 
CYC6 
his/CRK7 
CYC7 
his/CRK7 
CYC9 
his/CRK7 
CYC10 
his/CRK7 
CYC3 
his/CRK7 
MexCYCA 
his/CRK7 
pGL1342  CYCA 
his/CRK8 
CYC6 
his/CRK8 
CYC7 
his/CRK8 
CYC9 
his/CRK8 
CYC10 
his/CRK8 
CYC3 
his/CRK8 
MexCYCA 
his/CRK8 
 
2.19 Bacterial co-expression and purification 
Co-transformed E. coli BL21 capable of expressing one his-tagged CYC protein and one 
non-his-tagged  CRK  were  grown  to  0.6  O.D.  in  th e  presence  of  ampicillin  and 
Chlorophenicol. When an O.D. of 0.6 was reached, the culture was transferred to 19
oC and 
induced  for protein expression using 1mM IPTG overnight, shaking  for  better aeration. 
From  the  total  culture  volume  of  200  ml,  half  was  us ed  to  co-purify  cyclin-kinase 
complexes using the same protocol for purification of CRK3 described above.  
2.20 Preparation of CRK3 Aminolink column 
To bind CRK3 to the Aminolink resin (PIERCE), 1ml of slurry containing 500µl of resin 
bed was placed  into the protein purification tube (plastic disposable protein purification 
columns  from  PIERCE.  Storage  l iquid  was  left  to  flow  out  of the  column  and  3 ml 
Coupling  Buffer  was  added  to  equilibrate  the column  and  left  to  flow  by  gravity.  The 
column was closed at the bottom and 2 ml of CRK3 solution at 1mgml
-1 was added to the 
column. 200 µl of reducing agent was also added to the protein column mix. The mix was       60 
then incubated at 4
oC mixing gently overnight. To block inactive sites of the column after 
the  overnight  incubation,  2  ml  of  quenching  buffer  and  200  µl  of  reducing  agent  were 
added to the column and incubated mixing at 4
oC for 30 min. The column was then washed 
with 5 ml of washing buffer and finally 3 ml of PBS 0.05% azide was added as a storage 
buffer. 
2.21  Purification  of  CRK3  inte racting  proteins  from 
Leishmania lysates 
The Aminolink column with recombinant CRK3 attached was used to try to purify proteins 
that interact with CRK3 present in the S-100 Leishmania lysate. Immobilized CRK3 was 
expected co-purify of ligants like cyclins or subunit inhibitors that would be identified by 
mass-spectrometry. The column was incubated overnight at 4
oC with S-100 obtained from 
500 ml of cell culture of mid log phase Leishmania major cells. The column was then 
washed in the lysis buffer 2x (3ml) and eluted in 5 ml for ligants with IgG Elution Buffer 
(0.2 M glycine HCl, pH 3.0). The washes and elutions were concentrated using Vivaspin 4 
spin concentrator columns according to manufactures instructions. The washes and 
elutions were analyzed in SDS-PAGE gels stained with BIORAD sypro ruby staining 
according to the manufactures instructions.61 
Table 2.5 List of constructs that were used in the experiments 
 
Plasmid 
number 
 
Gene 
pGL975 
pGEM-T+TbCKS1  PCR  product  from  gDNA   (OL1260/OL861) 
NdeI/XhoI 
pGL976  pET15b+TbCKS1 from pGL975 
pGL977 
pGEM-T+TbCRK3  PCR  product  from  gDNA  (OL1412/OL427) 
BamHI/SalI 
pGL978  pET15b+TbCRK3 NdeI/BamHI 
pGL979 
pGEM-T+TbCYC6  box  PCR  product  from gDNA  (OL1413/OL1414) 
BamHI/SalI 
pGL980  pGEX5X-1+TbCYC6 box BamHI/SalI 
pGL1036  pET15b+TbCRK3 amplified from pGL798 XhoI/NdeI 
pGL1071  pGL751+LmeCRK3 TLM mutant –lacks Thr
161 residue 
pGL1072 
pET21a+LmeCRK3  XhoI-NdeI,  it  expresses  a  non-tagged  version  of 
CRK3 
pGL1073 
pGL900+TbCYC6 3’end on NcoI with OL1418 and OL1419/3’flank on 
ApaI  with  OL1420  and  OL1421  (TbCY C6  C-terminal  TAP  TAG 
construct) 
pGL1243  pGEM-T+LmCYCA from gDNA PCR with OL813/OL814 (NdeI/XhoI) 
pGL1244 
pGEM-T+LmCYCA 5’flank (915bp) from gDNA with OL1750/OL1751 
(HindIII/SalI) for CYCA KO
- construct 
pGL1245 
pGEM-T  and  LmCYCA  3’flank  (905bp)  f rom  gDNA  with 
OL1752/OL1753 (SmaI/BglI) for CYCA KO
- construct 
pGL1246 
pGEM-T+LmCYCA (CDS) (937bp) from gDNA with OL1754/OL1755 
(NdeI/KpnI) for N-term TAP TAG construct 
pGL1247 
pGEM-T+LmCYCA (CDS) (941bp) from gDNA with OL1754/OL1759 
(NdeI/SmaI) for C-term TAP TAG construct 
pGL1249 
pGL345+3’flank  (BglII/SmaI)  and  5’flank  ( HindIII  and  SalI)  of 
LmCYCA (Ho- construct, Hyg resist) 
pGL1250  pGL955+LmCYCA from gDNA OL1754/OL1759 NdeI/SmaI 
pGL1253  pGEM-T+LmCYC9 from gDNA PCR, OL1770/OL1771 XhoI/NdeI 
pGL1254  pGEM-T+LmCRK1 from gDNA PCR, OL1783/OL1784 BamHI/NdeI 
pGL1255  pGEM-T+LmCRK3 from gDNA PCR, OL1787/OL1788 BamI/NdeI 
pGL1256  pGEM-T+LmCRK7 from gDNA PCR, OL1793/OL1794 BamI/NdeI       62 
pGL1265 
pGL345+Flanking  regions  of  CYC A  cloned  into  BglII/SmaI  and 
HindIII/GalI (BSD resistant) 
pGL1266 
pGEM-T+LmCRK3 cloned into pGEM-T OL1765/OL1766 XhoI/NdeI 
but the gene has two XhoI sites 
pGL1267  pGEM-T+LmCRK7 cloned into pGEM-T L1767/OL1768 XhoI/NdeI  
pGL1268  pGEM-T+LmCRK10 cloned into pGEM-T OL1772/OL1773  
pGL1269 
pGEM-T+LmCRK2  cloned  into  pGEM -T  OL1785/OL1786 
BamHI/NdeI  
pGL1270 
pGEM-T+LmCRK4  cloned  into  pGEM -T  OL1789/OL179 0 
BamHI/NdeI 
pGL1271 
pGEM-T+LmCRK6  cloned  into  pGEM -T  OL1791/OL1792 
BamHI/NdeI 
pGL1272 
pGEM-T+LmCRK8  cloned  into  pGEM -T  OL1795/OL1796 
BamHI/NdeI 
pGL1334  pET15b+LmCYCA XhoI/NdeI 
pGL1335  pET15b+LmCYC7 XhoI/NdeI 
pGL1336  pET15b+LmCYC9 XhoI/NdeI 
pGL1337  pET15b+LmCYC10 XhoI/NdeI 
pGL1338  pET15b+LmCRK1 XhoI/NdeI 
pGL1339  pET15b+LmCRK2 XhoI/NdeI 
pGL1340  pET15b+LmCRK3 XhoI/NdeI 
pGL1341  pET15b+LmCRK6 XhoI/NdeI 
pGL1342  pET15b+LmCRK8 XhoI/NdeI 
pGL1349 
pET15b+LmCRK7  from  pGL1256  subcloned  in  NdeI/BamHI  C-term 
His Tag for E. coli expression 
pGL1350 
pET-15b LmCRK3 from pGL1266 subcloned in NdeI C-term His Tag 
for E. coli expression 
pGL1369 
PCRscript LmeCYCA amplified from pGL630 using OL1935/OL1936, 
adds C-term HA tag and SmaI/BamHI sites 
pGL1370 
PCRscript LmeCYCA amplified from pGL630 using OL1937/OL1938, 
adds N-term HA tag and SmaI/BamHI sites 
pGL1371 
PCRscript LmeCYCA amplified from pGL630 using OL1943/OL1944, 
adds N-term HA tag and XhoI/NotI sites 
pGL1372 
PCRscript LmeCYCA amplified from pGL630 using OL1945/OL1946, 
adds C-term HA tag and XhoI/NotI sites 
pGL1387  pET-15b and LmCRK7 into BamHI/NdeI       63 
pGL1388 
pGL102 and LmeCYCA PCR from pGL630 with OL1938/1937 N-term 
HA TAG for overexpression 
pGL1389 
pGL102 and LmeCYCA PCR from pGL630 with OL1935/1936 C-term 
HA TAG for overexpression 
pGL1392 
pGL102  LmCRK6  C -term  HA  TAG  PCR  from  pGL1341  i nto 
SmaI/BamHI OL1939/1940 
pGL1393 
pGL631  LmCRK6  N -term  HA  TAG  PCR  from  pGL1341  i nto 
SmaI/BamHI OL1947/1948 
pGL1394 
pGL631  LmCRK6  C -term  HA  TAG  PCR  from  pGL1341  i nto 
XhoI/NotI OL1949/1950 
pGL1436 
PCRscript  C-term  HA  TAG  of  LmCYCA  OL1935/1 936  Epissomal 
(XmaI/BamHI) 
pGL1437 
PCRscript  N-term  HA  TAG  of  LmCYCA  OL1937/1 938  Epissomal 
(XmaI/BamHI) 
pGL1438 
PCRscript  N-term  HA  TAG  of  LmCYCA  OL1943/1 944  Intergration 
(XhoI/NotI) 
pGL1439 
PCRscript  C-term  HA  TAG  of  LmCYCA  OL1945/1 946  Intergration 
(XhoI/NotI) 
pGL1483  pGL631 C-term CYC6 HA TAG cloned into XhoI/NotI, OL2154/2155 
pGL1484  pGL631 N-term CYC6 HA TAG cloned into XhoI/NotI, OL2156/2157 
pGL1536  pET21a+ TbCRK3 non-tagged NdeI/BamHI 
pGL1558 
pGL1249  Inserted  PUR  res  gene  from  pGL236  into  BamH I/SpeI 
LmCYCA KO- construct 
pGL1616  pET15b LmCRK4 into NdeI/BamHI of pET15b 
pGL1621 
PACYC  Duet  +LmCRK1  from  pGL1338  digested  with  NdeI/BamHI 
(No tag is expressed) 
pGL1622 
PACYC  Duet  +LmCRK2  from  pGL1339  digested  with  N deI/BamHI 
(No tag is expressed) 
pGL1623 
PACYC  Duet  +LmCRK3  from  pGL1340  digested  with  NdeI/BamHI 
(No tag is expressed) 
pGL1624 
PACYC  Duet  +TbCRK3  from  pGL1036  digested  with  NdeI/BamHI 
(No tag is expressed) 
pGL1625 
PACYC  Duet  +LmCRK4  from  pGL1270  digested  with  NdeI/BamHI 
(No tag is expressed) 
pGL1626  PACYC  Duet  +LmCRK6  from  pGL1341  digested  with  NdeI/BamHI       64 
(No tag is expressed) 
pGL1627 
PACYC  Duet  +LmCRK8  from  pGL1342  digested  with  NdeI/BamHI 
(No tag is expressed) 65 
 
 
 
Chapter 3 
Analysis of the cyclin dependent kinase CRK3 and 
its interaction with CYCA In vitro       66 
3.1 Introduction 
CRK3 is believed to be the functional cdc2 homologue from L. mexicana
 since it shares a 
number of attributes with cdc2 from other eukaryotic
 species: it binds the S. pombe protein 
p13
suc1 and its L. mexicana homologue p12
Cks1; it phosphorylates the cdc2 substrate histone 
H1, and its activity
 correlates with the division status of the parasite, being active
 in the 
proliferative life cycle stages (promastigote and amastigote)
 and inactive in the cell cycle-
arrested metacyclic stage (Mottram et al., 1996a;Grant et al., 1998). The predicted
 protein 
encoded by the leishmanial CRK3 gene shows the greatest
 degree of homology to the cdc2 
family of serine/threonine protein
 kinases. CRK3 has an
 unusual 19-amino acid N-terminal 
extension when compared with
 human cdc2, which is not highly conserved in sequence 
when compared to other trypanosomatid CRK3s and has only
 one conserved residue, an 
arginine  at  position  10 (Hassan  et  al.,  2001).  The  leishmanial  CRK3
  contains  all  the 
domains  and  residues  characteristic  of  the  serine/threonine
  protein  kinase  family.  In 
addition, CRK3 also contains the conserved
 residues and domains which are important for 
the regulation of
 cdc2 activity. This includes equivalent residues to human cdc2
 at Thr-14 
and  Tyr-15,  in  the  ATP-binding  domain,  and  Thr-161.  These  three  residues  are highly 
conserved both within the
 CDK  family and  between  species (Hassan et al., 2001). This 
implies that CRK3 activity
 may be controlled by similar post-translational mechanisms as
 
exist in other eukaryotes (through a regulating kinase,
 wee1 and phosphatase, cdc25). In 
addition to that there is the possibility of regulation through conserved threonine residue 
Thr-161 that is conserved in the trypanosomatid CRK3 at position Thr-178. 
Phosphorylation  of  the  conserved  threonine  residue  (T161  in human  CDK1  and  T160 
CDK2)  is  performed  by  a  separate  protein  kinase  known  as  the  CDK-activating  kinase 
(CAK).  In  mammalian  cells  the activating  kinase  is  another  c yclin  dependent  kinase, 
CDK7/CyclinH associated with a third protein called MAT-1 (Fisher et al., 1995). In yeast 
cells this activation is performed by a single protein kinase (CAK or Civ1) (Desai et al.,       67 
1995).  CAK  complex  phosphorylated  a  conserved  threonine  residue  to  activated  CDKs 
which play an important role in cell cycle control. 
The  16-amino  acid  "PSTAIRE"  sequence in  cyclin  dependent  kinases,  i s  a  conserved 
domain involved
 in the recognition and binding of the cyclin partner (Pines and Hunter, 
1989;Jeffrey  et  al.,  1995).  The
 corresponding  domain  in  the  leishmanial  CRK3  has  six 
substitutions in comparison with Human cdc2 homologue and
 is highly conserved in other 
trypanosome CRK3s. The
 presence of this domain in the leishmanial kinase suggests that
 
cyclin binding may play an important regulatory role. 
Cyclin genes have initially being identified from T. brucei based on biochemical and yeast 
complementation  assays (Affranchino  et  al.,  1993).  Two other  genes  CYC2  and  CYC 3 
were  also  described  based  on  f unctional  complementation  of  a  S.cerevisiae  G1  cyclin 
mutant (van Hellemond et al., 2000). Although the first described cyclin was later found to 
be a cyclin (Hammarton et al., 2000) more evidence and data were added about this family 
of protein in kinetoplastids (van Hellemond et al., 2000;Banerjee et al., 2003;Hammarton 
et al., 2003b;da Cunha et al., 2005) . 
CYCA from L. mexicana is a cyclin gene with no homologues in other trypanosomatids and 
as such, appears to be unique to Leishmania species genomes. In addition to that, CYCA 
from Leishmania is more similar to mitotic cyclins by sequence homology to any other 
known cyclin from vertebrates or yeast and it possesses all features of a mitotic cyclin. 
Mitotic  cyclins  like  cyclin  B,  are  the  key  regulatory  proteins  controlling  mitosis  in  all 
eukaryotes,  where  it  binds  cyc lin-dependent  kinase,  cdk1,  forming  a  complex  which 
initiates the mitotic program through phosphorylation of select proteins. It also regulates 
the activation, subcellular localization, and substrate specificity of cdk1 (Petri et al., 2007). 
Previous studies  have  shown that CRK3 encodes a 35.6kDa CRK with activity towards 
histone  H1  that  is  essential  for  the  progression  of  L.  mexicana cell  cycle (Grant et  al.,       68 
1998). It has also been shown to have 54% of sequence identity with the human cyclin 
dependent  kinase  CDK1  and  is  almost  identical  to other Leishmania  species  CRK3. T. 
brucei CRK3 and L. major CRK3 have 77.8% identity and therefore are highly conserved 
among these pathogenic organisms. Furthermore, CRK3 is a single copy gene, and mRNA 
levels are 5-fold higher in the replicative promastigote life cycle stage than in non-dividing 
metacyclic or mammalian amastigote forms (Grant et al., 1998;Hassan et al., 2001). 
The aim of the present chapter was to investigate the in vitro interaction of L. mexicana 
CRK3 and T. brucei CRK3 with L. mexicana CYCA, as well as the activati on of these 
cyclin:kinase complexes and their activity towards histone H1. Additionally, the role of the 
phosphorylation  at  the  Thr178 residue  in  CRK3  from L.  mexicana  and T.  brucei  was 
assessed using yeast Civ1. Finally, T. brucei Cks1 homologue (a cyclin dependent kinase 
accessory protein) was assessed for its role in the in vitro cyclin/kinase complex activity.  
3.2 Results 
3.2.1 Sequence alignments 
A sequence alignment for several trypanosomatid CRK3s, human CDK1 and yeast cdc2 
was performed using align X program from Invitrogen Vector NTI package (Figure 3.1). 
The alignment shows that this protein is highly  conserved between Leishmania species, 
with 99.5% identity and only one amino acid difference at position 7. It also show that 
between the trypanosome species (T. cruzi and T. brucei), the identity observed is 82.6% 
while  comparison  of  Leishmania  or  Trypanosome  CRK3  with  huma n  CDK1  or  S. 
cereviseae Cdc2 shows identity ranging from 52% to 54% at matching positions (Table 
3.1).  
A sequence alignment for several Leishmania CYCA homologues is shown in Figure 3.2. 
The sequence alignment shows that this protein is highly conserved between Leishmania       69 
species. The  sequences  from L. major, L. donovani, L. infantum and L. mexicana were 
used  in the  alignment. Only a few substitutions  are observed along the sequences. In a 
phylogenetic tree that compares the CYCA from L. major with mitotic cyclins as well as 
other cyclins it is shown that CYCA clusters with mitotic cyclins A and B suggesting that 
CYCA is probably a mitotic cyclin (Figure 3.3). 
The alignment for p12
CKS1 from different organisms can be observed in Figure 3.4. The 
trypanosomatid  p12
CKS1  proteins  are  well  conserved  a nd  share  a  poorly  conserved  N -
terminal extension not present in the human protein. The yeast protein possesses a 9 amino 
acid  insertion  in  the  core  of  the  protein  and  a  C -terminal  extension  not  present  in  the 
trypanosomatid and human orthologues (Figure 3.4). 
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                1                                                                                           105 
Human CDK1    (1) -------------------MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPN----IVSLQDVLMQDSRLYLIFEF 
Yeast Cdc2    (1) -------------------MENYQKVEKIGEGTYGVVYKARHKLSGRIVAMKKIRLEDESEGVPSTAIREISLLKEVNDENNRSNCVRLLDILHAESKLYLVFEF 
    TbCRK3    (1) MTMLGALTGRQLSSGLKDQFDRYNRMDILGEGTYGVVYRAVDRATGQIVALKKVRLDRTDEGIPQTALREVSILQEIHHPN----IVNLLDVICADGKLYLIFEY 
    TcCRK3    (1) MTTLTTLPSRPLSSNAREQFERYNRMDILGEGTYGVVYRAVDKITGQIVALKKVRLDRTEEGIPQTALREVSILQEIHHPN----VVNLLDVICTDGKLYLIFEY 
    LdCRK3    (1) MSSFGRATARSGDAGTRDSLDRYNRLDVLGEGTYGVVYRAVDKITGQYVALKKVRLDRTEEGIPQTALREVSILQEFDHPN----IVNLLDVICSDGKLYLVFEY 
    LiCRK3    (1) MSSFGRATARSGDAGTRDSLDRYNRLDVLGEGTYGVVYRAVDKITGQYVALKKVRLDRTEEGIPQTALREVSILQEFDHPN----IVNLLDVICSDGKLYLVFEY 
    LmCRK3    (1) MSSFGRVTARSGDAGTRDSLDRYNRLDVLGEGTYGVVYRAVDKITGQYVALKKVRLDRTEEGIPQTALREVSILQEFDHPN----IVNLLDVICSDGKLYLVFEY 
   LmeCRK3    (1) MSSFGRVTARSGDAGTRDSLDRYNRLDVLGEGTYGVVYRAVDKITGQYVALKKVRLDRTEEGIPQTALREVSILQEFDHPN----IVNLLDVICSDGKLYLVFEY 
                  106                                                                                                   210 
Human CDK1   (83) LSMDLKKYLDSIPPG--QYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPV 
Yeast Cdc2   (87) LDMDLKKYMDRISETGATSLDPRLVQKFTYQLVNGVNFCHSRRIIHRDLKPQNLLIDKEGNLKLADFGLARSFGVPLRNYTHEIVTLWYRAPEVLLGSRHYSTGV 
    TbCRK3  (102) VDHDLKKALEKRGGA----FTGTTLKKIIYQLLEGLSFCHRHRIVHRDLKPANILVTTDNSVKIADFGLARAFQIPMHTYTHEVVTLWYRAPEILLGEKHYTPAV 
    TcCRK3  (102) VDYDLKKAIEKRGCT----FTGVTLKKLVYQLLDGLFFCHRHRIVHRDLKPANILITSDNVLKLADFGLARTFQIPMHTYTHEVVTLWYRAPEILLGEKHYTPAV 
    LdCRK3  (102) VEADLKKAIEKQEGG----YSGMDLKRLIYQLLDGLYFCHRHRIIHRDLKPANILLTSGNVLKLADFGLARAFQVPMHTYTHEVVTLWYRAPEILLGEKHYTPAV 
    LiCRK3  (102) VEADLKKAIEKQEGG----YSGMDLKRLIYQLLDGLYFCHRHRIIHRDLKPANILLTSGNVLKLADFGLARAFQVPMHTYTHEVVTLWYRAPEILLGEKHYTPAV 
    LmCRK3  (102) VEADLKKAIEKQEGG----YSGMDLKRLIYQLLDGLYFCHRHRIIHRDLKPANILLTSGNVLKLADFGLARAFQVPMHTYTHEVVTLWYRAPEILLGEKHYTPAV 
   LmeCRK3  (102) VEADLKKAIEKQEGG----YSGMDLKRLIYQLLDGLYFCHRHRIIHRDLKPANILLTSGNVLKLADFGLARAFQVPMHTYTHEVVTLWYRAPEILLGEKHYTPAV 
                  211                                                                                                   315 
Human CDK1  (186) DIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEV--WPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFN 
Yeast Cdc2  (192) DIWSVGCIFAEMIRRSPLFPGDSEIDEIFKIFQVLGTPNEEV--WPGVTLLQDYKSTFPRWKRMDLHKVVPNGEEDAIELLSAMLVYDPAHRISAKRALQQNYLR 
    TbCRK3  (203) DMWSIGCIFAELARGKVLFRGDSEIGQLFEIFQVLGTPMDAEGSWLGVSSLPDYRDVFPKWSGKPLTQVLPALDGDAVDLLSQMLRYNPAERISAKAALQHPWFS 
    TcCRK3  (203) DIWSVGCIFAELARGKVIFRGDSEIGQLFEIFQILGTPMDNEGSWPGVSSLPDYRDVFPRWAGKPLAQVIPQLDSEAIDLLSRMLKYSPAERISAKEALQHSWFS 
    LdCRK3  (203) DMWSVGCIFAELARRKVLFRGDSEIGQLFEIFQVLGTPTDTEGSWPGVSRLPDYRDVFPKWTAKRLGQVLPELHPDAIDLLSKMLKYDPRERISAKEALQHPWFS 
    LiCRK3  (203) DMWSVGCIFAELARRKVLFRGDSEIGQLFEIFQVLGTPTDTEGSWPGVSRLPDYRDVFPKWTAKRLGQVLPELHPDAIDLLSKMLKYDPRERISAKEALQHPWFS 
    LmCRK3  (203) DMWSVGCIFAELTRRKVLFRGDSEIGQLFEIFQVLGTPTDTEGSWPGVSRLPDYRDVFPKWTAKRLGQVLPELHPDAIDLLSKMLKYDPRERISAKEALQHPWFS 
   LmeCRK3  (203) DMWSVGCIFAELARRKVLFRGDSEIGQLFEIFQVLGTPTDTEGSWPGVSRLPDYRDVFPKWTAKRLGQVLPELHPDAIDLLSKMLKYDPRERISAKEALQHPWFS 
                  316 
Human CDK1  (289) DLDNQIKKM 
Yeast Cdc2  (295) DFH------ 
    TbCRK3  (308) DAMF----- 
    TcCRK3  (308) EIRT----- 
    LdCRK3  (308) DLRW----- 
    LiCRK3  (308) DLRW----- 
    LmCRK3  (308) DLRW----- 
    LmeCRK3 (308) DLRW----- 
Figure 3.1 Sequence alignments of different species CDK1 homologues.  For this alignment human CDK1 from (NP_001777), yeast Cdc2 from S. pombe 
(NP_595629), LiCRK3 from L. infantum (XP_001469549), LmCRK3 from L. major (LmjF36.0550), LmeCRK3 (CAA04648) from L. mexicana, TbCRK3 from T. 
brucei (Tb10.70.2210) and TcCRK3 from T. cruzi (Tc00.1047053506583.40) were used. In the alignment the yellow colour represents amino acids residues that 
are conserved throughout all species, the blue colour represents amino acids residues that are conserved throughout most of the species analysed but not in 
all of them. These proteins have 38.6% identity among each other. Finally, the amino acid residues that are poorly conserved throughout all the species are 
represented in green. 71 
 
 
 
Table 3.1 Sequence identity between CRK3 from different species and human CDK1/yeast 
Cdc2. The comparison shows that LmCRK3 and LmeCRK3 are more similar to yeast Cdc2, 
with more than 50% sequence identity, than TbCRK3 and TcCRK3. However. TbCRK3 and 
TcCRK3 are closely related to human CDK1, with more than 49% sequence identity.  
 
  Human CDK1  Yeast Cdc2 
LmeCRK3  49.4%  50.2% 
LmCRK3  49.1%  50.2% 
TbCRK3  49.4%  47.3% 
TcCRK3  49.7%  48.6% 
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                 1                                               50 
 LmeCYCA     (1) MAVPLRMRILLSNQTNLVREPYQKPAAQPPTPLTNESRFVSEYGSEILTY 
   LdCYCA    (1) MAVPPRMRIPLSNQTNLVREPYQKPAAQPPTPLTNESRFVSEYGSEILTY 
   LiCYCA    (1) MAVPPRMRIPLSNQTNLVREPYQKPAAQPPTPLTNESRFVSEYGSEILTY 
   LmCYCA    (1) MAVPLRMRIPFSNQTNLVREPYHKPAAQPPTPLTNESRFVSEYGSEILTY 
                 51                                             100 
  LmeCYCA   (51) FLEVERVVYSERMYMSRQSEVTDRMRKILIDWLIDVVTEFKLHPETFFLA 
   LdCYCA   (51) FLEVERVVYSERMYMSRQSEVTDRMRKILIDWLIDVVTEFKLHPETFFLA 
   LiCYCA   (51) FLEVERVVYSERMYMSRQSEVTDRMRKILIDWLIDVVTEFKLHPETFFLA 
   LmCYCA   (51) FLEVERVVYSERMYIDRQSEVTDRMRKILIDWLVDVVTEFKLHPETFFLA 
                 101                                            150 
  LmeCYCA  (101) VDIIDRFLFFYSIPRTKLQLVGVTAILVAAKHEEIWPPTVNDCVAVTANT 
   LdCYCA  (101) VDIIDRFLFFYSIPRTKLQLVGVTAILVAAKHEEIWPPTVNDCVAVTANT 
   LiCYCA  (101) VDIIDRFLFFYSIPRTKLQLVGVTAILVAAKHEEIWPPTVNDCVAVTANT 
   LmCYCA  (101) VDIIDRFLFFYSIPRTKLQLVGVTAILVAAKHEEIWPPTVNDCVAVTANT 
                 151                                            200 
  LmeCYCA  (151) YTSREVIDMEFDVVTTLRFKFTVPTTYPITCRLLESCHMAPAVRHATFLF 
   LdCYCA  (151) YTSREVIDMEFDVVTTLRFKFTVPTTYPITCRLLESCHMAPAVRHATFLF 
   LiCYCA  (151) YTSREVIDMEFDVVTTLRFKFTVPTTYPITCRLLESCHMAPAVRHATFLF 
   LmCYCA  (151) YTSREVIDMEFDVVTTLRFKFTVPTTYPITCRLLESCHMAPAVCHATFLF 
                 201                                            250 
  LmeCYCA  (201) LESAAHCYPLLQFLPSRIAAGAVLLGAFLIRYNRSKGVISLQGLWEIEVS 
   LdCYCA  (201) LESAAHCYPLLQFLPSRIAAGAVLLGAFLIHYNRSKGVISLQGLWEIEVS 
   LiCYCA  (201) LESAAHCYPLLQFLPSRIAAGAVLLGAFLIRYNRSKGVISLQGLWEIEVS 
   LmCYCA  (201) LESAAHCYPLLQFLPSRIAAGAVLLGAFLIRYNRSKGAISLQGLWEIEVS 
                 251                                            300 
  LmeCYCA  (251) PFAQGIGFEELQPVTEQLLPFTQRLCSGSSRLQAVRRKYSSSEYDCVASL 
   LdCYCA  (251) PFAQGIGFEELQPVTEQLLPFTQRLCSGSSRLQAVRRKYSSSEYDCVASL 
   LiCYCA  (251) PFAQGIGFEELQPVTEQLLPFTQRLCSGSSRLQAVRRKYSSSEYDCVASL 
   LmCYCA  (251) PFAQGIGFDELQPVTEQLLPFTQRLCSGSSRLQAVRRKYSSSEYDCVASL 
                 301     311 
  LmeCYCA  (301) EFPFISTSA-- 
   LdCYCA  (301) EFPFISASA-- 
   LiCYCA  (301) EFPFISASA-- 
   LmCYCA  (301) EFPFISTSA-- 
 
 
Figure 3.2 Sequence alignment of CYCA from different Leishmania species. LmeCYCA from 
L. mexicana (CAD20131), LdCYCA from L. donovani (AAM95631), LiCYCA from L. infantum 
(XP_001466184), LmCYCA from L. major (CAJ05300). In the alignment, the yellow colour 
represents amino acids residues that are conserved throughout all species, the blue colour 
represents  amino  acids  residues  that  are  conserved  throughout  most  of  the  species 
analysed but not in all of them. Finally, the amino acid residues that are poorly conserved 
throughout all the species are represented in green. 
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LmCYCA (0.3449)
Human Cyclin A1 (0.2701)
Human Cyclin A2 (0.2775)
Human Cyclin B1 (0.2554)
Human Cyclin B2 (0.2585)
Human Cyclin C (0.3867)
Human Cyclin H (0.4009)
Human Cyclin D1 (0.3963)
Human Cyclin E1 (0.2685)
Human Cyclin E2 (0.2628)  
Figure 3.3 A phylogenetic tree of different cyclins. Human Cyclins A1, A2, B1, B2, C, D1, E1, 
E2  and  H  were  used  to  be  compared  with  L.  major  CYCA.  Sequences  from  gene  bank 
accession numbers are NM_057749 for human cyclin E2, NM_001238 for human cyclin E1, 
NM_004701 for human cyclin B2, NM_031966 for human cyclin B1, NM_001237 for human 
cyclin A2, NM_003914 for human cyclin A1, NM_053056 for human cyclin D1, NM_005190 for 
human cyclin C, NM_001239 for human cyclin H and LmjF25.1470 for L. major CYCA. 
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                  1                                               50 
    TbCKS1    (1) ---MSGRDYFSITDPVQREQARMMISKLQSKILYSDKYYDDEYEYRHVIL 
    LmCKS1    (1) MPAKPAQDFFSLDANGQRE-ALIIIKKLQCKILYSDKYYDDVFEYRHVIL 
Human CKS1    (1) --------------------------MAHKQIYYSDKYFDEHYEYRHVML 
 YeastCKS1    (1) ----MYHHYHAFQGRKLTDQERARVLEFQDSIHYSPRYSDDNYEYRHVML 
 Consensus    (1)      A DYFSI A  QREQARIII KLQ KILYSDKYYDD YEYRHVIL 
                  51                                             100 
    TbCKS1   (48) PKDFSRLVP---------RGRLMEESEWRQLGVQQSVGWRHYMLHAPEPH 
    LmCKS1   (50) PKDLARLVP---------TSRLMSEMEWRQLGVQQSQGWVHYMIHKPEPH 
Human CKS1   (25) PRELSKQVP---------KTHLMSEEEWRRLGVQQSLGWVHYMIHEPEPH 
 YeastCKS1   (47) PKAMLKVIPSDYFNSEVGTLRILTEDEWRGLGITQSLGWEHYECHAPEPH 
 Consensus   (51) PKDLSKLVP         TSRLMSEDEWRQLGVQQSLGWVHYMIHAPEPH 
                  101                                            150 
    TbCKS1   (89) VLLFKRPKTQ---------------------------------------- 
    LmCKS1   (91) VLLFKRPRT----------------------------------------- 
Human CKS1   (66) ILLFRRPLPKDQQK------------------------------------ 
 YeastCKS1   (97) ILLFKRPLNYEAELRAATAAAQQQQQQQQQQQQQQQQHQTQSISNDMQVP 
 Consensus  (101) ILLFKRPLT D                                        
                  151 
    TbCKS1   (99) ---- 
    LmCKS1  (100) ---- 
Human CKS1   (80) ---- 
 YeastCKS1  (147) PQIS 
 Consensus  (151)      
 
Figure  3.4  Sequence  alignments  of  different  species  CKS1  homologues.    For  this 
alignments  human  CKS1  from  (NP_001818),  yeast  CKS1  from  S.  cerevisiae  (YBR135W), 
LmCKS1 from L. major (LmjF32.3790) and TbCKS1 from T. brucei (Tb11.01.8085) were used. 
In the alignment, the yellow colour represents the amino acids residues that are conserved 
throughout all species, the blue colour represents amino acids residues that are conserved 
throughout most of the species analysed but not in all of them. Finally, the amino acid 
residues that are poorly conserved throughout all the species are represented in green. 
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3.2.2 Purification of recombinant LmeCRK3his 
E. coli BL21 DE3 pLYS was transformed with  pGL751 (Grant, et al 1998)  in order to 
express LmeCRK3his. This pET28a+ plasmid yielded a high level of expression of soluble 
LmeCRK3his  (Figure  3.5).  The  cell  culture  was  then  used  to  p urify  the  LmeCRK3his 
using Ni-NTA agarose metal chelate affinity chromatography (as described in methods). 
The  result  from  this  purification  was  analyzed  (Figure  3.5).  Some  LmeCRK3his  was 
detected in the insoluble fraction (lane 1), however, when the soluble fraction was analysed 
most  of  the  expressed  LmeCRK3his  was  detected  as  a  35  kDa  pr otein  (lane  2).  This 
soluble fraction was loaded onto the affinity column and the flow through (FT) fraction 
was  analysed  (Lane  3).  The  aff inity  column  did  not  remove  al l  of  the  soluble 
LmeCRK3his,  as  some  LmeCRK3his  was detected  in  the  FT.  After  the column  was 
washed with sonication buffer containing 20mM imidazole, the bound protein was eluted 
with 0.5M imidazole, a highly concentrated and relatively contamination free sample of 
LmeCRK3his was obtained. A western blot using anti-histidine antibody was performed to 
confirm  that  the  purified  protein  was  indeed  LmeCRK3his.  A  p rotein  around  35kDa, 
corresponding  to  the  LmeCRK3hi s  was  detected  (lanes  5 -8).  The  eluted  fractions 
containing purified LmeCRK3his were usually more than 2mg/ml and around 20mg of this 
protein could be obtained from 1L of cell culture. 
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Figure 3.5 L. mexicana CRK3his purification and western blot. E. coli BL-21 DE3 pLYS cells 
were used to induce the expression of LmeCRK3his from pGL751. The purification of the 
IPTG induced culture was carried out and samples were analyzed on an SDS-PAGE gel 
stained  with  Coomassie  Blue  (Lanes  1-4)  and  analysed  by  western  blot  (Lanes  5-8). 
Sonicated  cell  suspension  was  centrifuged  at  20.000  g,  pellets  were  resuspended  and 
analysed as the insoluble fraction (lane1 and 5). The total supernatant was analysed in lane 
2  and  6  and  was  used  in  the  purification,  where  it  was  incubated  with  the  Ni-Agarose 
column. The flow through of this incubation was analysed in lanes 3 and 7. Finally, the 
Elution of the column can be observed in lanes 4 and 8. Lanes 5-8 correspond to western 
blot carried out with mouse α-his antibody diluted 1:5,000 as primary antibody and α-mouse 
HRP conjugated antibody as secondary, diluted 1:5,000. A protein around 35kDa (arrowed) 
can be observed in the Coomassie and in the western blot, this protein corresponds to 
LmeCRK3his. 
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3.2.3 Purification of recombinant LmeCYCAhis 
Plasmid pGL630 (Ali, 2002) is based on the pET21a+ vector that adds a 6 histidine tail to 
the C-terminal end of the protein and allows purification using Qiagen Ni-NTA agarose 
beads.  This  vector  was  used  to   express  and  purify  recombinant  CYCA  (Fi gure  3.6). 
However, in contrast to LmeCRK3his, LmeCYCAhis from pGL630 did not give a high 
level of expression. On Coomassie staining of a SDS-PAGE gel a protein around 34kDa 
was detected weakly in the elution fraction (lane 4). Confirmation that the 34kDa protein 
was LmeCYCAhis was achieved by western blot (Figure 3.6) using α-his antibody (lanes 
5-8).  Purified  LmeCYCAhis  was  used  to  test  if  recombinant  LmeC RK3his  could  be 
activated. In the best preparations, purified LmeCYCAhis samples could provide a total 
protein  concentration  of  0.2  mg/ml  giving  around  0.2  mg  from   1L  of E.  coli  culture. 
However,  the  same  yield  was  no t  reproducible  and  pGL630  show ed  a  much  lower 
expression levels in subsequent preparations. The elution of soluble LmeCYCAhis from 
the  columns  yielded  amounts  of   protein  that  were  not  always detectable  in  Coomasie 
stained gels; instead, silver stained procedures had to be implemented to actually visualise 
the presence of CYCA in the gel. A western blot using α-his antibody was again used to 
confirm the presence of LmeCYCAhis. In addition to the decreased levels of expression of 
CYCA, much higher levels of contaminating proteins were also observed. 
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Figure 3.6 LmeCYCAhis purification and western blot. E. coli BL-21 DE3 pLYS cells were 
used to induce the expression of LmeCYCAhis from pGL630. The purification of the IPTG 
induced culture was carried out and analyzed on SDS-PAGE gel stained with Coomassie 
Blue  (Lanes  1-4)  and  identification  analysed  by  western  blot  (Lanes  5-8).  The  same 
procedure used to purify LmeCRK3 was used. Sonicated cell suspension was centrifuged at 
20.000 g, pellets were resuspended and analysed as the insoluble fraction (lane1 and 5). The 
total supernatant was analysed in lane 2 and 6 and was used in the purification where it was 
incubated with the Ni-Agarose column. The flow through of this incubation was analysed in 
lanes 3 and 7. Finally, the Elution of the column can be observed in lanes 4 and 8. Lanes 5-8 
correspond to western blot carried out with mouse α-his antibody diluted 1:5,000 as primary 
antibody and α-mouse HPR conjugated antibody as secondary, diluted 1:5,000. A protein 
(arrowed) around 35kDa is identified in the Coomassie and in the western corresponding to 
LmeCYCAhis. 
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3.2.4 Expression of recombinant LmeCRK3: 
LmeCRK3 was inserted into pET21a to generate pGL1072 (see methods), a plasmid used 
to transform BL21 DE3 pLys and to express a non tagged LmeCRK3. The soluble fraction 
of  induced E.  coli  culture  was  used  in  binding  a ssays  using  LmeCYCAhis.  Cells  were 
grown  to  an  O.D.  of  0.7  and  in duced  over  night  at  19
OC  with  2mM  IPTG.  A  soluble 
fraction containing untagged CRK3 was obtained as described for LmeCRK3his (Figure 
3.7, lane 2). 
 
 
 
 
 
 
 
Figure 3.7 (A) A map of plasmid, pGL1072, which is a pET21a derived vector that expresses 
a non-tagged version of L. mexicana CRK3. (B) A Coomassie gel. Lane 1; protein markers 
lane 2; the expressed E. coli soluble lysate obtained after sonication and centrifugation at 
20.000g for 20min. The arrow shows LmeCRK3. 
 
 
 
(A) 
 
(B) 
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3.2.5 Purification of recombinant LmeCRK3his
T178E. 
LmeCRK3his
T178E  is  a  mutant  CRK3  from L.  mexicana  derived  from  pGL751.  It  was 
developed  by  site  direct  mutag enesis  (Ali,  2002)  and  the  thr eonine  178  residue  was 
replaced by a glutamic acid. The plasmid containing the mutated CRK3 gene was named 
pGL1071 and was used to express and purify LmeCRK3his
T178E (Figure 3.8). As it was 
derived from pGL751, the levels of expression and purity of LmeCRK3
T178Ehis, as well as 
the  obtained  protein  concentration,  were  very  similar  to that observed  in  the  wild  type 
LmeCRK3his (Figure 3.8). 
3.2.6 Purification of recombinant Yeast Civ1protein 
A plasmid containing the Saccharomyces cerevisiae Civ1 gene (Brown et al., 1999) was 
obtained from the Endicott group (Oxford University, Biochemistry Department) and was 
named pGL716. This plasmid expresses a Civ1-GST fusion from pGEX-5X1. Conditions 
for the expression and purification are described in methods. In BL21 DE3 pLYS, pGL716 
provided low levels of expression of the Civ1-GST fusion protein (Figure 3.9). This 66 
kDa protein was detected by SDS-PAGE gel stained with Coomassie blue and by western 
blot with α-GST antibody (Figure 3.9). Although low levels of expression were obtained, 
the  sample  was  relatively  free  of  contaminants  and  contained  a  highly  active  protein 
kinase.  The  combined  eluted  fr actions  containing  purified  Civ1  were  usually  around 
0.5mg/ml.  
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Figure  3.8  Purification  and  western  blot  of  L.  mexicana  LmeCRK3
T178Ehis.  The  same 
procedures used to purify LmeCRK3his were used for LmeCRK3
T178Ehis. The purification of 
the induced protein was carried out and analyzed on SDS-PAGE gel stained with Coomassie 
Blue (Lanes 1-3). Lane 1: Insoluble fraction. Lane 2: Soluble fraction. Lane 3: Elution. Lanes 
4-6 correspond to Western blot of the same samples carried out with α-his antibody. A 
protein  (arrowed)  around  35kDa  corresponding  to  the  mutated  LmeCRK3his  can  be 
observed both in the Coomassie and in the western blot. 
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Figure 3.9 Yeast Civ1-GST fusion purification and western blot. E. coli BL-21 DE3 pLYS cells 
were used to induce the expression of yeast Civ1-GST from pGL716. The purification of the 
IPTG  induced  culture  was  carried  out  and  analyzed  on  SDS-PAGE  gel  stained  with 
Coomassie  Blue  (Lanes  1-4)  and  samples  were  analysed  by  western  blot  (Lanes  5-8). 
Sonicated  cell  suspension  was  centrifuged  at  20.000  g,  pellets  were  resuspended  and 
analysed as the insoluble fraction (lane1 and 5). The total supernatant was analysed in lane 
2 and 6 and was used in the purification where it was incubated with the Sepharose 4B 
(Pharmacia) column. The flow through of this incubation was analysed in lanes 3 and 7. 
Finally, the Elution of the column can be observed in lanes 4 and 8. Lanes 5-8 correspond to 
Western  blot  carried  out  with  Sigma  rabbit  α-GST  antibody  diluted  1:2.000  as  primary 
antibody and α-rabbit HPR conjugated antibody as secondary, diluted 1:5.000. A protein 
(arrowed) around 66kDa can be observed in the Comassie and in the western blot, this 
protein correspond to Civ1-GST. 
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3.2.7 Purification of recombinant Tbp12
CKS1 
The  gene  coding  for  a T.  brucei  12  kDa  protein  corresponding to  the  yeast  CKS1 
homologue was cloned in pET15b expression vector generating pGL976. This construct 
provided high levels of expression of soluble histidine tagged Tbp12
CKS1 that could be used 
in kinase assays. A protein of 14 kDa corresponding to the Tbp12
CKS1his was observed in 
the elution fraction indicating its purification (lane 1, Figure 3.10). The western blot with 
α-histidine antibody  confirmed the presence of the purified Tbp12
CKS1his, as previously 
seen on the Coomassie stained gel. Combined eluted fractions containing this protein were 
normally  around  0.1  mg/ml  of  total  protein  concentration  and  around  0.1  mg  could  be 
isolated from 1L of cell culture. 
3.2.8 Purification of recombinant TbCRK3his:  
The T.  brucei  EATRO  795 homologue  of  LmeCRK3  was  cloned from  genomic  DNA, 
sequenced  for  confirmation  and  subcloned  in  the  expression  vector  pET15b,  generating 
pGL1036. For T. brucei CRK3his purification, BL21 DE3 E. coli cells were transformed 
with plasmid pGL1074 and grown to 0.6 O.D. at 37
oC and induced for protein expression 
at 19
oC over night using 2.5mM IPTG. A high level of expression was observed for the T. 
brucei CRK3. A protein around 35 kDa was detected in the elution fraction (Figure 3.11, 
lane 4) using Coomassie stained SDS-PAGE gels. Confirmation that this was TbCRK3his 
was achieved by western blot (Figure 3.11, lanes 5-8) using α-his antibody. The protein 
was detected also in the insoluble, soluble and in the flow through samples (lanes 5-7), but 
mainly  in  the  elution  sample  (lane  8).  Elutions  containing  purified  CRK3  were  usually 
more than 2mg/ml of total protein concentration. Around 20mg of this protein could be 
obtained from 1L of cell culture. 
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Figure  3.10  T.  brucei  p12
CKS1his  purification  and  western  blot.  T.  brucei  p12
CKS1his  was 
purified  from  E.  coli  BL21  DE3pLYS  containing  pGL976  using  the  same  procedure  as 
LmeCRK3his. Western blot using α-his antibody confirmed the size of the purified protein. 
Lane 1: Coomassie staining of eluted fraction. Lane 2: Western blot of the eluted fraction. A 
12kDa protein (arrowed) corresponding to purified Tbp12
CKS1his can be observed in both the 
Coomassie stained gel and the western blot. 
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Figure 3.11 Purification and western blot of TbCRK3his. T. brucei CRK3his was expressed 
and purified from E. coli BL21 DE3 pLys using pGL1074. The purification of the induced 
culture was carried out using the same procedure used for LmeCRK3his and analyzed on 
SDS-PAGE gel stained with Coomassie Blue (Lanes 1-4) and by western blot (Lanes 5-8). 
Lane 1: Insoluble fraction. Lane 2: Soluble fraction. Lane 3: Flow Through. Lane 4: Elution. 
Lanes 5-8 correspond to western blot of the same samples carried out with α-his antibody. 
A protein (arrowed) corresponding to TbCRK3his can be observed in the Coomassie and in 
the western blot around 35kDa. 
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3.2.9 In vitro interaction of LmeCYCAhis with LmeCRK3his 
To  assess  if CRK3  and  CYCA  could  interact, a  binding  assay  was  designed. Purified 
LmeCYCAhis bound to the affinity column was used to bind and co-purify a non tagged 
LmeCRK3  present  in  a  total E.  coli  cell  lysate.  LmeCRK3  was  foun d  to  bind 
LmeCYCAhis immobilized onto the Ni-NTA beads and was co-eluted from the column 
(Figure 3.12). The binding of LmeCYCAhis to LmeCRK3 was assessed by detection of 
LmeCRK3 using a polyclonal rabbit antibody against CRK3 (Grant et al., 1998). As shown 
in Figure 3.12, LmeCRK3 was detected when LmeCYCAhis was present in the column, 
whereas  no  LmeCRK3  bound  to  th e  column  in  the  absence  of  Lme CYCAhis.  This 
experiment demonstrates that these two proteins have affinity for each other and bind to 
form a cyclin kinase complex (Figure 3.12). 
3.2.10 Activation of LmeCRK3/LmeCYCA kinase complex 
Following the results that showed that CRK3 interacts with CYCA the next step was to test 
if CYCA would indeed activate CRK3 to provide an active kinase complex. In a previous 
study, in vivo purified CRK3 was show to have kinase activity towards histone H1 (Grant 
et al., 1998), however the identity of the cyclin partner remained to be determined. Early 
experiments  showed  that  recombinant  monomeric  LmeCRK3  had  no  activity  towards 
histone  H1,  suggesting  that  a cyclin  was  needed  to  activate  th e  CRK3  kinase  from 
Leishmania.  The L.  mexicana  CRK3his  and  CYCAhis  purified proteins  were  tested  for 
kinase activity in an in vitro kinase assay using histone H1 as a substrate. LmeCRK3his 
was  shown  to  exhibit  kinase  ac tivity  dependent  on  the  presence  of  the  LmeCYCAhis 
(Figure 3.13). LmeCRK3his was activated with LmeCYCAhis, as more kinase activity was 
observed when more LmeCYCAhis was added to a fixed quantity of LmeCRK3his (lanes 
2 to 7, Figure 3.13). No kinase activity was observed in the absence of LmeCYCAhis (lane       87 
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1) or in the absence of LmeCRK3his (lane 8). Maximum activity was observed in lane 7, 
where an approximate 1:1 molar ratio was used. 
 
 
 
 
 
 
 
 
 
Figure  3.12  LmeCRK3/LmeCYCAhis  binding  assay.  An  affinity  purification  column  was 
made  using  Ni-agarose  beads  with  bacterially  expressed  L.  mexicana  CYCAhis. 
LmeCYCAhis  was  bound  to  the  Ni-agarose  column.  This  column  was  used  to  bind 
bacterially expressed non-his tagged CRK3 from a soluble E. coli lysate. After extensive 
washing, the elution fraction was tested for the presence of CRK3 by western blot with α-
CRK3 antibody. The negative control consisted of Ni-agarose column without LmeCYCAhis 
bound  which  was  subjected  to  the  same  procedure  of  incubation  to  an  E.  coli  lyasate 
containing LmeCRK3.        88 
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Figure  3.13  Activation  of  CRK3:CYCA  complex.  Phosphorylation  of  histone  H1  by  L. 
mexicana  CRK3:CYCA  complex  was  performed  by  mixing  increasing  quantities  of 
LmeCYCAhis (0.5µg on lane 2 to 3µg on lane 8) to a fixed amount of CRK3his (4µg) in an in 
vitro kinase assay buffer containing 5µg of histone H1 as substrate and γ-ATP labelled with 
P
32. The reaction was incubated at 30
oC for 30 min. The reactions were then stopped by 
adding 2X protein loading Buffer. The samples were then loaded in a 12% SDS-PAGE gel, 
stained with Coomassie, dried and exposed to a 
32P particle emission sensitive film.  The gel 
was exposed over night to a general purpose Kodak film.        89 
3.2.11 Kinase assay using the mutant LmeCRK3
T178Ehis  
Following the results showing that CRK3 is able to form a complex with CYCA and that 
the complex is active in an in vitro system, it was possible to use this system to study the 
role  of  the  residue  T178.  This  residue  has  been  shown  to  be important  for  the  kinase 
activity of cyclin dependent kinases in other organisms. Phosphorylation at the threonine 
residue by a CDK activating kinase increases protein kinase activity of the human CDK2 
up to 300 fold (Russo et al., 1996).  
Previous results (Ali, 2002), have shown that a substitution at the Thr178 (replacing this 
threonine for a negatively charged glutamic acid amino acid) does not make monomeric 
CRK3  active.  This  was  attempte d  following  the  suggestions  th at  substitution  of  the 
threonine  residue  for  a  negati vely  charged  glutamic  acid  was   able  to  mimic  the 
phosphorylation (Levin and Zoller, 1990) resulting in an active kinase. From these results 
it was suggested that monomeric CRK3 lacks kinase activity even if it is phosphorylated 
and that a cyclin partner is essential for activating the kinase. However, it was also possible 
that  the  phosphorylation  does not  have  a  physiological  role in  the  protein  or  that  the 
substitution itself resulted in an inactive kinase.  
The in vitro kinase assay developed for CRK3 and CYCA made it possible to assess the 
mutated CRK3 in complex with CYCA, as it is known that activation of the CDKs requires 
both phosphorylation at the Thr178 and binding of the cyclin (Brown et al., 1999). The 
results presented here show that LmeCYCAhis is not able to activate LmeCRK3
T178Ehis, 
while  it  can  activate  LmeCRK3h is  (Figure  3.14).  This  suggests  that  the  mutatio n 
completely abolished the kinase activity. Initially, it was thought that the substitution of the 
threonine  residue  for  a glutamic  acid  would  possibly  m imic  the  negative  charge  of  a 
phosphorylated  protein  and  therefore  fully  activates  the  kinase.  However,  this  was  not 
confirmed in the present study, the substitution of the Thr178 did not further activate the       90 
kinase;  instead  it  caused  tota l  loss  of  activity  (Figure  3.1 4).  Increasing  amounts  of 
LmeCYCAhis  were  used  to  activa te  wild  type  LmeCRK3his  and  Lm eCRK3
T178Ehis 
(Figure 3.14, lanes 1-4). While increasing kinase activity was observed for LmeCRK3his, 
no activity was detected with LmeCRK3
T178Ehis. A fully activated LmeCRK3his and an 
inactive kinase corresponding to LmeCRK3
T178Ehis are shown in Figure 3.14. In addition, 
it  can  also  be  observed  that  L meCRK3
T178Ehis  appears  to  have  a  higher 
autophosphorylation activity than LmeCRK3his (Figure 3.16 lanes 5-8). 
3.2.12  Phosphorylation  of  LmeC RK3his  by  S.  cerevisiae  Civ1 in 
vitro 
To test if phosphorylation on the threonine residue of LmeCRK3his by CDK activating 
kinase would further activate the complex, the S. cerevisiae Civ1-GST was purified from 
E. coli as described above.. The yeast Civ1-GST was able to phosphorylate LmeCRK3his, 
but  not  LmeCRK3
T178Ehis  (Figure  3.14A).  These  data  show  that  Thr178  is  t he  site  of 
phosphorylation for yeast Civ1-GST. Furthermore, increasing amounts of Civ1 promoted 
an increase in the amount of phosphorylated LmeCRK3his (Figure 3.15, lanes 2-6), while 
controls  with  no  Civ1 -GST  (lane1)  or  no  Lme CRK3his  (lane  7)  showed  no 
phosphorylation. 
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Figure 3.14 LmeCRK3
T178Ehis kinase assay. Panel A, histone H1 kinase activity was assayed 
using the same procedure described in Figure 3.13. In lane 1 wild type LmeCRK3his was 
activated with LmeCYCAhis to phosphorylate histone H1. In lane 2 LmeCRK3
T178Ehis in the 
presence of LmeCYCA shows no kinase activity. Panel B, increasing amounts of CYCA are 
used to activate LmeCRK3his and LmeCRK3
T178Ehis. CYCA was added at 0.5µg, 1µg, 1.5µg 
and  2µg.  LmCRK3his  and  LmCRK3
T178Ehis  were  constant  at  3µg  in  all  reactions.       92 
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Figure 3.15 Phosphorylation of LmCRK3his by Civ1. LmeCRK3his was used as a substrate 
for yeast S. cerevisiae Civ1. Lane 1 has no Civ1 and 2µg of CRK3. Lane 2 to lane 6 has 
increasing amounts of Civ1 from 0.5µg in lane 2 to 2.5µg in lane 6. Lane 7 has no CRK3 and 
2.5µg of Civ1. On lane 8, 3µg of LmeCRK3
T178Ehis were added.       93 
3.2.13 Activation of LmeCRK3his by Civ1-GST 
In  order  to  assess  whether  the   phosphorylation  of  Thr178  in LmeCRK3his  increased 
histone H1 kinase activity several experiments were performed. In the first assay (Figure 
3.16), LmeCYCAhis and LmeCRK3his were added to two separated sets of reactions. In 
the first group of reactions (+Civ1), Civ1 was also added, so that LmeCRK3his could be 
phosphorylated.  In  the  second set  (-Civ1),  no  Civ1  was  present  and   there  was  no 
phosphorylation of LmeCRK3his Thr178. The presence of a phosphorylated LmeCRK3 
slightly  increased the kinase activity (Figure 3.17). The difference  in the activity of the 
phosphorylated  LmeCRK3his  and the  non-phosphorylated  LmeCRK3his  was quantified 
using  the  Pharmacia  Typhoon  sc anner.  Phosphorylated  LmeCRK3his  had  its  activity 
increased by 5 times (Figure 3.18). 
3.2.14 RINGO kinase activation assay 
In  order  to  evaluate the  specificity  of  the  activation  of  LmeCRK3  by  LmeCYCA,  the 
ability of RINGO (rapid inducer of G2/M progression in oocytes) to activate LmeCRK3his 
and LmeCRK3
T178Ehis was tested. RINGO is a protein from Xenopus and a potent Cdc2 
and Cdk2 kinase activator (Karaiskou et al., 2001) that is not related to the cyclin family 
and does not require threonine residue phosphorylation  for full  activation of the kinase. 
RINGO  was  not  able  to  activate   LmeCRK3his  or LmeCRK3
T178Ehis,  while  it  fully 
activated a Plasmodium falciparum cell cycle related protein PfPK5 (Merckx et al., 2003) 
(Figure 3.19). 
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Figure 3.16 Thr178 phosphorylation effect. The procedure for kinase assay was the same as 
previously  described.  In  order  to  assess  the  role  of  phosphorylation  of  Thr178  on  the 
activity of CRK3 a time scale was used where the reactions were blocked by adding protein 
loading buffer after 5 minutes (lanes 1 and 6), 10 minutes (2 and 7), 15 minutes (3 and 8), 20 
minutes (4 and 9) and 25 minutes (lanes 5 and 10). LmeCYCAhis (2µg), LmCRK3his (2µg) 
and Civ1-GST (2µg) were present in constant amounts for all reactions.        95 
 
 
 
 
 
 
 
Figure 3.17 T178 phosphorylation effect. A kinase assay using TbCRK3his and LmeCYCAhis 
was performed to assess the Thr178 phosphorylation effect on the T. brucei protein. The 
kinase assays reactions are as described previously. In lane 1 no Civ1 or LmeCYCA was 
added and histone H1 was not phosphorylated. From lane 2 to 5 increasing amounts of Civ1 
was added to the assay, 0.5µg to 2µg, with constant quantity of TbCRK3his/LmeCYCAhis 
(2µg). TbCRK3 more intensely phosphorylated in lane 5 and TbCRK3his has its peak activity 
phosphorylating histone H1. In lane 6 no Civ1 was added and although the histone H1 was 
phosphorylated, it was less intense than in lane 5, demonstrating the stimulatory effect 
produced by the activation phosphorylation on Thr178 by Civ1. In lane 8 LmeCYCAhis was 
not present  and  Civ1  was  still  capable of phosphorylating TbCRK3his.  As  observed  for 
LmeCRK3his, TbCRK3his can be phosphorylated in the absence of a cyclin.   
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Figure 3.18 The chart shows the difference in kinase activity obtained with the LmeCRK3his 
combined with LmeCYCAhis in the presence or absence of Civ1-GST. Kinase assays that 
compared  the  activity  of  LmeCRK3his  phosphorylated  by  Civ1-GST  with  that  of  the 
unphosphorylated were analysed with the typhoon phosphoimager (Pharmacia). The band 
intensities were quantified by the instrument and the mean values were plotted in a bar 
chart. The error bars represent the standard deviation of the mean.       97 
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Figure 3.19 RINGO kinase assay. Three proteins (PfPK5, LmeCRK3
T178Ehis and LmeCRK3his) 
were tested for activation by RINGO protein using as substrate histone H1. PfPK5 was used 
as a positive control since it is known to be activated by RINGO. Conditions used were the 
same used for the previous assays. RINGO was added at 0.5µg per reaction, PfPK5 at 0.5µg, 
LmeCRK3his and LmeCRK3
T178Ehis at 2µg. For each of these proteins two reactions were 
made, with (+) or without (-) RINGO.  
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3.3.15 p12
CKS1 kinase assays 
Most cyclin dependent kinases form a tight complex with a small protein known as CKS1. 
Although its function is not fully understood, it is believed to modulate the kinase substrate 
affinity  (Harper,  2001).  Purified  Tbp12
CKS1his  (CKS1  homologue)  from T.  brucei  was 
assessed  for  its  effect  on  Lme CRK3his/LmeCYCAhis  and  TbCRK3his/LmeCYCAhis 
kinase activity towards histone H1. Tbp12
CKS1his had an  inhibitory effect on the kinase 
activity of both LmeCRK3his and TbCRK3his kinases (Figures 3.20 and 3.21).  
3.2.16 inhibition of LmeCRK3his/CYCAhis 
L.  mexicana CRK3  purified  from  the  parasite  has  been  shown  to  have  kinas e  activity 
towards histone H1 (Grant et al., 1998). Although it is not known which cyclin activates 
CRK3 in vivo or the Thr178 phosphorylation status, the IC50 of the in vivo purified CRK3 
(Grant  et  al. ,  2004)  could  b e  compared  to  the  recombinant purified 
LmeCRK3his/LmeCYCAhis.  Indirubin-3′-monoxime  (Indirubin)  (Hoessel  et  al.,  1999) 
and Flavopiridol (Losiewicz et al., 1994) are two well-studied CDK inhibitors (Grant et 
al., 2004). IC50 values for the in vitro complex were similar to those found for the in vivo 
purified CRK3. The concentrations of the compounds used are shown in Table 3.2. The 
effect of Indirubin and Flavopiridol inhibition can be seen in Figures 3.22 and 3.23. The 
intensity of the bands were quantified and compared to compound concentration in a Mini 
Tab plotted graph (Figures 3.24 and 3.25) based on values of  band  intensities given  by 
Typhoon 860 phosphoimager. IC50 values were found to be 25 nM for Flavopiridol and 33 
nM for Indirubin. 
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Figure 3.20 p12
CKS1 assay. p12
CKS1 protein was assessed for its effect on the kinase activity 
of the CYCA/CRK3 complex: lane 1, no LmeCYCAhis. All lanes contain 2µg of LmeCRK3his 
and LmeCYCAhis. p12
CKS1 was added in increasing amounts (0.5, 1, 1.5 and 2µg) from lane 3 
to lane 6 and kinase activity towards histone H1 was assessed.       100 
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Figure 3.21 p12
CKS1 assay. In lane 1 no LmeCYCAhis was added. All lanes contained 2µg of 
TbCRK3his. From lane 2 to lane 5 LmeCYCAhis was present in increasing amounts. The 
same amount (2µg) of LmeCYCAhis and TbCRK3his were added in lanes 5-8. From lane 5 
until  lane  8  p12
CKS1  was  added  in  increasing  amounts  in  the  same  way  as  used  for 
LmeCRK3his.       101 
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Figure 3.22 Flavopiridol kinase inhibitor activities over LmeCRK3his/LmeCYCAhis complex.  
Flavopiridol decreased the kinase activity and less phosphorylation of substrate histone H1 
was achieved. Flavopiridol concentration increases from lanes 1 to 13. As a result a less 
intense band was observed. The quantities of the inhibitor added are shown in Table 3.2. 
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Figure  3.23  Indirubin  kinase  inhibitor  activity  over  LmeCRK3his/LmeCYCAhis  complex.  
Indirubin decreased the kinase activity and less phosphorylation of substrate histone H1 
was  achieved.  Indirubin  concentration  increases  from  lanes  1  to  13.  As  a  result  a  less 
intense band was observed. The quantities of the inhibitor added are shown in Table 3.2.       103 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24 Flavopiridol IC
50 inhibition assay graphic. The gels from the inhibition assays 
were  analysed  in  the  Typhoon  scanner  and  the  band  intensities  were  determined.  The 
values  were  plotted  using  the  program  Mat-Lab.  Plotted  values  of  Flavopiridol  log 
concentration (x, axis) and band intensity (y, axis) produced the curve in the graphic above 
that allowed the IC50 value to be determined. IC
50 for Flavopiridol was 25nM according to 
Table 3.2. 
 
0 1 2 3
5000000
10000000
15000000
20000000
Log Conc (nM)
B
a
n
d
 
I
n
t
e
n
s
i
t
y
Flavopiridol IC50 curve      104 
 
 
 
 
 
 
 
 
 
Figure 3.25 Indirubin IC
50 inhibition assay graphic. The gels from the inhibition assays were 
analysed in the Typhoon scanner and the band intensities were determined. The values 
were plotted using the program Mat-Lab. Plotted values of Indirubin log concentration (x, 
axis) and band intensity (y, axis) produced the curve in the graphic above that allowed the 
IC50 value to be determined. IC
50 for Indirubin was 0.033µM according to Table 3.2. 
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Table  3.2  Indirubin  and  Flavopiridol  inhibition  assays.  Samples  final  concentrations  in  µM  (Indirubin)  and  nM  (Flavopiridol)  for  kinase  assay  using 
LmeCRK3:CYCA complex. These concentrations of the inhibitors aforementioned were used to inhibit the complex kinase activity and produce a graph that 
was used to determine the IC50 values.  
 
Sample number  1  2  3  4  5  6  7  8  9  10  11  12  13 
Indirubin 
concentration (µM) 
0  0.0003  0.001  0.003  0.01  0.033  0.1  0.333  1  3.3  10  33  33 
Flavopiridol 
concentration (nM) 
0  3.5  6.25  12.5  25  50  100  200  400  800  1600  3200  3200 
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3.3 Discussion 
The results presented in this chapter have shown that recombinant Leishmania CRK3 and 
CYCA form a complex and that CYCA can activate CRK3 in an in vitro system. Although 
the interaction of CRK3 with CYC6 and CYC2 in T. brucei has been demonstrated in an in 
vivo study (van Hellemond et al., 2000;Hammarton et al., 2003a), this is the first time that 
any recombinant cyclin related kinase from trypanosomatids has been activated in an in 
vitro system. This system, containing the active CRK3, was used in studies that addressed 
the importance of phosphorylation of Thr178 on the activation site of the structural T-loop 
characteristic of cyclin-dependent kinases. The protein used to phosphorylate the CRK3 
Thr178 in the present study was yeast CAK (also known as Civ1). The homologous protein 
to Civ1 in Leishmania and Trypanosoma is still unknown. The active complex was also 
used in inhibition assays using two kinase inhibitors, Indirubin and Flavopiridol. Finally, 
the effect of p12
Cks1 accessory protein was tested and shown to have an inhibitory effect on 
the CRK3:CYCA activity. 
The Leishmania and Trypanosoma CRK3s were expressed in high levels using the pET 
vector system in E. coli, while the cyclin CYCA was not. The low level of expression of 
the cyclin may be due to toxicity of the protein to the bacteria or due to DNA structure of 
the  gene  in  the  plasmid,  which   may  impair  proper  functioning  of  the  plasmid  or  the 
bacteria. Only small quantities of protein were observed  in Coomassie stained gels,  but 
western blots using α-his monoclonal antibody were able to detect its expression.  
The construction of an affinity column where LmeCYCAhis was used to bind non tagged 
LmeCRK3 demonstrated that these two proteins have strong affinity to each other. There 
are 10  cyclin genes in T. brucei and 11 cyclin genes in Leishmania (Naula et al., 2005). 
CRK3 has been shown to interact in vivo with CYC2 (van Hellemond et al., 2000) and 
CYC6 in T. brucei (Hammarton et al., 2003a). L. donovani CYCA, also known as CYC1,       107 
was  shown  to  interact  with  CRK 3  (Banerjee  et  al.,  2003;Banerjee  et  al.,  2006).  The 
binding experiment shown in Figure 3.12 confirmed that recombinant L. mexicana CYCA 
was able to bind L. mexicana CRK3 and that CYCA may be one of the CRK3 activating 
partners in Leishmania. The purified CYCA and CRK3 were next used for kinase activity. 
Activating kinases, such as L. mexicana and T. brucei CRK3 with the L. mexicana CYCA, 
was shown to be possible (Figure 3.13). However, the data reported in the current study 
refers to the activity of proteins expressed and assayed in vitro. An  active L. mexicana 
CRK3  complex,  as  well  as L.  donovani,  had  already  been  described (Grant  et  al., 
1998;Banerjee et al., 2006), but the in vivo activators of L. mexicana remained unknown. 
In L. donovani and the immunoblot analysis confirmed that the protein is also expressed 
during  S-phase  suggesting  its  involveme nt  in  activities  related  to  DN A  replication 
(Banerjee et al., 2006). 
 The  biochemistry  of  these  complexes  was  also  not  accessed. The  in  vivo  activator  of 
CRK3 in L. mexicana will be accessed in the following chapters. In the present chapter of 
this  study  it  was  shown  that  k inase  activity  is  achieved  ind ependently  of  the 
phosphorylation  of  the  Thr178,   T-loop  activation  phosphorylation.  However,  it  is 
important to point out that it was shown that this residue was free for phosphorylation by 
Civ1 and therefore was not previously activated by phosphorylation in this site by the E. 
coli  lysate.  Considering  the  unphosphorylated  status  of  CRK3,  th e  question  that  this 
experiment  raised  was  in  relation  to  the  physiological  need for  phosphorylation  of  the 
T178 in the CRK3:CYCA complex. It is known that phosphorylation of the T-loop residue 
increases kinase activity 100 fold (Brown et al., 1999). The effect of phosphorylation of 
CRK3 was tested using as controls the unphosphorylated CRK3his, the LmeCRK3his
T178E 
mutant and Civ1 from yeast. The LmeCRK3his
T178E was not able to be phosphorylated by 
Civ1 demonstrating the specificity of the phosphorylation site. The mutant CRK3 was also 
inactive  against  histone  H1  when  complexed  with  CYCA.  Total loss  of  activity  by  the       108 
mutant might have been due to conformation failure on the protein’s structure caused by 
synthesis misfolding due to the mutation. The inactivity might have also been due to the 
inability of the mutant to bind to the cyclin. This could be tested by expressing a non-his 
tagged CRK3
T178E mutant. However as observed in the experiment shown in Figure 3.14, 
the  mutant  may  autophosphorylate  at  a  higher  rate   than  the  wild  type  CRK3.  The 
autophosphorylation  must  occur  on  a  Ser  or  Thr  residue  since   CDKs  are  not  tyrosine 
kinases. Therefore the autophosphorylation is unlikely to be on the inactivation sites Tyr15 
but may occur on the Thr14 or in another unknown site. However, independently of the 
exact  position  of  this  autophosphorylation,  it  seems  to  be  stimulated  in  the  mutant  and 
might be inactivating the kinase towards H1 substrate. The mutant CRK3 was successfully 
used to confirm that the phosphorylation of the wild type CRK3 by Civ1 occurs on the 
Thr178  residue.  Based  on  this finding,  the  difference  in  act ivity  between  the 
phosphorylated and nonphosphorylated CRK3 was compared and the role of this important 
phosphorylation site was assessed. 
As it is known from other models like vertebrates and yeast, cyclin binding is one of two 
major  steps  in  CDK  activation;  complete  activation  requires the  phosphorylation  of  the 
conserved threonine residue (e.g Thr161 in human CDK1) (Gould et al., 1991;Krek and 
Nigg, 1992;Gu et al., 1992). It has been suggested that affinity of the interaction between 
CDKs and cyclins may be affected by phosphorylation at the activating threonine. Previous 
studies have reported that cyclin binding to Cdc2 is inhibited by mutation of the threonine 
161, suggesting that phosphorylation at this site stabilizes Cdc2-cyclin complexes (Gould 
et al., 1991;Ducommun et al., 1991;Norbury et al., 1991). On the other hand, it has also 
been  reported  that  Cdc2  and  cy clin  bind  with  high  affinity  i n  the  absence  of 
phosphorylation (Desai et al., 1992;Solomon et al., 1992;Atherton-Fessler et al., 1993). For 
the human CDKs and cyclins, it was shown that CDK1 binds to cyclin B, but not to cyclin 
A in the absence of Thr161 phosphorylation, while CDK2 binds to both cyclin A and B 
without  requiring  Thr161  phosphorylation (Desai et  al.,  1995).  Furthermore, the  crystal       109 
structure  of  the  unphosphorylated  CDK2-Cyclin  A  complex  revealed  that   the  cyclin 
induced activation results from conformational changes in the catalytic cleft that realign 
active site residues and relieve the blockade of the catalytic cleft (Jeffrey et al., 1995). A 
comparison between the unphosphorylated and phosphorylated CDK2-cyclin A complex 
revealed that the presence of the phosphate group induces conformational changes in the 
T-loop and C-terminal lobe of CDK2, as well as new interactions within CDK2 and cyclin 
A (Russo et al., 1996).  
Despite universal conservation of the two-step CDK activation requirement (cyclin binding 
and  CAK  phosphorylation),  the identity  of  the  CAK  has  diverg ed  (Fisher,  2005).  In 
metazoans, the only CAK identified to date is the Cdk7/cyclin H/Mat1 complex, which is 
also a component of the RNA polymerase II general transcription  factor IIH. Cdk7 has 
evolved  to  recognize  two  distinct  and  structurally  dissimilar  substrates,  the  T  loops  of 
CDKs and the carboxy-terminal domain of the largest subunit of Pol II (Larochelle et al., 
2006).  Kin28  is  the  yeast S.  cerevisiae  orthologue  of  Cdk7,  which  is a  kinase  that 
phosphorylates  the  carboxy-terminal  domain  RNA  polymerase  II  complex, but  has  no 
CAK  activity.  T  loops  of  CDKs are  instead  phosphorylated  by Cak1,  a  single-subunit 
kinase related only distantly to CDKs (Thuret et al., 1996;Kaldis et al., 1996;Espinoza et 
al.,  1996).  Differently,  two  CAKs  are  found  in  the  fission  yeast S.  pombe,  the  Mcs6 
complex and the  nonessential  Csk1. Csk1  is the actual orthologue to the  metazoan and 
budding yeast enzymes (Hermand et al., 1998;Lee et al., 1999;Saiz and Fisher, 2002). 
In  the  present  study,  phosphorylation  of  CRK3  by  C iv1  from  both T.  brucei  and L. 
mexicana was shown to enhance protein kinase activity toward histone H1 by around 5 
fold. However, binding of the cyclin to the kinase and the kinase activity on the complex 
do not appear to be dependent on the phosphorylation of the Thr178. The 5-fold increase in 
kinase activity observed in the phosphorylated complex was very subtle when compared to 
the 100 fold increase in the human or yeast complexes (Morgan, 1997). The reason for that       110 
is unknown, but it may be that yeast Civ1 used in the assays did not phosphorylate all of 
the CRK3  in the reaction. This would have  been expected since Civ1  is a heterologous 
enzyme and the sequence of the phosphorylation site differs in Leishmania and T. brucei 
from  that of  yeast.  While  in  Leishmania  the  sequence  is MHTXTXXVX,  in  yeast  it  is 
LRNXTXXIVT.  However,  no  Civ-like  proteins  from  the Leishmania  or Trypanosoma 
(Parsons et al., 2005) genomes could be readily identified by sequence homology and as 
such,  yeast  Civ1  was  used  instead.  The  procedures  that  are  used  to  phosphorylate  the 
kinase complexes  in  humans,  yeast and CRK3 (the present study) are  similar  and Civ1 
appears to be fully active with CRK3 as a substrate. In addition to that, the protein band 
corresponding  to  the  phosphory lated  CRK3  observed  in  the  autoradiographic films 
appeared to be as intense as the ones corresponding to the histone H1 substrate suggesting 
that at least some of CRK3 was indeed phosphorylated by Civ1.  
The RINGO protein (Karaiskou et al., 2001) was used as a test to assess the specificity of 
the interaction between CRK3 and CYCA and the consequent activation of this complex. 
RINGO (rapid inducer of G2/M progression in oocites) is the putative protein responsible 
for triggering Cdc2 homologue in Xenopus oocytes in the absence of the conserved T-loop 
phosphorylation.  Due  to  fact  t hat  RINGO  is  not  a  cycl in  and  can  activate  CDKs 
independently of the Thr phosphorylation, it was also possible that RINGO could activate 
CRK3 in a similar manner to CYCA. RINGO can directly activate Cdk1 and Cdk2 using 
bacterially  produced  proteins  (Nebreda,  2006)  .  Mammalian  RINGO/Speedy  fami ly 
members can also bind to and activate Cdk1 and Cdk2, albeit with different efficiencies, 
but  they  do  not  bind  to  or  activate  Cdk4  and   Cdk6  (Nebreda,  2006).  In  vitro  and 
overexpression experiments suggest that most RINGO/Speedy proteins might bind to and 
activate Cdk2 more efficiently than Cdk1 (Karaiskou et al., 2001;Porter et al., 2002;Cheng 
et  al.,  2005;Dinarin a  et  al.,  2005) .  However,  complexes  between  end ogenous 
RINGO/Speedy proteins and Cdk1 or Cdk2 have yet to be detected. As shown in Figure 
3.19 there  was  no  activation  of  CRK3  by  RINGO,  whereas  the  control  (a Plasmodium       111 
falciparum cell cycle related kinase PfPK5) (Holton et al., 2003) was fully activated by 
RINGO. This result provides more evidence for the specificity of the activation of CRK3 
by CYCA, which is a mitotic cyclin. This does not mean that different cyclins are not able 
to activate CRK3 as well. This possibility will be addressed in the following chapters. 
Human Cks1 and Cks2 were isolated (Richardson et al., 1990b) and it was found that Cks 
proteins  were  structurally  and  functionally  conserved  throughout  eukaryotes  and  could 
directly bind to cyclin/CDK complexes.  Although it is known that Cks proteins are crucial 
for CDK function and cell division in yeast, the molecular details of their functions have 
remained  unclear.  Recently,  Cks1  was  reported  to  be  an  essen tial  cofactor  for  SCF
Skp2 
ubiquitin ligase to ubiquitinate p27
Kip1, whereas Cks2 exhibited no such activity (Harper, 
2001;Ganoth  et  al.,  2001;Spruck  et  al.,  2001).  p27
Kip1  is  one  of  the  kinase  inhibito rs 
regulating G1-S progression and is degraded via the ubiquitin-proteasome pathway (Pagano 
et  al.,  1995;Vlach et  al.,  1997;Shirane et  al.,  1999).  It  was  also  recently  shown  that it 
modulates  transcription  of  the  APC/C  pr otein-ubiquitin  ligase  activator  Cdc 20  in  S. 
cerevisiae  (Brizuela  et  al.,  1987;Morris et  al.,  2003).  The  cyclin-dependent  kinase 
complexes from several organisms have been purified from cell extracts using their affinity 
to Cks1 (Brizuela et al., 1987). This protein can be immobilized onto an affinity column 
and  the  column  can  be  used  to purify  the  cyclin-dependent  kinase  complexes  from 
trypanosomatids  (Mottram  et  al.,  1996a).  In  the  present  study,  a  recombinant  Cks1 
homologue  from  T.  brucei  was  cloned  expressed,  purifie d  and  added  to  the  system 
developed with CRK3:CYCA to analyse the effect on the kinase activity. It was found that 
T. brucei Cks1 had an inhibitory effect on the LmeCRK3his kinase activity toward histone 
H1  (Figure  3.20  and  3.21).  How ever,  the  inhibition  was  less pronounced  for  the 
TbCRK3his:LmeCYCAhis  complex. The  reason  for  the  inhibitory effect  has  yet  to  be 
elucidated. Because Cks1 is believed is responsible for modulating the affinity between the 
kinase complexes and the substrates (Harper, 2001), it is possible that TbCks1 acts as a 
modulator in the affinity of the complex towards histone H1.       112 
In order to evaluate the similarity between the active recombinant kinase complex reported 
here and the in vivo purified CRK3 (Grant et al., 2004), the IC50 for two different kinase 
inhibitors  (Flavopiridol  and  I ndirubin  5’  monoxide)  was  dete rmined.  These  kinase 
inhibitors are known to have different IC50 values for different kinases. Flavopiridol IC50 
for human CDK1 and CDK2 are 500nM and 100nM respectively. Indirubin IC50 for CDK1 
and CDK2 are 10mM and 2.2-7.5mM (Losiewicz et al., 1994;Carlson et al., 1996;Hoessel 
et al., 1999). In the present study, the IC50 values for the recombinant complex were found 
to  be  in  a  similar  range  with those  from  the in  vivo  purified  CRK3. In  vivo purified 
CRK3his had an IC50 of 1350 nM for Indirubin (Grant et al., 2004) while the recombinant 
LmeCRK3his:LmeCYCAhis complex had an IC50 of 33nM for the same compound. For 
Flavopiridol the in vivo complex presented an IC50 of 100nM (Hassan et al., 2001) while 
the recombinant complex was 25nM , suggesting that the former reflects the latter. Given 
the similar values for the IC50 for these 2 kinase inhibitors it could be suggested that CRK3 
is activated by CYCA in vivo and that phosphorylation on the Thr178 residue may not be 
essential in vivo. 
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Chapter 4 
Cloning, expression and activity of L. major CRKs 
and CYCs  
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4.1 Introduction  
Cyclin-dependent kinases (CDKs) are serine-threonine kinases that play pivotal roles in the 
control  of  the  eukaryotic  cell  cycle.  In   yeast,  cell-cycle  progression  is  predominantly 
regulated  by  one  CDK,  p34  cdc2  in  Schizosaccharomyces  pombe  or  p34  cdc28  in 
Saccharomyces cerevisiae whereas in higher eukaryotes many cdks are involved. To date 
13 CDKs  and 25 cyclins encoded  in the  human  genome  have  been described (Morgan, 
1997;Pavletich, 1999;Dhavan and Tsai, 2001). Although CDKs were initially studied for 
their cell cycle functions, it was later observed that some members of the family have roles 
in  different  contexts (Knockaert et  al.,  2002)  In  humans,  for  example,  four CDKs  are 
involved  in  the  regulation  of transcription  (Knockaert  et  al.,  2002).  CDK7–cyclin-H–
MAT1 is a part of the transcription factor TFIIH. Both CDK7–cyclin H and CDK8–cyclin 
C phosphorylate the large subunit of RNA polymerase II, required for elongation (Fisher, 
2005). CDK9–cyclin T is a component of the transcription factor P-TEFb. It is required for 
the kinase-dependent HIV-1 Tat transactivation (Pumfery et al., 2003). CDK11 is also very 
important in regulating RNA processing and transcription, in association with the recently 
described cyclin L (Ania-6) (Hu et al., 2003). 
Progression through the G1, S, G2 and M phases of the cell division cycle is regulated by 
CDKs. In early–mid G1, extracellular signals modulate the activation of CDK4 and CDK6 
associated with D-type cyclins (Sherr and Roberts, 2004;Kozar and Sicinski, 2005). The 
phosphorylation  of  pRB  in  G1  b y  cyclin  D/CDK4/6  (and  subsequently  by  CDK2)  is 
believed to be a requisite event in reversing the repressive effects of pRB and de-repressing 
transcription of a number of genes required for exit from G1 and initiation and completion 
of  S  phase.  These  phosphorylat ion  inactivates  pRb  and  releas e  the  E2F  and  DP1 
transcription  factors  responsi ble  for  essential  genes  requir ed  at  G1/S  transition 
(Haberichter  et  al.,  2007).  The  G1/S  phase  transition  an d  centrosome  duplication  is 
governed by CDK2–cyclin E complex (Cowan and Hyman, 2006). Still during S phase,       115 
CDK2–cyclin A phosphorylates various substrates allowing DNA replication (Kaldis and 
Aleem, 2005). Around the S/G2 transition, CDK1 associates with cyclin A. Later, CDK1–
cyclin B appears and triggers the G2/M transition by phosphorylating several substrates. 
Phosphorylation  of  the  ‘anaphase  promoting  complex’  by  CDK1 –cyclin  B  results  in 
transition to anaphase and completion of mitosis (Petri et al., 2007). The ordered action of 
different  CDK–cyclin  complexes  is  dependent on  post-translational  modifications  and 
intracellular  translocations.  Complexion  of  phases  are  regula ted  through  so-called 
‘checkpoint’ controls (Knockaert et al., 2002). 
The fission yeast suc1 gene encodes an essential protein (p13) which interacts with cdc2 
and was first identified as a plasmid-borne suppressor of certain temperature-sensitive cdc2 
mutants (Hayles et al., 1986). The budding yeast homologue of suc1, CKS1 (cdc2 kinase 
subunit  1),  was  identified  in  a similar  manner  (Hadwiger  et  al.,  1989).  Two  human 
homologues  of  suc1,  ckshs1  and   ckshs2  capable  of  rescuing  nu ll  mutations  of  the 
Saccharomyces  cerevisiae  CKS1  gene (Richardson  et  al.,  1990a).  The  specificity  of 
binding is high and shown to bind higher eukaryotic cdc2 and CDK2 strongly but not other 
CDKs (Meyerson et al., 1992). The high affinity with which CKS1 binds to Cdc2 in vitro 
has been exploited in the isolation of cdc2 kinase complexes from a variety of organisms 
including Leishmania (Mottram et al., 1996a).  
Unicellular S. cerevisiae and S. pombe have a single cyclin dependent kinase to control 
their cell cycle. Other yeast Cdks like PHO85 are also cyclin dependent kinases and do 
have role in cell cycle progression, however, cell cycle progression occur in its absence 
suggesting overlapping of functions (Huang et al., 2007). Kin28 and Srb10 are also cyclin 
activated proteins in yeast that are not essential for cell cycle progression (Espinoza et al., 
1998). Also unicellular eukaryotic cells of parasites from the genus Leishmania have 11 
genes of CRKs (CRKs 1, 2, 3, 4, 6, 7, 8, 9, 10, 11 and 12). CRK5 initially included in the 
CRK family because of its similarities with Cdc2 was later removed as it showed more       116 
characteristics of MAP kinase than of cyclin dependent kinase.  The cyclin family is also 
large with 11 genes (CYCA, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11) (Naula et al., 2005). The 
CYC1 protein, initially thought to be a mitotic cyclin (Affranchino et al., 1993) was later 
found  to  be  more  similar  to  a serine  peptidase (Hammarton et  al.,  2000).  CYCA  is  an 
exclusive gene of the genus Leishmania with no orthologue in trypanosomes. Although it 
is  well  known  that  CDKs  associ ates  with  its  subunit  cyclin  t o  be  active,  only  a  few 
cyclin:kinase pairs have being identified in kinetoplastids. In mammalian cells the 10 CDK 
proteins associates with around 14 different cyclins. These pairs are well established and 
their function defined (Knockaert et al., 2002). The association of the numerous cyclins 
with  the  numerous  kinases  in  kinetoplastids  was  never  assessed  in  further  detail.  It  is 
known that CRK3 forms a complex with the CYC6 mitotic cyclin and the association  is 
essential for G2/M phase progression being the functional homologue of CDK1 (Hassan et 
al., 2001;Hammarton et al., 2003a;Tu et al., 2004;Tu et al., 2005). It is also known that the 
same  CRK3  in  complex  with  CYC2   is  essential  for  G1  progressi on  (Li  et  al., 
2003a;Hammarton et al., 2004). 
In yeast, a single protein acts as CDK activating kinase, CAK or Civ1. In humans, another 
CDK associated to MAT1 is responsible phosphorylation of the Threonine residue at the 
activation  loop  (Martinez  et  al.,  1997).  In  Leishmania  no  CAK/Civ1  or 
CDK7/MAT/Cyclin  H  can  be  identified  by  sequence  homology.  Al though  Leishmania 
CRKs have conserved Threonine at the activation loop, it is still unknown if these protein 
need phosphorylation for full activation. In chapter 3 of this thesis it was shown that Civ1-
GST purified from E. coli can phosphorylate LmCRK3 at position Thr178 and that this 
enhances the kinase activity around 5 times. In this chapter, Leishmania CRK1, CRK2, 
CRK4, CRK6 and  CRK7 were cloned, expressed and tested as  substrates for Civ1.  An 
analysis of the Leishmania cyclin genes was carried out and the CYC9 was found to be the 
closest  related  gene  product  to  human  cyclin  C  and  cyclin  H.  Leishmania  CYC9  was 
expressed in E. coli, purified and used to assess whether it could activate CRK1, CRK2,       117 
CRK3,  CRK4,  CRK6  and  CRK7  in  s earch  of  the  kinase  activating  kinase  complex  in 
Leishmania. 
Following the successful activation of CRK3 in vitro with CYCA and CYC6, a strategy 
was  developed  to  defi ne  cyclin-dependent  kinase  complexes  in Leishmania,  such  as 
CRK3:CYC6his  complex.  In  the  p resent  chapter,  the  strategy  u sed  involved  the  co-
transformation  of  E.  coli  BL-21  DE3  with  two  different  plas mids,  one  containing  an 
untagged CRK gene and another containing a histidine tagged cyclin. Co-transformed cells 
were then used to express and purify possible interacting kinase:cyclin pairs to be tested in 
kinase assays. The kinase genes used were CRK1-4 and  CRK6-8  from L. major which 
were cloned into the plasmid pACYC Duet to express a recombinant and untagged version 
of these proteins. The cyclin genes from L. major used were CYCA, CYC3, CYC6, CYC7, 
CYC9 CYC10 and CYCA from L. mexicana.  
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4.2 Results 
4.2.1 Sequence Alignments 
All alignments and a phylogenetic trees were generated using Invitrogen program package 
Vector Nti wich includes Align X. Align X uses Clustal W algorithms. 
4.2.1.1 Cyclins 
The sequences of the major human cyclins and the sequences of trypanosomatid cyclins 
were analysed. A phylogenetic tree containing all L. major cyclins and the human cyclins 
was generated (Figure 4.1). These alignments show that LmCYCA and CYC6 are clustered 
together with human  mitotic cyclins  A and B. It shows that that CYC3 is  most closely 
related to human cyclin E and that CYC8 and CYC9 are more related to human cyclins C 
and H, while other L. major cyclins  like CYC2, 4, 5, 7, 10 and 11 do not appear have 
closer relation with any of these human cyclins analysed.  
A phylogenetic tree of different Human Cyclins (A1, A2, B1, B2, C, D1, E1, E2 and H) 
and CYC9 from L. brasiliensis, L. infantum, L. major and T. brucei was built. The tree 
shows all Leishmania CYC9 proteins clustering close to transcriptional cyclins C and H. 
TbCYC9 which share only 30.1% identity with the Leishmania homologue also clusters 
with these transcriptional cyclins (Figure 4.2). An alignment of the protein sequence from 
TbCYC9, LmCYC9 and human transcriptional cyclins H and C is shown in Figure 4.3. 
The sequence alignment between human cyclin C, H and L. major CYC9 provided a low 
identity (17.6% for cyclin C and 13.4% for cyclin H). A sequence alignment between the 
three Leishmania CYC9 proteins and the T. brucei CYC9 (Figure 4.4) shows that this gene 
product  is  much  more  conserved   between  the Leishmania  species  (identity  of  88.2% 
between Leishmania  species)  suggesting  that  this  may  be  due  to  the  existence  o f  high       119 
selective  pressure  on  these  genes  and  that  this  protein  migh t  have  different  function 
between Leishmania and Trypanosoma species. 
4.2.1.2 CRKs 
A sequence analysis of LmCRKs was carried out. A phylogenetic tree with LmCRKs and 
human  CDK1  and  CDK2  is  shown  i n  Figure  4.5.  The tree  shows that  LmCRK3  is  the 
protein from the CRK family that clusters with human CDK1 and CDK2. The similarity of 
all LmCRKs to human Cdc2 was analysed in the Table 4.1. In this table LmCRK3 has the 
highest level of sequence identity to both human Cdc2 and Yeast Cdc2 41.8% and 50.2% 
respectively.  A  sequence  alignment  using  all  LmCRKs  is  shown   in  Figure  4.6.  In  this 
alignment  it  can  be  observed  that  CRK1,  CRK4  and  CRK7  have  a  s horter  N-terminus 
when compared to the other CRKs. CRK4 possesses two large insertions in central regions 
and an extended C-terminus. LmCRK8 has a large N-terminal and C-terminal insertion not 
found in any other CRK, it also possesses a small insertion in its central region. Finally, it 
is important to notice in the LmCRKs alignment the cyclin binding motif (PSTAIRE in 
Cdc2) is highly polymorphic (103aa-109aa) for an unknown reason.  
Another important motif in the LmCRKs was analysed in Figure 4.7. The T-loop activation 
motif  from  all Leishmania  CRKs  was  aligned.  The  threoni ne  residue  at  this  motif  is 
phosphorylated  by  a  kinase  act ivating  kinase  (CAK/Civ1  in  ye ast  and  CDK7  in 
mammalian cells) is conserved in LmCRK1-3, LmCRK6 and LmCRK8. It is substituted by 
a serine residue in LmCRK4 and LmCRK7. 
4.2.2 RT-PCR to detect the expression of cyclin genes in L. major 
An  RT-PCR  to  detect  the  expression  o f  cyclin  genes  in L.  major  promastigotes  was 
performed  (Figure  4.8).  Using  cDNA  obtai ned  from  total  RNA  extractions   from 
promastitgote L. major, PCR reactions were performed to confirm the expression of the       120 
cyclin genes in these cells. All PCRs used as sense primer the SL primer (OL1760) and a 
specific anti-sense primer specific for the cyclin sequence tested. It was possible to confirm 
the expression of LmCYCA, CYC7 and CYC9, while it was not possible to amplify the 
specific fragment from LmCYC3. For LmCYC10 a fragment that differed in size from that 
expected was obtained and therefore the expression could not be confirmed.  
4.2.3 Cloning of L. major CYCs 
To assay which cyclins might activate the different CRK in L. major, plasmids expressing 
tagged  cyclins  were  made.  The cloning  of  these  proteins  and expression  attempts  were 
described  in  previous  chapters.  The  genes  corresponding  to L.  major  CYCA,  CYC3, 
CYC6,  CYC7,  CYC9,  CYC10  and  CY C11  were  amplified  by  PCR  as  d escribed  and 
cloned  into  pGEM-T  vector.  The  genes  were  excised  with NdeI  and BamHI  restriction 
sites,  gel  purified  and  ligated  into  previously  digested  and  gel purified  pET15b  vector 
generating pGL1334 (LmCYCA), pGL1218 (LmCYC6), pGL1335 (LmCYC7), pGL1336 
(LmCYC9), pGL1337 (LmCYC10), pGL1350 (LmCYC11), pGL630 (LmeCYCA). 
4.2.4 Purification of L. major cyclins 
4.2.4.1 LmCYC3 
The plasmid pGL1350, derived from pET-15b+ and containing the gene for LmCYC3, was 
used to express and affinity purify the LmCYC3his fusion protein. The plasmid was used 
to transform E. coli BL21 DE3 pLys, induced with IPTG overnight and standard histidine 
tagged protein purification was carried out. The result of this purification can be observed 
in Figure 4.9 (B). Lane 1 shows insoluble His tagged CYC3 around 46.9 kDa, which was 
also detected in a western blot using α-his antibody. No soluble protein could be purified 
and used in kinase assays from these preparations.       121 
4.2.4.2 LmCYC7 
The  plasmid  pGL1335,  derived  from  pET-15b+  and  containing  the  gene  for  LmCYC7,  
was used to express and affinity purify the LmCYC7his fusion protein. The plasmid was 
used  to transform E.  coli  BL21  DE3  pLys,  induced  with  IPTG  overnight  and  standard 
histidine tagged protein purification was carried out. The result of this purification can be 
observed in Figure 4.9 (C). Lane 1 shows insoluble His tagged CYC7 around 27.6 kDa, 
which was also detected in a western blot using α-his antibody. No soluble protein could 
be purified and used in kinase assays from these preparations. 
4.2.4.3 LmCYC10 
The plasmid pGL1337, derived  from pET-15b+  and containing the gene  for LmCYC10 
was used to express and affinity purify the LmCYC10his fusion protein. The plasmid was 
used  to transform E.  coli  BL21  DE3  pLys,  induced  with  IPTG  overnight  and  standard 
histidine tagged protein purification was carried out. The result of this purification can be 
observed in Figure 4.9 (A). Lane 1 shows insoluble His tagged CYC10 around 68.7 kDa, 
which was also detected in a western blot using α-his antibody. No soluble protein could 
be purified and used in kinase assays from these preparations. 
4.2.4.4 LmCYC9 
The plasmid pGL1336, derived from pET-15b+ and containing the gene for was used to 
express  and  affinity  purify  th e  LmCYC9his  fusion  protein.  The  plasmid  was  used  to 
transform E. coli BL21 DE3 pLys,  induced with IPTG overnight and standard  histidine 
tagged protein purification was carried out. The result of this purification can be observed 
in  Figure  4.10.  Lane  4  shows  s oluble  His  tagged  CYC9  (32.9  kDa)  purified  at  the 
concentration of 1.5mg/ml. Around 15mg of this protein could be obtained from 1L of cell 
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4.2.5 Purification of LmeCRK3:LmCYC6his complex 
L. mexicana CRK3 was co-expressed in E. coli with CYC6his (Rod Walker, unpublished). 
The  complex  was  purified  from E.  coli  cell  pellets  by  Nickel -chelate  affinity 
chromatography.  After  purification  with  POROS  MC  20  Column  ( Ni2+  charged),  the 
samples  were  further  purified by  Ion-Exchange  Chromatography  and  the  elutions  were 
loaded onto a Coomassie gel (Figure 4.11). A clear doublet corresponding to CYC6his and 
CRK3 can be observed in the elutions. A Histone H1 kinase assay demonstrated that the 
purified CRK3/CYC6his complex was active in vitro. This complex was used in further 
kinase assays, as a substrate and as a positive control. 
4.2.6 Purification of CRK1-4 and CRK6-8 
LmCRK genes were amplified from gDNA and subcloned in the expression vector pET-
15b+,  which  was  pre-digested  with BamHI  and NdeI  generating  pGLs  containing  His 
tagged  LmCRKs.  The  tagged  proteins
  were  successfully  purified  using  pGL1342  for 
LmCRK8 (44.4 kDa), pGL1349 for CRK7 (32.4 kDa), pGL1341 for CRK6 (37.3 kDa), 
pGL1616 for CRK4 (51.7 kDa), pGL1340 for CRK3 (35 kDa), pGL1339 for CRK2 (36.4 
kDa) and pGL1338 for CRK1 (34.4 kDa) (Figure 4.12 to 4.18). Soluble His tagged CRKs 
can  be  observed  in  lane  4  of  F igures  4.12  to  4.18.  These  proteins  were  used  in  kinase 
assays with purified CYC9. 
4.2.7 Cloning of untagged CRKs 
To purify new recombinant L. major cyclin:kinase complexes it was necessary to design 
DNA  constructs  that  could  express  these  protein  without  a  histidine  tag.  As  described 
previously, it was possible to express untagged CRK3 and purify this protein from E. coli 
lysate using histidine tagged CYC6 or CYCA immobilized to an affinity column. The L. 
major CRKs were excised from their plasmids (see methods) using restriction sites BamHI       123 
and XhoI. DNAs fragments corresponding to the correct sizes were gel purified and ligated 
into dual expression vector pACYC Duet. This plasmid, which confers chloramphenicol 
resistance  to the  cells, was  previously  digested with BamHI  and XhoI  and  gel  purified. 
pACYC  Duet  plasmids  containing  the L.  major  CRKs  were  named  pGL1338  (CRK1), 
pGL1339  (CRK2),  pGL1340  (CRK3),  pGL1616  (CRK4),  pGL1341  (CRK6),  pGL1349 
(CRK7), pGL1342 (CRK8) and pGL1072 (TbCRK3). 
4.2.8 Co-transformation 
Successful cloning of cyclins genes in pET15b and of CRKs into pACYC Duet allowed 
further  co-transformation  experiments  to take  place.  pET15b  derived  pGLs  containing 
cyclin genes (CYCA, CYC6, CYC7, CYC9, CYC10, CYC11) were transformed into BL21 
E. coli cells and these were made ampicillin resistant competent cells. The cells were co-
transformed with a second plasmid containing the CRK gene generating a double resistant 
E. coli strain capable of expressing one His-tagged CYC protein and one non-His-tagged 
CRK. The ampicillin resistance pET15b derived pGLs containing cyclins genes and the 
chloramphenicol  pACYC  Duet  derived  pGLs  containing  the  CRKs generated  double 
resistant cell lines. Each of the CYC containing cell line was transformed with a different 
CRK and in total, 24 different strains were generated. Each of the 24 cell lines contained 
two different plasmids, each capable of expressing a single cyclin and a single CRK. These 
cell lines were used in expression and purification assays. 
4.2.9 Phosphorylation of the LmCRK T-loop threonine using Civ1 
Each of the purified CRKs was tested as to whether they were substrates for Civ1. This 
was  to  assess  if  the  threonine   or  serine  residue  in  the  activation  l oop  would  be 
phosphorylated by Civ1 in a similar manner as CRK3. CRKs 1-3, 6 and 8 have a threonine 
residue conserved in the activation loop, whereas CRKs 4 and 7 have a serine (Figure 4.7).       124 
The only L. major CRK phosphorylated by Civ1 was CRK3 (Figures 4.19-4.21). Although 
CRK1,  CRK2,  CRK6  and  CRK8  have  a  conserved  threonine  residue,  like  CRK3,  they 
could  not  be  phosphorylated  by  Civ1.  Although  there  is  no  ev idence  that  Civ1  targets 
serines, the serine residue in CRK7 and CRK4 have the potential to be phosphorylated by 
Civ1 since this protein is a serine/threonine kinase. Nevertheless these proteins were not 
phosphorylated by Civ1 (Figures 4.19-4.21). 
4.2.10 Co-expressions and purifications 
Co-transformed E. coli BL21 cells capable of expressing one his-tagged cyclin protein and 
one  non-his-tagged  CRK  were  grown  to  0.6  O .D.  in  the  presence  of  ampicil lin  and 
chloramphenicol antibiotics. When an O.D. of 0.6 was reached, the culture was transferred 
to 19
oC and induced for protein expression using 1mM IPTG overnight shaking for better 
aeration. From the total culture volume of 200ml, half was used to co-purify cyclin-kinase 
complexes using the same protocol used for purification of CRK3. 
All cell lines containing different kinases and LmCYCA, LmeCYCA, LmCYC6, LmCYC7 
and LmCYC9 were tested and the co-purification  attempted. All of the co-purifications 
were inconclusive and none of the 35 attempts generated a kinase cyclin pair as had been 
observed  previously  for  CYC6:CRK3.  Most of  the purifications  appeared  to  follow  the 
same  pattern,  where  no  eluted protein  could  be  detected  (Figure  4.22).  Another  similar 
pattern can be observed in Figure 4.23, where the cyclin appears to be insoluble and is 
detected in lane 1. However no cyclin or CRK was eluted in lanes 5 and 6, as observed in 
Figure  4.22.  Finally,  the  last  pattern  observed  is  shown  in Figure  4.24,  where  a  band 
corresponding to the size of the CRKs is detected in the elution, but no band corresponding 
to the cyclin was observed as it would be expected. This was observed only in one of the 
purifications, containing LmCYC7 and LmCRK1, suggesting that the kinase was eluted.  
However, the apparent absence of the cyclin in the eluted fraction requires explanation.       125 
4.2.11 Kinase assays using CYC9 to activate LmCRKs 
All CRKs were tested for autophosphorylation and for cyclin-independent activity against 
three different substrates, histone H1, MBP and β-Casein. None of the kinases tested had 
autophosphorylation activity or activity towards the substrates tested on their own. Protein 
kinase  assays  using  CYC9  to  ac tivate  different  L.  major  CRKs  were  performed  as 
described previously.  CYC9  was used to activate CRK1, CRK2, CRK3, CRK4, CRK6, 
CRK7  and  CRK8.  HistoneH1,  MBP and  β-Casein  were  used  as  substrates.  No  activity 
from these kinases was observed against any of the substrates used. When Civ1 was added 
to the kinase assays, the presence of CYC9 did not activate the complex and Civ1 did not 
phosphorylate any of the aforementioned CRKs as previously reported. 
4.2.12 Kinase assays of co-eluted purifications  
Elutions from co-expressed purifications were assayed in vitro kinase assays. Figure 4.25 
shows the result of a kinase assay performed with two different kinases and CYC7 (CRK1 
+ CYC7 and CRK6 + CYC7) against three different substrates Histone H1, β-Casein and 
MBP. Reactions were performed in kinase assay buffer containing 5µg of histone H1 or β-
Casein or MBP as substrate and γ-ATP labelled with P
32. The samples were analysed on 
12% SDS-PAGE gel, stained with Coomassie, dried and exposed to a 
32P particle emission 
sensitive film. As a positive control, the active CRK3:CYC6his complex was used. It was 
observed that these purifications contained no active cyclin:kinase complexes against the 
substrates used (Figure 4.25), while the complex LmeCRK3:LmCYC6his was shown to 
phosphorylate Histone H1, (Figure 3.13) as well as MBP and β-casein (Figure 4.25).       126 
4.2.13  Western  blot  and  kinase  assay of  in  vivo  expressed  HA 
epitope tagged LmCRK6 
L.  major cell  lines  were  transfected  wi th  pGL1392  and  pGL1394.  For  pG L1392  a  C-
terminal  HA  tag was  added  by  PCR  to  LmCRK6  for  overexpression  i n  an  episomal 
plasmid. For pGL1394 a C-terminal HA tagged LmCRK6 was expressed by integration of 
the  construct  into  the  rDNA  locus.  The  integration  plasmid  was  generated  from  pRIB 
plasmid backbone that was digested with PacI and PmeI before transfection of L. major. 
Lysates from Wild type cells and from the transfected cell lines were prepared and S-100 
soluble extracts were used in Western blots using α-HA antibody (Figure 4.26). The HA 
tagged CRK6 was detected in the western blot for both overexpressor and integrated cell 
lines, while no protein was detected in wild type cells. The result from the western blot 
suggested that LmCRK6 was successfully tagged and could be purified. The same S-100 
was  used  for  immunoprecipitation  of  HA  tagged  proteins  using   a  HA  affinity  matrix 
(Roche). After washes the matrix containing the active kinase was tested for kinase activity 
(Figure  4.26).  Kinase  activity  was  detected  using  Histone  H1  a s  substrate  for  both 
overexpressor  and  integrated cell  lines,  while  no  activity was  detected  after  affinity 
purification from wild type cells. 
4.2.14  Immunofluorescense  assa y  for  cell  lines  expressing 
LmCRK6 HA tagged 
An Immunofluorescense assay to detect LmCRK6HA was performed in the transfected L. 
major  cell  lines  and  in  the  wild  ty pe  cells.  The  primary  antibody, -HA  Roche  mouse 
monoclonal was diluted 1 in 500 in 0.1% Triton X-100, 0.1% BSA and added to the top of 
the slide to incubate for 1 hour at room temperature The secondary antibody was α-mouse 
FITC conjugated diluted at 1 in 1,000. A cytoplasmic localisation was observed in both 
WCMP 7653 (L. major containing pGL1392) and WCMP 7654 (pGL1394 integrated into       127 
L. major), which was not observed in the wild type cells (Figure 4.27). This suggests that 
LmCRK6 is present in the cytoplasm of L. major cells throughout the cell. 128 
Human Cyclin A1 (0.2799)
Human Cyclin A2 (0.2856)
LmCYC6 (0.3180)
LmCYCA (0.3164)
Human Cyclin B1 (0.2411)
Human Cyclin B2 (0.2362)
Human Cyclin E1 (0.2618)
Human Cyclin E2 (0.2630)
LmCYC3 (0.4152)
Human Cyclin D1 (0.4021)
LmCYC8 (0.4271)
Human Cyclin C (0.3755)
Human Cyclin L (0.3960)
Human Cyclin K (0.3973)
Human Cyclin H (0.4257)
LmCYC9 (0.4356)
LmCYC5 (0.4282)
LmCYC11 (0.4218)
LmCYC10 (0.4107)
LmCYC2 (0.3154)
LmCYC4 (0.3533)
LmCYC7 (0.3978)
 
 
 
 
 
 
 
Figure 4.1 Phylogenetic tree of different Human Cyclins cyclins and L. major CYCs. From Human: A1, A2, B1, B2, C, D1, E1, E2, H and L. From L. major CYC2-
11 and CYCA. Sequences from gene bank accession numbers are NM_057749 for human cyclin E2, NM_001238 for human cyclin E1, NM_004701 for human 
cyclin B2, NM_031966 for human cyclin B1, NM_001237 for human cyclin A2, NM_003914 for human cyclin A1, NM_053056 for human cyclin D1, NM_005190 for 
human cyclin C, NM_001239 for human cyclin H, LmjF32.0760 and NM_020307 for human cyclin L. for L. major gene bank accession numbers: in the order 
CYC2-11 and CYCA; LmjF32.0820, LmjF30.0080, LmjF05.0710, LmjF33.0770, LmjF32.3320, LmjF30.3630, LmjF26.0330, LmjF32.0760, LmjF24.1890, LmjF24.1880 
and  LmjF25.1470.  Lines  represent  the  degree  of  divergence  between  the  sequences  while  the  calculated  distance  values  are  shown  in  parenthesis. 129 
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Figure 4.2 Phylogenetic tree of different cyclins. Human Cyclins A1, A2, B1, B2, C, D1, E1, 
E2 and H were used. CYC9 from L. brasiliensis, L. infantum, L. major and T. brucei were also 
used. Sequences from gene bank accession numbers are NM_057749 for human cyclin E2, 
NM_001238 for human cyclin E1, NM_004701 for human cyclin B2, NM_031966 for human 
cyclin B1, NM_001237 for human cyclin A2, NM_003914 for human cyclin A1, NM_053056 for 
human  cyclin  D1,  NM_005190  for  human  cyclin  C,  NM_001239  for  human  cyclin  H, 
LmjF32.0760  for  L.  major  CYC9, Tb11.01.5600  for  T.  brucei  CYC9, LinJ32_V3.0800  for L. 
infantum CYC9 and LbrM32_V2.0850 for L. braziliensis CYC9. Lines represent the degree of 
divergence  between  the  sequences  while  the  calculated  distance  values  are  shown  in 
parenthesis. 
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                      1                                               50 
        LmCYC9    (1) -------MSSSPLSPVYSSPASTGFGAPYLPS------------------ 
        TbCYC9    (1) ----MAGFTETPSWPSLSCEQSSAAAVSVSYS------------P----F 
Human Cyclin C    (1) MAGNFWQSSHYLQWILDKQDLLKERQKDLK-------------------F 
Human Cyclin H    (1) ---MYHNSSQKRHWTFSSEEQLARLRADANRKFRCKAVANGKVLPNDPVF 
                      51                                             100 
        LmCYC9   (26) -FTRRYFRLSQSAFVISDYLVRKFC--LTESVLLTSLCYWHEFVAAHGLR 
        TbCYC9   (31) VVEMSYYTIAIQAYSMTRYVVENLR--LDSAVVGTAMTYWHIFVSVHGLK 
Human Cyclin C   (32) LSEEEYWKLQIFFTNVIQALGEHLK--LRQQVIATATVYFKRFYARYSLK 
Human Cyclin H   (48) LEPHEEMTLCKYYEKRLLEFCSVFKPAMPRSVVGTACMYFKRFYLNNSVM 
                      101                                            150 
        LmCYC9   (73) KVNEVVLATTCVFLAAKVEHAHIRLARLVETALDLDANTTAAAELEQWCR 
        TbCYC9   (79) KVDEIVLSAACTFLASKVEHHKVRLSDIVALVFEVDPVGGVMESWR---- 
Human Cyclin C   (80) SIDPVLMAPTCVFLASKVEEFGVVSNTRLIAAATSVLKTRFSYAFPKEFP 
Human Cyclin H   (98) EYHPRIIMLTCAFLACKVDEFNVSSPQFVGNLRESPLGQE-----K---- 
                      151                                            200 
        LmCYC9  (123) ----AVLDVELVLCDTIRFDFVRIFPLADTLRSVQTLAEAGQLQDAARQE 
        TbCYC9  (125) ---DVVGQAELLLCYTLKFNFQVIHPVNRINELVFDGNKAVLECA----- 
Human Cyclin C  (130) YRMNHILECEFYLLELMDCCLIVYHPYRPLLQYVQDMGQEDMLLP----- 
Human Cyclin H  (139) -ALEQILEYELLLIQQLNFHLIVHNPYRPFEGFLIDLKTRYPILENPEIL 
                      201                                            250 
        LmCYC9  (169) IGTAVRRVFLFSFVTPLCTKVSMQRLCTSILYMIVTAARREPVPAFQSIW 
        TbCYC9  (167) -----QRLFLLSFVTPLCTRASAEEIVEALVYLAADGAERLEVYANGFNI 
Human Cyclin C  (175) ---LAWRIVNDTYRTDLCLLYPPFMIALACLHVACVVQQKDARQWFAELS 
Human Cyclin H  (188) R-KTADDFLNRIALTDAYLLYTPSQIALTAILSSASRAGITMESYLSESL 
                      251                                            300 
        LmCYC9  (219) SAPEAEFPDEAELEGITAVLMDVFAYLHKKFG-----VPALDDVNEARYK 
        TbCYC9  (212) TSSERR-------DGIISVMLDALVAMRKT-----TKLPKIDNVISARRK 
Human Cyclin C  (222) VDMEK----------ILEIIRVILKLYEQ--------WKNFDERKEMATI 
Human Cyclin H  (237) MLKENRT-CLSQLLDIMKSMRNLVKKYEPPRSEEVAVLKQKLERCHSAEL 
                      301                                338 
        LmCYC9  (264) RRRSQHGNDVGVASSVFSSASADFTPLMKMSEQ----- 
        TbCYC9  (250) RLREQESTRPSVACSSVGTASTDNTPCAPSVE------ 
Human Cyclin C  (254) LSKMPKPKPPPNSEGEQGPNGSQNSSYSQS-------- 
Human Cyclin H  (286) ALNVITKKRKGYEDDDYVSKKSKHEEEEWTDDDLVESL 
 
 
Figure  4.3  Sequence  alignment  of  human  cyclin  C  (NM_005190),  L.  major  CYC9 
(LmjF32.0760) and T.brucei CYC9 (Tb11.01.5600). The sequence identity between LmCYC9 
and TbCYC9 is low (30.1%). When LmCYC9 is compared to Human cyclin C and cyclin H the 
sequence identity between then is 17.9% and 11.9% respectively. In the alignment the yellow 
colour represents the amino acids residues that are conserved throughout all species, the 
blue colour represents amino acids residues that are conserved throughout most of the 
species analysed but not in all of them. Finally, the amino acid residues that are poorly 
conserved throughout all the species are represented in green. 
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               1                                               50 
 LmCYC9    (1) ---MSSSPLSPVYSSPASTGFGAPYLPS---FTRRYFRLSQSAFVISDYL 
 LiCYC9    (1) ---MSSSPSSPVHSSPASTGFAAPYLPS---FTRRYFRLSQSAFVISDYL 
 LbCYC9    (1) ---MSSNPLSPLYSSPASTGFAAPYLPS---FTSRYFRLSQSAFVISDYL 
 TbCYC9    (1) MAGFTETPSWPSLSCEQSSAAAVSVSYSPFVVEMSYYTIAIQAYSMTRYV 
               51                                             100 
 LmCYC9   (45) VRKFCLTESVLLTSLCYWHEFVAAHGLRKVNEVVLATTCVFLAAKVEHAH 
 LiCYC9   (45) VRKFRLTESVLLTSLCYWHEFVAAHGLRKANEIVLATTCVFLAAKVEHAH 
 LbCYC9   (45) VRKFRLTESVLLTSLCYWHEFVAVHGLRKANEIVLATTCVFLAAKVEHAH 
 TbCYC9   (51) VENLRLDSAVVGTAMTYWHIFVSVHGLKKVDEIVLSAACTFLASKVEHHK 
               101                                            150 
 LmCYC9   (95) IRLARLVETALDLDANTTAAAELEQWCRAVLDVELVLCDTIRFDFVRIFP 
 LiCYC9   (95) IRLARLVEAAFDLDVNTTAPAELEQWCRAVLDVELVLCDTIGFDFVRIFP 
 LbCYC9   (95) IRLARLVEAAFDLDANTTPPAELEQWCRAVLDVELVLCDTIRFDFVRIFP 
 TbCYC9  (101) VRLSDIVALVFEVDP--VG-GVMESWRDVVGQAELLLCYTLKFNFQVIHP 
               151                                            200 
 LmCYC9  (145) LADTLRSVQTLAEAGQLQDAARQEIGTAVRRVFLFSFVTPLCTKVSMQRL 
 LiCYC9  (145) LADTLRSVQTLAEAGQLQDAARQEIGTAVRRVFLFSFVTPLCIKVSMQRL 
 LbCYC9  (145) LADTLRSVQTLTETGQLPYAAQQEIGTAVRRVFLFSFVTPLCVKVSMQQL 
 TbCYC9  (148) -VN--R-------INELVFDGNKAVLECAQRLFLLSFVTPLCTRASAEEI 
               201                                            250 
 LmCYC9  (195) CTSILYMIVTAARREPVPAFQSIWSAPEAEFPDEAELEGITAVLMDVFAY 
 LiCYC9  (195) CTSILYMIVTAARRELVTAFQSIWSAPEAEFPDEAELEGITAVLMDVFAY 
 LbCYC9  (195) CTTILYMIVTAGHKELVPAFQSTWSASGAEFPDEAELEGITAVLMDVFAY 
 TbCYC9  (188) VEALVYLAADGAERLEVYANGFNITSSERR-------DGIISVMLDALVA 
               251                                            300 
 LmCYC9  (245) LHKKFGVPALDDVNEARYKRRRSQHGNDVGVASSVFSSASADFTPLMKMS 
 LiCYC9  (245) LHKKFGVPALDDVNEARYKRCRSQHGNDAGVASSVFSSASADFTPLMKMS 
 LbCYC9  (245) LHKKFGVPALDDVNEARYKRRRSQHGNDAGVISSVFSSASADFTPLMKMS 
 TbCYC9  (231) MRKTTKLPKIDNVISARRKRLREQESTRPSVACSSVGTASTDNTPCAPSV 
               301 
 LmCYC9  (295) EQ 
 LiCYC9  (295) EQ 
 LbCYC9  (295) EQ 
 TbCYC9  (281) E- 
 
 
Figure 4.4 Sequence alignment of different CYC9 proteins from trypanosomatid. From line 1 
to line 4, L. major CYC9 (LmjF32.0760), L. infantum CYC9 (LinJ32_V3.0800), L. brasiliensis 
CYC9 (LbrM32_V2.0850), and T. brucei CYC9 (Tb11.01.5600). In the alignment the yellow 
colour represents the amino acids residues that are conserved throughout all species, the 
blue colour represents amino acids residues that are conserved throughout most of the 
species analysed but not in all of them. Finally, the amino acid residues that are poorly 
conserved throughout all the species are represented in green. 
 
 132 
Human CDK1 (0.1761)
Human CDK2 (0.1651)
LmCRK3 (0.2227)
LmCRK1 (0.2402)
LmCRK4 (0.3179)
LmCRK2 (0.2968)
LmCRK7 (0.3431)
LmCRK8 (0.4009)
LmCRK6 (0.3145)
 
 
 
 
 
 
 
 
 
Figure 4.5 Phylogenetic tree of Leishmania major CRKs and human CDKs. Human CDK1 and CDK2, as well as L. major CRK1, 2, 3, 4, 6, 7 and 8 were used. 
Sequences from gene bank accession numbers are NP_001777 for human CDK1, NM_001798 for human CDK2, LmjF21.1080 for LmCRK1, LmjF05.0550 for 
LmCRK2, LmjF36.0550 for LmCRK3, LmjF16.0990 for LmCRK4, LmjF27.0560 for LmCRK6, LmjF26.0040 for LmCRK7 and LmjF11.0110 for LmCRK8. Lines 
represent the degree of divergence between the sequences while the calculated distance values are shown in parenthesis. 
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Table 4.1 Sequence identity comparison between L. major CRKs compared to yeast Cdc2. Accession numbers for L. major proteins are CRK1 (LmjF21.1080), 
LmCRK2 (LmjF05.0550), LmCRK3 (LmjF36.0550), LmCRK4  (LmjF16.0990), LmCRK6 (LmjF27.0560), LmCRK7  (LmjF26.0040), LmCRK8 (LmjF11.0110), Yeast 
(S.pombe) cell division gene (CDC2) (M12912) and human Cdc2 (NM_004196). 
 
  LmCRK1  LmCRK2  LmCRK3  LmCRK4  LmCRK6  LmCRK7  LmCRK8 
S. pombe Cdc2 
 
47.6% 
 
39.4%  50.2%  24.4%  39.9%  34.4%  18.8% 
H. sapiens Cdc2  31.1%  26.4%  41.8%  18.9%  25.5%  25.1%  17.7% 
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                 1                                                                                                          110 
   LmCRK3    (1) -----------------------------------MSSFGRVTARSGDAGTRDSLDRYNRLDVLGEGTYGVVYRAVDKITGQYVALKKVRLDRTEE----GIPQTALREV 
   LmCRK2    (1) -----------------------------------MRSSGPTPARP------TGFQRYQRQHKVGEGSYGKVFLCTDVVEGGTVAVKTSQWNSGEE----GLSVSSIREV 
   LmCRK1    (1) -----------------------------------------------------MTSRYERQEKIGEGTYGVVYKARDTSTSATVALKRIRLDSEEE----GVPCTAIREI 
   LmCRK4    (1) ---------------------------------------------------MSTAGRYKHVVKLGEGTYGSVYKGTEIQTGKVVAFKRMVVTSDDE----GVPGAAIREI 
   LmCRK8    (1) MGGELDNQNKDVPDDGNAACKRACMERLLPSMQQRFAELAHTGVGESSLTVEALFQRYQRVLKVGEGTFGEVFVLYDTVAHTYITMKRMHTLLSLRRRSLGIHRCTFREV 
   LmCRK6    (1) ----------------------------------MSASVNDLDGKLDLVDITALSAAYEPEEVLGEGTYGIVFRARNKATGAKYAIKKLRLDGFSE----GVPATTIREA 
   LmCRK7    (1) ------------------------------------------------------MDKYALGPVIGEGQFGSVRMATVKATGQTVAVKLLHVPRLTE----GIPHPVAREL 
                 111                                                                                                        220 
   LmCRK3   (72) SILQEF-DHPNIVNLLDV-ICSDGKLYLVFEYVEADLKKAIEKQ------------------EGGYSGMDLKRLIYQLLDGLYFCHRHRIIHRDLKPANILL-------- 
   LmCRK2   (66) SLLKEI-RHPNVVRLLDL-FTEEKKLCIVFERMEKDLRSVLSTR------------------QTPIVGRKLKHMMYQLLSALHACHSRRVVHRDIKPGNILVS------- 
   LmCRK1   (54) SLLKEL-RHENIVKLLDV-CHSEHRLTIVFEYLDLDLKKYLDRE------------------NGNLDAATIQHFMRDLLRGVAFCHQRSVLHRDLKPQNLLIS------- 
   LmCRK4   (56) CLLKEL-RHDNVVDLFEV-LFDPPKITMIFELCDCDLKRFMESRP----------------KRLLDAEAEMRPILKQIFIGLEYLHSRSVVHRDMKPQNIFVNVRAPDFA 
   LmCRK8  (111) ELLAAL-QHPNIVQVLDYHILSDGSLVMLMPVIAHDLTSLLRRWPSTPQSSDHGTASTAASTRPRMPLHVVKCIFRQIIAGVAYLHKHKVVHRDLKPSNVMVD------- 
   LmCRK6   (73) TLLHDLNDNPNVVKLLDV-VCSDHRVYLVFELLDEDLRIFIKRYRPV--------SGQKPTNGTAVPLHLVREFTRQILYALWTCHNNRILHRDLKPGNILVAN----YR 
   LmCRK7   (53) LIASRV-DSPFLVKTIEI-TPCGSHMAVVMERCMEDLACVLRKCSP----------------AHPLPLLLTQSYLRMLLTALHALHSSGILHRDVKPSNCFVS------- 
                 221                                                                                                        330 
   LmCRK3  (154) ------------------------------------------------------------TSGNVLKLADFGLARAFQVPMHTYTHEVVTLWYRAPEILLGEKHYTPAVD 
   LmCRK2  (149) ------------------------------------------------------------ADEQTVKLADFGMGRAFGLALQSYTYRIATLYYRAPEVLLGDRYYLPSVD 
   LmCRK1  (137) ------------------------------------------------------------REKE-LKLGDFGLGRSFAIPVRKFTNEVVTLWYRPPDVLLGSMQYGPPVD 
   LmCRK4  (148) ALTASPSSRQDHLQPPPFSGVPTAVGGDAQSAAGSGGRPNPFAGVDSVPPREAATAPSNTPNQLIVKIGDFGLARVEEIPVKKYSHEVVTLWYRSPDVLMGSALYSYPVD 
   LmCRK8  (213) -------------------------------------------------------------HTGVVKLIDFGWSRFCAAAGAMTGPPCVTAFRPPEVLMGAHNHYTFSLD 
   LmCRK6  (170) N--------------------------------------------------------TNGETKFYVKLADFGLARMFEMSVQTYTHEVMTLWYRSPEIILGDRHYTPAAD 
   LmCRK7  (138) ------------------------------------------------------------VDGC-LKLGDFGLSRPLG---SDMSHEVVSRWYRAPELLFGQRRYGGEVD 
                 331                                                                                                        440 
   LmCRK3  (204) MWSVGCIFAELTR--RKVLFRGDSEIGQLFEIFQVLGTPTD-TEGSWPGVSRLPDYRDVF----------PKWT------------------------------------ 
   LmCRK2  (199) MWSMGCVMAELAL--RRALFRGEGEYSQLITIFGIMGTP---SERVWPGVSRLPHYNAEF----------PSWV------------------------------------ 
   LmCRK1  (186) VWSVGCIFSEMAT--GTPLFAGKNDADQLMRIFRFLGTP---NNRVWPSMNQYPNSNNMLSQPEFLQNFEPEWSN----------------------------------- 
   LmCRK4  (258) IWSMGAIFFEMAT--SKVLFSGLHEDEQVLRMFWLLGSP---TRETWPSMLSYPGTMERLERASRAAAERPDLRFGSDVCVQQQPPSSQSHSGSRAPDLLTQIAHKRFYH 
   LmCRK8  (262) IWCCGCILFEMLTG-GTPFAKSRNEAECLANIVDWLGSPPSSSEVYYRRAARCPFPLAPGR----------P-------------------------------------- 
   LmCRK6  (224) VWSVGCIVAEMIL--GYSLFRGENWRDQLDKVFYVVGTP---TEQTWPGVTKLPGYDRNFKV------------YH---------------------------------- 
   LmCRK7  (184) MWAAGCVFAELLRGHGRPFFTGDGDISQIAKIFDVFGTP---TGATCSFYRQLPDWEKVYFEEKK--------------------------------------------- 
                 441                                                                                                      548 
   LmCRK3  (265) ----------------------------------AKRLGQVLPELHPDAIDLLSKMLKYDPRERISAKEALQHPWFSDLRW--------------------------- 
   LmCRK2  (258) ----------------------------------PTSLEKYIPTLDPEGIALLKAMLRYDPQRRITALQAMQHPFFDDVRDECEARLQQQQQQQQS------------ 
   LmCRK1  (256) ----------------------------------VLGSVPGYEKLGCAGVDLLEKLLRYEPSERITAADALNHPYFSLQF---------------------------- 
   LmCRK4  (363) SLKTIQQREESARSSANTYQLPVELWFDRPLFGEYMSATGFDSCVTAEGVDLLRQCLLYEPNHRITAAAAVRHAYLHAVPVPTAGALDVLMTSLLQTMEACHLL---- 
   LmCRK8  (323) ---------------------------------DTFAQRCSNYGIKSAEAMFLRRMLCLEPGERATAEALLRDPWFTTAPTMCVPRAVPLPAHNMFRLVEVKRKELEH 
   LmCRK6  (283) ----------------------------------VAPLPTRLRDYDEKAVEFIAYLLVTNPKLRPTIPDILEHPFMKDA----------------------------- 
   LmCRK7  (246) ----------------------------------GTGLRVLLPFVPPEALDLLTKMLALDPASRCSAAEALTHSFFALSDTLLRA----------------------- 
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Figure 4.6. Sequence alignment between L. major CRK1-4 and 6-7. Sequences from gene bank accession numbers are LmjF21.1080 for LmCRK1, LmjF05.0550 
for LmCRK2, LmjF36.0550 for LmCRK3, LmjF16.0990 for LmCRK4, LmjF27.0560 for LmCRK6, LmjF26.0040 for LmCRK7 and LmjF11.0110 for LmCRK8. In the 
alignment the yellow colour represents the amino acids residues that are conserved throughout all species, the blue colour represents amino acids residues 
that are conserved throughout most of the species analysed but not in all of them. Finally, the amino acid residues that are poorly conserved throughout all 
the species are represented in green. 
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                        1               18 
Human CDK1 T loop   (1) FGIPIRVYTHEVVTLWYR 
    LmCRK1 T loop   (1) FAIPVRKFTNEVVTLWYR 
    LmCRK2 T loop   (1) FGLALQSYTYRIATLYYR 
    LmCRK3 T loop   (1) FQVPMHTYTHEVVTLWYR 
    LmCRK4 T loop   (1) EEIPVKKYSHEVVTLWYR 
    LmCRK6 T loop   (1) --MSVQTYTHEVMTLWYR 
    LmCRK7 T loop   (1) SRPLGSDMSHEVVSRWYR 
    LmCRK8 T loop   (1) FCAAAGAMTGPPCVTAFR 
 
Figure  4.7  Sequence  alignments  between  T-loop  regions  of  human  CDK1  and  L.  major 
CRK1-4 and 6-8. Sequences from gene bank accession numbers are NP_001777 for human 
CDK1,  LmjF21.1080  for  LmCRK1,  LmjF05.0550  for  LmCRK2,  LmjF36.0550  for  LmCRK3, 
LmjF16.0990  for  LmCRK4,  LmjF27.0560  for  LmCRK6,  LmjF26.0040  for  LmCRK7  and 
LmjF11.0110  for  LmCRK8.  The  alignment  shows  that  the  threonine  residue,  which  is 
targeted for phosphorylation by CAK1, is conserved in LmCRK1, 2, 3, 6 and 8. It also shows 
that for CRK4 and CRK7 the threonine residue is substituted for a serine residue. In the 
alignment  the  yellow  colour  represents  the  amino  acids  residues  that  are  conserved 
throughout all species, the blue colour represents amino acids residues that are conserved 
throughout most of the species analysed but not in all of them. Finally, the amino acid 
residues that are poorly conserved throughout all the species are represented in green.  
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Figure  4.8.  RT-PCR  to detect  the  expression of cyclin genes in  L.  major promastigotes. 
Using cDNA from L. major PCR reactions were performed to confirm the expression of the 
cyclin genes in these cells. All PCRs used as sense primer the SL primer (OL1760) In lane 1, 
PCR using oligos OL1760/OL814 that amplify 1Kb from CYCA gene; In lane 2, PCR using 
oligos OL1760/OL1764 that amplify 0.6Kb fragment of CYC2; In lane 3, PCR using oligos 
OL1760/OL1766 that did not amplify a fragment of 1.2 Kb from CYC3; in lane 4, PCR using 
oligos OL1760/OL1768 that amplify a 0.8Kb fragment from the CYC7; in lane 5, PCR reaction 
using oligos OL1760/OL1771 that amplify a 1.1Kb fragment of CYC9; in lane 6, PCR reaction 
using oligos OL1764/OL1773 that did not amplify a fragment of 2Kb from the gene CYC10. 
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Figure 4.9 Attempt to purify L. major CYC proteins. LmCYC10, LmCYC3 and LmCYC7 were 
cloned into the expression vectors pGL1337, pGL1350, and pGL1335 respectively and were 
used  for  affinity  purification  with  the  Ni-Agarose  column. The  procedure  used  to  purify 
LmCRK3his, was also used for the proteins above. The purification of the induced proteins 
was carried out and analyzed on SDS-PAGE gel stained with Coomassie Blue (Lanes 1-4). 
Lane 1: Insoluble fraction. Lane 2: Soluble fraction. Lane 3: Flow through. Lane 4: Elution. 
Western blot carried out with mouse α-his antibody diluted 1:5.000 as primary antibody and 
α-mouse HPR conjugated antibody as secondary, diluted 1:5.000. The proteins are arrowed 
and can be observed only in the insoluble Lane 1. 
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Figure 4.10 Purification of L. major CYC9. The same procedure used to purify LmCRK3his 
was  used  for  LmCYC9his.  The  purification  of  the  induced  protein  was  carried  out  and 
analyzed on  SDS-PAGE  gel  stained  with  Coomassie  Blue  (Lanes  1-4).  Lane  1: Insoluble 
fraction. Lane 2: Soluble fraction. Lane 3: Flow through. Lane 4: Elution. A protein of around 
34kDa (arrowed) can be observed in the Coomassie gel, which corresponds to LmCYC9his. 
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Figure 4.11 L. mexicana CRK3: L. major CYC6his purification and kinase assay. (A) E. coli 
BL-21 DE3 pLYS cells were used to induce the expression of LmCRK3 from pGL1072 and 
CYC6his  from  pGL1218.  The  purification  of  the  induced  protein  was  carried  out  and 
analyzed on an SDS-PAGE gel stained with Coomassie Blue (Lanes 1-6). Lane 1: Insoluble 
fraction. Lane 2: Soluble fraction. Lane 3 to 6: obtained from the flow through of the ion 
exchange purification. (B) A kinase assay shows Histone H1 band phosphorylated by the 
purified complex. 
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Figure 4.12 Purification of L. major CRK1. The same procedure used to purify LmCRK3his 
was used for LmCRK1his. The purification was analyzed on SDS-PAGE gel stained with 
Coomassie Blue (Lanes 1-4). Lane 1: Insoluble fraction. Lane 2: Soluble fraction. Lane 3: 
Flow through. Lane 4: Elution. A protein of 34.4kDa can be observed in the Coomassie 
(arrowed) which corresponds to LmCRK1his. 
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Figure 4.13 Purification of L. major CRK2. The same procedure used to purify LmCRK3his 
was used for LmCRK2his protein. The purification of the induced protein was carried out 
and analyzed on SDS-PAGE gel stained with Coomassie Blue (Lanes 1-4). Lane 1: Insoluble 
fraction.  Lane  2:  Soluble  fraction.  Lane  3:  Flow  through.  Lane  4:  Elution.  A  protein  of 
36.4kDa can be observed in the Coomassie (arrowed), which corresponds to LmCRK2his. 
 
 
 
 
 
 
LmCRK2       143 
1     2    3    4      
12
25
32.5
45
63
kDa
1     2    3    4      
12
25
32.5
45
63
kDa
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Purification of L. major CRK3. The same procedures used to purify LmeCRK3his 
were  used  for  LmCRK3his. The  purification of  the  induced  protein  was  carried  out  and 
analyzed on  SDS-PAGE  gel  stained  with  Coomassie  Blue  (Lanes  1-4).  Lane  1: Insoluble 
fraction. Lane 2: Soluble fraction. Lane 3: Flow through. Lane 4: Elution. A protein of 35kDa 
can be observed in the Coomassie (arrowed), which corresponds to LmCRK3his. 
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Figure 4.15 Purification of L. major CRK4. The same procedures used to purify LmCRK3his 
were used for LmCRK4his proteins of 51.7 kDa. The purification of the induced protein was 
carried out and analyzed on SDS-PAGE gel stained with Coomassie Blue (Lanes 1-4). Lane 
1: Insoluble fraction. Lane 2: Soluble fraction. Lane 3: Flow through. Lane 4: Elution. A 
protein  of  51.7kDa  can  be  observed  in  the  Coomassie  (arrowed)  which  corresponds  to 
LmCRK4his. 
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Figure 4.16 Purification of L. major CRK6. The same procedures used to purify LmCRK3his 
were also used for LmCRK6his protein of 37.3 kDa. The purification of the induced protein 
was carried out and analyzed on SDS-PAGE gel stained with Coomassie Blue (Lanes 1-4). 
Lane 1: Insoluble fraction. Lane 2: Soluble fraction. Lane 3: Flow through. Lane 4: Elution. A 
protein  of  37.3kDa  can  be  observed  in  the  Coomassie  (arrowed)  which  corresponds  to 
LmCRK6his. 
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Figure 4.17 Purification of L. major CRK7. The same procedures used to purify LmCRK3his 
were also used for LmCRK7his protein of around 32.4 kDa. The purification of the induced 
protein was carried out and analyzed on SDS-PAGE gel stained with Coomassie Blue (Lanes 
1-4). Lane 1: Insoluble fraction. Lane 2: Soluble fraction. Lane 3: Flow through. Lane 4: 
Elution.  A  protein  of  32.4kDa  can  be  observed  in  the  Coomassie  (arrowed)  which 
corresponds to LmCRK6his. 
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Figure 4.18 Purification of L. major CRK8. The same procedures used to purify LmCRK3his 
were also used for LmCRK8his protein of around 44.4 kDa. The purification of the induced 
protein was carried out and analyzed on SDS-PAGE gel stained with Coomassie Blue (Lanes 
1-4). Lane 1: Insoluble fraction. Lane 2: Soluble fraction. Lane 3: Flow through. Lane 4: 
Elution.  A  protein  of  44.4kDa  can  be  observed  in  the  Coomassie  (arrowed)  which 
corresponds to LmCRK6his. 
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Figure 4.19 Kinase assay using CRK1 as a substrate for Civ1. (A)Coomassie stained gel and 
(B) the overnight exposed film. LmCRK3 was used as a control on lanes 1 to 4 and CRK1 on 
lanes 6-9 as a substrate for Civ1. Lanes 5 and 10 contained no CRK and 2.5µg of Civ1. 
Lanes 1 and 6 contained no Civ1 and 2µg of CRK3 and CRK6 respectively. On lanes 2 to 4 
and 7 to 9 Civ1 was added at 1, 1.5 and 2µg while amounts of CRKs were constant at 2µg.  
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Figure 4.20 Kinase assay using CRK2 as a substrate for Civ1. (A)Coomassie stained gel and 
(B) the overnight exposed film. LmCRK3 was used as a control on lanes 1 to 4 and CRK2 on 
lanes 6-9 as a substrate for Civ1. Lanes 5 and 10 contained no CRK and 2.5µg of Civ1. 
Lanes 1 and 6 contained no Civ1 and 2µg of CRK3 and CRK2 respectively. On lanes 2 to 4 
and 7 to 9 Civ1 was added at 1, 1.5 and 2µg, while amounts of CRKs were constant at 2µg.  
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Figure 4.21 Kinase assay using CRK7 as a substrate for Civ1. (A) Coomassie stained gel 
and (B) the overnight exposed film. LmCRK3 was used as a control on lanes 1 to 4 and 
CRK7 on lanes 6-9 as a substrate for Civ1. Lanes 5 and 10 contained no CRK and 2.5µg of 
Civ1. Lanes 1 and 6 contained no Civ1 and 2µg of CRK3 and CRK7 respectively. On lanes 2 
to 4 and 7 to 9 Civ1 was added at 1, 1.5 and 2µg while amounts of CRKs were constant at 
2µg.  
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Figure 4.22 Co-purification of CRK2/CYC7his complex. An attempt to purify this complex 
was carried out.  Lane 1, the insoluble fraction; lane 2, the soluble total extract; lane 3 the 
flow through; lane 4 the column wash and lanes 5 and 6 the elutions.  
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Figure 4.23 Co-purification of CRK1/CYCAhis complex. An attempt to purify this complex 
was carried out. Lane 1, the insoluble fraction; lane 2, the soluble total extract; lane 3 the 
flow through; lane 4 the column wash and lanes 5 and 6 the elutions.  
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Figure 4.24 Co-purification of CRK1/CYC7his complex. An attempt to purify this complex 
was carried out. Lane 1, the insoluble fraction; lane 2, the soluble total extract; lane 3 the 
flow through; lane 4 the column wash and lanes 5 and 6 the elutions.  
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Table 4.2 Co-expression of cyclin-kinase pairs in E. coli. Summary of co-expressions used to attempt the purification of new 
cyclin:kinase complexes. 
 
 
  pGL1334  pGL1218  pGL1335  pGL1336  pGL1337  pGL1350  pGL630 
pGL1338  CYCA 
his/CRK1 
CYC6 
his/CRK1 
CYC7 
his/CRK1 
CYC9 
his/CRK1 
CYC10 
his/CRK1 
CYC3 
his/CRK1 
MexCYCA 
his/CRK1 
pGL1339  CYCA 
his/CRK2 
CYC6 
his/CRK2 
CYC7 
his/CRK2 
CYC9 
his/CRK2 
CYC10 
his/CRK2 
CYC3 
his/CRK2 
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his/CRK2 
pGL1340  CYCA 
his/CRK3 
CYC6 
his/CRK3 
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CYC3 
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his/CRK3 
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his/CRK8 
CYC7 
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Figure  4.25  Kinase  assays  with  Co-eluted  complexes.  Elutions  from  the  co-expression 
purifications were assayed in in vitro kinase assays using three different substrates Histone 
H1, β-Casein and MBP. Reactions were performed in kinase assay buffer containing 5µg of 
histone H1 or β-Casein or MBP as substrate and γ-ATP labelled with P
32. The reaction was 
incubated at 30
oC for 30 min. The reactions were then stopped by adding 2X protein loading 
buffer. The samples were then loaded in a 12% SDS-PAGE gel, stained with Coomassie, 
dried and exposed to a 
32P particle emission sensitive film.  The gel was exposed over night 
to a general purpose Kodak film. As a positive control, the active CRK3:CYC6his complex 
was used. 
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Figure 4.26 Western blot and kinase assay of in vivo expressed and purified LmCRK6HA 
(HA-tagged). (A) Affinity purified CRK6 from overexpressing L. major cell lines is detected 
with HA specific antibody (lane 2). Affinity purified CRK6 from L. major cell lines expressing 
HA tagged CRK6 from a genomic integration in the rRNA locus was also detected with HA 
antibody (3A). Purification using the same affinity column was performed with WT cells and 
no protein was detected by the antibody (1A). These purifications were assayed for kinase 
activity (B). No histone H1 phosphorylation is observed in the WT (1B) elution while both 
CRK6 HA tagged cell lines possess kinase activity towards histone H1 (2B, overexpressed 
and 3B, integrated). 157 
 
 
 
 
 
 
 
 
Figure 4.27 Immunofluorescense of L. major cell lines expressing HA tagged LmCRK6. On (A), α-HA, DAPI and greyscale can be seen. On (B), merged α-HA 
and DAPI are shown for LmCRK6HA expressing cell lines. The primary antibody was diluted at 1 in 500 and incubated for 1 hour at room temperature or 
alternatively overnight at 4
oC. The cells were then washed 3 times with 1 ml of PBS. The secondary antibody was diluted at 1 in 1,000 and incubated in the dark 
for 1 hour at room temperature. 
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4.3 Discussion 
Cyclins  regulate  the  cell  cycle  by  binding  to  and  activating   cyclin-dependent  kinases. 
Phosphorylation  of  specific  targets  by  cyclin-Cdk  complexes  sets  in  motion  d ifferent 
processes that drive the cell cycle in a timely manner. In yeast, a single Cdk is activated by 
multiple cyclins to drive the cell cycle. In mammalian cells 11 CDKs are known (Parsons 
et al., 2005). In trypanosomatids there are also a large number of CRKs and cyclins. While 
in yeast and mammalian many cyclin:kinase pairs have been identified, in trypanosomatids 
these interactions are still largely unknown. The ability of these cyclins to target specific 
proteins and to initiate different cell-cycle events might, in some cases, reflect the timing 
of the expression of the cyclins; in others, it might reflect intrinsic properties of the cyclins 
that render them better suited to target particular proteins. Cyclin:kinase pairs have been 
identified in many different organisms using different strategies (Bloom and Cross, 2007). 
In T. brucei the cyclin E1 partners were assigned via complex  formation with different 
CRKs (Gourguechon et al., 2007).  
In the current chapter, it was shown that His tagged CYC6 can be used to co-purify non 
tagged  CRK3  from E.  coli  lysates  in  the  form  of  a  cycl in  kinase  complex  (R.  Walker, 
unpublished and see Figure 4.11). The complex was shown to be active against Histone 
H1, MBP and β-Casein as substrates (Figure 4.25). Other His tagged CRKs from L. major 
were  then  purified  successfully  and  assayed in  vitro.  It  was  first  tested  whether these 
kinases possess activity as monomers against Histone H1, MBP and β-Casein or have auto 
phosphorylation capability. It was observed that none of the CRKs tested (CRK1-4 and 
CRK6-8)  had  auto  pho sphorylation  capacity  or  activ ity  as  monomers  towards  the 
substrates assayed. It was then tested if Civ1 had activity towards CRK1, CRK2, CRK6 
and CRK8 kinases, as they all contained a conserved threonine residue at the activation 
loop (Figures 4.19-4.21). The ability of Civ1 to phosphorylate the serine residue of CRK4 
and CRK7 was also tested, since they replace the threonine  in these proteins and could       159 
potentially behave like an activation residue. Except for L. major CRK3, none of the CRKs 
tested were phosphorylated by Civ1. These data confirmed the  findings that CRK3  is a 
substrate for yeast Civ1 and provides some evidence that the T-loop region of CRK3 is 
similar  to  the  Cdc2  T -loop.  CRK3  indeed  has  been  pro posed  to  be  the  functional 
homologue  of  this  protein  (Grant  et  al.,  1998;Hassan  et  al.,  2001).  The  other  CRKs 
assayed that could not be phosphorylated by Civ1 may require a different kinase capable of 
recognizing their T-loop or their residues are not suitable for Civ1. 
The fact that none of the CRKs tested had monomeric activity towards the substrates used 
was expected since  all  CDKs  homologues  in  humans depend upon,  not only the cyclin 
partner, but the phosphorylation of the threonine residue at the activation loop. Recently, it 
has been shown that human CDK2 can autophosphorylate its T160 residue (Kaldis et al., 
1996;Abbas et al., 2007). As it was observed from the experiments in this chapter, none of 
the CRKs tested as monomers can auto phosphorylate like the human CDK2. It may also 
be the case that a cyclin is needed to bind and modify structurally the kinase to expose T-
loop of other CRKs but not of CRK3. The use of a Leishmania CDK7 or Civ1 homologue 
was not attempted, because no similar protein could be unambiguously be identified in the 
Leishmania genome.  
Taken that LmCYC3, LmCYC7 and CYC10 were insoluble (Figure 4.9) and not suitable 
for purification and assays,  L. major CYC9 was then purified (Figure 4.10) and used to try 
to activate other L. major CRKs. This cyclin, as it was shown in the sequence alignments 
and the phylogenetic tree  is the closest cyclin  in the Leishmania genome to resemble a 
transcriptional cyclin (C or H). Cyclin H is the human cyclin that activates CDK7/MAT1, 
the  kinase  activating  kinase  that  phosphorylates  the  Threonine  residue  at  the  activation 
loop of  mammalian  cells (Thuret et al., 1996;Kaldis et al., 1996). None of the purified 
CRKs from L. major could be activated by CYC9. It is unknown if Leishmania possesses a 
single monomeric CAK like yeast or a tripartite complex like humans. But since no clear       160 
homologues  from  CDK7/MAT1/Cyclin  H  or  CAK  can  be  identified in  the  genome 
databases  from  the Leishmania  or  Trypanosoma,  CYC9  had  to  be  tested  against   all 
possible CRKs available. The lack of activity from the CRKs when CYC9 was added may 
be due to the wrong choice of substrates used, or CYC9 may activate other kinases not 
tested, or it may require a third protein, MAT1-like, yet to be identified. 
In the present chapter the identification of cyclin kinase activating partners was attempted 
using  an E. coli based system. Cyclin genes were cloned  in pET15b  vectors to express 
these proteins with a histidine tag. The kinase genes were cloned in a different expression 
vector pACYC Duet to express the kinases free from any histidine tag. It is important to 
note that pET plasmids and pACYC plasmids  have different origins of replications and 
therefore  are  compatible  for  co-existing  inside  the  same  cell.  They  are  suitable  for  co-
transformation and co-expression also because they possess different antibiotic resistance 
markers.  Plasmids  from  the  fam ily  pET15  are  ampicillin  resis tant  and  pACYC  are 
chloramphenicol resistant. Despite the fact that a low expression yield was observed for 
several of the cyclins tested before, it was expected that if these proteins could  bind to 
kinase subunit as they are synthesised, they would stay soluble. This was already true for 
the purification of CRK3:CYC6 complex (Figure 4.11).  
To explain why no cyclin:kinase complexes could be purified from the co-transformed and 
induced cell lines it was postulated that pACYC Duet plasmid was expressing the kinases 
at a low level or not expressing the kinase at all. Although kinases could be observed in 
some of the purifications, the corresponding band for the histidine-tagged cyclin was not 
seen  (Figure  4.22-4.24).  The  elution  from  several  of  these  purifications  was  tested  for 
kinase  activity  using  three  different  substrates,  histone  H1,  β-casein  and  MBP  (Figure 
4.27). No kinase activity could be detected. To explain this result it was postulated that no 
pair of cyclin kinase was present in the elution or no appropriated substrate was used.       161 
The immunoprecipation of HA tagged LmCRK6 was successful since kinase activity could 
be detected in the transfected cell lines and not in the wild type cells control (Figure 4.26). 
This purification took place after confirmation that an HA tagged protein sized around 36 
kDa was detected in the western blot of cell lines S-100 lysates. This result suggests that 
CRK6 is active in L. major but its role in the cell cycle remains unknown. The role of T. 
brucei CRK6 in the cell cycle was analysed using RNAi and it was postulated that CRK6 
may play either a minor role or no role at all (Tu et al., 2005). It is unknown if a cyclin 
subunit  is  activating  the  acti ve  purified  HA  LmCRK6,  however ,  it  is  likely  as  the 
monomeric  recombinant  CRK6  did  not  have  kinase  activity  against  the  same  substrate. 
Further  purifications  could  be  used  to  co-purify  partners  that  interact  with  CRK6.  This 
approach  could  be  used  not  onl y  to  identify  cyclins,  but  als o  kinase  inhibitors  and 
accessory proteins. 
The immunofluorescense assays of the cell lines expressing LmCRK6HA to localize this 
protein in Leishmania cells was carried out. For both transfected cell lines expressing HA 
tagged LmCRK6  it was observed that this protein appears to be present throughout the 
cytoplasm of the cells (Figure 4.27). No immunofluorescense signal was detected in wild 
type cells.  Whilst indicative of a cytoplasmic localisation, conformation of the location 
would be best achieved with mono-specific antibodies raised to recombinant LmCRK6. In 
interphasic cells Cdk1 is localized in the cytoplasm in three forms: soluble, microtubule 
associated,  or  centrosome  associated.  In  late  prophase,  most  of  the  C dk1  is  rapidly 
transported  into  the  nucleus  (Takizawa  and  Morgan,  2000).  Other  Cdks  known  to  be 
shifted  to  the  nucleos  are Cdk2  and  Cdk4,  they  bind  bound  Cip/KIP  mol ecules  for 
transportation (LaBaer et al., 1997). In the presented experiments LmCRK6 is present in 
the cytoplasm of the cells in similar manner observed for other important cell cycle related 
Cdks.  Experiments  of  cell  cycle  synchronization  can  be  used to  determine  if  CRK6  is 
driven to the nucleos. However, L. major cell cycle synchonizing procedures have not been 
successful.162 
 
 
 
Chapter 5 
In vivo study of L. major CYCA 
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5.1 Introduction 
Genome sequence analysis of L. major has allowed the study of the cyclin gene family in 
this organism. It was found that there are 11 cyclin genes, CYC2-11 and CYCA. Ten of 
these  genes  (CYC2-11)  have  homologues  in T.  brucei,  while  CYCA  is  a  gene  found 
exclusively in the Leishmania genus. Further analysis of the CYCA gene has shown that the 
encoded protein has the highest level of sequence alignment with mitotic cyclinsl, assessed 
by sequence alignment (Figure 3.3). In this phylogenetic tree CYCA clusters with human 
mitotic cyclin B-type and dual cyclin A. The other known mitotic cyclin in Leishmania is 
CYC6. However, little is known about this mitotic cyclin. In T. brucei, it has  been shown 
that  CYC6  does  have  a  role  in the  cell  cycle  and  interacts  with  CRK3  to  regulate  the 
transition from G2 to M phase (Hammarton et al., 2004). The in vivo partner for CRK3 has 
yet to be identified in L. major. 
In  Chapter  3,  I  showed  that L.  mexicana  and L.  major CYCA  interact  and  activate L. 
major, L. mexicana and T. brucei CRK3 in vitro. Based on the aforementioned findings, 
the aim of this chapter was to identify in vivo CRKs with affinity to CYCA in L. major 
cells to confirm the in vitro results already obtained (Chapter 3). Furthermore, the study 
aimed to assess the role of this unique cyclin using gene knock out and in vivo tags.  
The plasmid pX63 has been used as a backbone to disrupt genes in Leishmania (Souza et 
al., 1994). A derived version of this plasmid pGL102 was used to attempt the disruption of 
the CYCA gene from L. major. The expression cassette of the drug resistance gene was 
flanked at both ends by CYCA flanking DNA.  This permitted subsequent excision of the 
entire insert free of vector DNA for homologous recombination with chromosomal CYCA 
sequence (Figure 5.1). 164 
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Figure 5.1 (A) Plasmid maps of pGL1249 and pGL1265. These plasmids were linearized by digestion with HindIII and BglII and were used to transfect L. major 
cells in an attempt to knock out CYCA. (B) Intergrated CYCA locus with pGL1249 (top, left) and pGL1265 (bottom). Primers used to check for correct integration 
are also shown in the Figure.  PCR details are described in m ethods. Targeted gene disruption of  CYCA (Right). A representation of the CYCA  locus and 
integrated targeting constructs. Changes in the size of the HindIII restriction fragment upon integration of either the CYCA-HYG or CYCA-BSD gene disruption 
cassettes are shown. 
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The Tandem Affinity Purification (TAP) method involves the fusion of the TAP tag to the 
target protein and the introduction of the construct into the host cell or organism. The in 
vivo expressed protein can be purified from cell extracts.  Proteins that are associated with 
the TAP-tagged target are recovered by two step specific affinity purification/elution. The 
TAP tag consists of two IgG binding domains of Staphylococcus aureus protein A (ProtA) 
and a Calmodulin binding peptide (CBP) separated by a TEV protease cleavage site (Puig 
et al., 2001). 
The HA epitope has been in use for many years (Field et al., 1988). Commercial antibodies 
for  immunoblot  and immunofluorescense  are  available  commercially.  The  HA  tag  i s  a 
small peptide from the haemaglutinin protein of the influenza virus (HA1). The antibodies 
against HA epitope are also used to purify proteins fused to it. This strategy was used to 
tag CYCA and CRK6 proteins from L. major. 
5.2 Results 
5.2.1 L. major CYCA knock out attempts 
L. major gDNA was used to amplify the flanking regions of LmCYCA and construct two 
plasmids  that  were  used  to  att empt  to  delete  the  CYCA  gene.  By  homologous 
recombination, attempts to replace the two alleles of LmCYCA with a drug resistance gene 
present in the plasmids were carried out. The plasmids that were designed and used are 
shown in Figure 5.1, pGL1249 and pGL1265 have the same 3’ and 5’ flanking regions but 
different drug markers that allowed the knock out of the two gene alleles. These plasmids 
were  digested  with HindIII  and BglII  restriction  enzymes  and  the  gel  purified  cassettes 
were used in transfections. However, no first allele knock out of CYCA was obtained. The 
plasmids  were  sequenced  again and  this  confirmed  their  seque nce.  An  alternative 
transfection  protocol  was  used (Robinson et  al.,  2003)  but  no  integration  was  obtained       167 
after several attempts. Resistant cell  lines were  selected  for both antibiotics used  in the 
plasmids, but PCR using gDNA from these cell lines showed that no correct integration 
was obtained. The PCRs used OL2060/OL2061 and OL2058/OL2059 for analysis of the 
recombined locus containing Hygromycin and OL2060/OL536 and OL2059/OL537 for the 
analysis of the Blasticidin recombined locus (Figure 5.1). PCR fragments corresponding to 
the correctly integrated locus were not detected. The strategy is outlined in Figure 5.1.  
5.2.2 L. major CYCA TAP tags attempts 
L. major CYCA was cloned into pGL955 (derived from plasmid pX53) and fused to a TAP 
TAG  at  the  C -terminal  end  of  the  protein  ge nerating  pGL1250.  This  plasmid  was                       
used  in several  attempts  to transfect  wild  type L.  major  cells.  Resistant  cell  lines  were 
obtained, grown and cell lysates were tested by western blot to detect of the TAP tagged 
CYCA.  Two  antibodies  were  used  to try  to  detect the  CYCA  TAP   tagged  fusion;  anti 
protein A (Sigma) and anti Calmodulin (Santa Cruz) antibodies. These antibodies failed to 
detect the TAP tag expression in Leishmania cell lysates.  
5.2.3 L. major CYCA HA TAG 
L. major CYCA was also amplified with a  C- or N-terminal HA TAG  and cloned  into 
pGL102 (derived from plasmid pXG). The two plasmids generated were named pGL1388, 
which  added  an  N-terminal  HA  TAG  (HA-CYCA),  and  pGL1389,  which  added  a  C-
terminal HA TAG (CYCA-HA) (Figure 5.2). These plasmids derived  from pGL102 are 
episomal vectors that overexpress the proteins in L. major WT cells. Cell lines resistant to 
neomycin were grown and cell lysates were used in western blot analysis using anti HA 
antibody (Roche). The expression of both C and N-terminal CYCA HA tagged proteins 
were detected at the predicted size of 35 kDa while no protein was detected in wild type 
cells (Figure 5.3).        168 
An immune-precipitation (IP) of HA tagged CYCA from L. major was performed using 
HA matrix (Roche). The IP result was analysed on a SDS-PAGE gel stained with silver. A 
protein corresponding to the expected size of HA tagged CYCA was observed in both HA-
CYCA and CYCA-HA immune-precipitates, but not wild type (Figure 5.4). The material 
bound  to  the  column  was  probed   with  an  antibody  specific  to CRK3  and  a  protein 
corresponding  to  CRK3  was observed  in  HA-CYCA  immunprecipitates  but  not  in  the 
CYCA-HA  immunprecipitates  (Figure  5.5)  suggesting  that  tag  may  interf ere  with  the 
ability of the cyclin to bind to the CRK3 when placed at the C-terminus of the protein. The 
same  CRK3  band  was  not  detect ed  in  the  WT  cells.  This  resul t  showed  that  CYCA 
interacts in vivo with CRK3 in L. major promastigote cells. 
The product of the IP was assayed for histone H1 kinase activity. Activity was detected in 
HA-CYCA and CYCA-HA immune-precipitated samples, but not in WT (Figure 5.6). The 
transfected cell lines expressing HA-tagged CYCA were used in immunofluorescence in 
an attempt to localize CYCA in L. major procyclic promastigotes. Using anti HA antibody 
(Roche), both HA-CYCA and CYCA-HA were localized throughout the cell, including the 
flagellum. Furthermore, it seemed to be present in the flagella pocket region (Figure 5.7).169 
pGL1388
7754 bp
amp
neo
L. major CYCA + N-ter HA tag
5'DST
3'13K
OL1938 (100.0%)
OL1937 (100.0%)
pGL1389
7751 bp
amp
neo
L. major CYCA + C-ter HA tag
5'DST
3'13K
OL1935 (100.0%)
OL1936 (100.0%)
pGL1388
7754 bp
amp
neo
L. major CYCA + N-ter HA tag
5'DST
3'13K
OL1938 (100.0%)
OL1937 (100.0%)
pGL1389
7751 bp
amp
neo
L. major CYCA + C-ter HA tag
5'DST
3'13K
OL1935 (100.0%)
OL1936 (100.0%)
 
 
 
 
 
 
 
 
Figure 5.2 Plasmid maps of pGL1388 and pGL1389. These plasmids were used to transfect L. major cells in an attempt to over express HA tagged CYCA.  
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Figure  5.3  Western  blot  of  procyclic  promastigote  L.  major  cell  lysates  with  anti-HA 
antibody. Lane 1: 35 kDa HA polypeptide as a positive control, Lane 2: Lysate of L. major 
transfected with CYCA-HA episome, Lane 3: Lysate of L. major transfected with HA-CYCA 
episome, Lane 4: WT cell lysate.  
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5.3 Discussion 
Cell proliferation is regulated by proteins involved in the control of the cell cycle, which is 
driven  by  cyclins  and  their  as sociated  kinases. The  plasmids  generated to  transfect L. 
major and knock out the CYCA gene were not able to disrupt the gene in the locus. As 
attempts to knock out CYCA in L. major failed, the sequences of pGL1249 and pGL1265 
plasmids used to transfect Leishmania cells were confirmed. Although resistant cell lines 
were obtained for some of the transfections, PCR analysis of these cell lines showed that 
plasmid DNA was either integrated in the wrong locus or present in the form of episome 
DNA,  suggesting  that  CYCA  migh t  be  an  essential  gene  in L.  major  procyclic 
promastigote forms 
Although this  view  is  now changing,  it has  been believed that some  cyclins and cyclin 
dependent kinases are  nonessential  mainly due to redundancy of  function (Welcker and 
Clurman,  2005).  In  trypanosomes  CYC2,  CRK1  and  CR K3  have  been  shown  to  be 
essential (Mottram et al., 1996b;Grant et al., 1998;van Hellemond et al., 2000;Hammarton 
et al., 2004). This raised the  hypothesis that  in these organisms  each cyclin-kinase pair 
might have
 an independent and essential function in the cell and also it provided further 
evidence that trypanosomatid CRKs are valid
 drug targets. In T. brucei CRKs as essential 
proteins  for  parasite  survival  has  been  addressed (Tu et  al.,  2004;Tu et  al.,  2005)  and 
shown  that  in  this  organism  not  all  CRKs  are  essential  for  c ell  cycle  progression  and 
parasite survival.  Knocking down CRK genes using RNAi  showed that CRK2, 4 and 6 
have  no  additional  effect  to  t hat  of  CRK3  silencing.  The  onl y  CRK  that  had  a 
complementary  effect  with  CRK3  in  these  double  knockdowns  experiments  was  CRK1 
(Tu et al., 2005). 
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Figure 5.4 Silver stained of SDS-PAGE gel containing eluted materials from the HA antibody 
affinity purification column. Lane 1: HA-CYCA elution, Lane 2: CYCA-HA elution, Lane 3: WT 
elution.  A  protein  around  35  kDa,  the  expected  size  of  HA-tagged  CYCA,  was  detected 
(arrows).  
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Figure 5.5 (A) Silver stained SDS-PAGE gel of immune-precipitated of HA-tagged CYCA. (B) 
Western blot of the same samples using anti CRK3 antibody. Lane 1: HA-CYCA immune-
precipitation,  Lane  2:  WT  lysate  purification.  CRK3  was  detected  only  when  CYCA  was 
attached to a N-terminal Tag. No CRK3 was detected in the elutions from C-terminal HA tag 
(not shown). 
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Some essential genes in Leishmania can be disrupted in their first allele while some others 
can not. Recently published L. major metacaspase study is an examples of gene where no 
single allele knock out can be obtained (Ambit et al., 2007). This is probably because the 
disruption  of  just  one  allele alters  the  levels  of  expression  and  the levels  are  down 
regulated in a manner that prevents cell proliferation. Essential genes when disrupted tend 
to cause changes in chromosome number or ploidy (Cruz et al., 1993). Because disruption 
of CYCA first allele was not possible it might be that the levels of expression are important 
for  the  parasite  viability.  To  test  this  hypothesis   a  cell  line  that  expresses  CY CA  at 
endogenous levels can be generated before knocking out the genes from the WT locus. 
Similarly  to  the  knock  out  pla smids  TAP  tagging  CYCA  plasmid   sequences  were 
confirmed  and  an  alternative  transfection  protocol  was  implemented  (Robinson  et  al., 
2003). Although resistant cell lines were again obtained, the TAP TAG fused protein could 
not be detected in Western blots. Tagging CYCA with an HA epitope was successful for 
both C- and N-terminal fusions. Western blots detected the expression of HA-CYCA and 
CYCA-HA in the lysates of L. major promastigotes (Figure 5.3). Based on this finding, 
purification  experiments  were carried  out  using  an  affinity purification  matrix  with  an 
attached HA antibody (Roche). It was shown that several proteins interact in a non-specific 
manner with the resin and very low amounts of CYCA were purified. The identity of the 
HA-tagged protein detected in the silver stained gels, was confirmed by the western blot 
with the HA antibody (Figure 5.4). The purified material was used in a kinase assay and 
both  C-  and  N-terminal  HA  tags  purified  show ed  kinase  activity  (Figure  5.6 ).  This 
suggests  that  the  presence  of the  tag  does  not  prevent  inter action  of  CYCA  with  the 
activating kinase. CRK3 was shown to be one of the kinases that interact with HA-CYCA 
(Figure 5.5). 
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Figure  5.6  In  vitro  Histone  H1  kinase  assay.  Activity  of  immune-precipitated  HA-tagged 
CYCA was assayed using Histone H1 as substrate. Lane 1: WT L. major elution, Lane 2: 
Elution of L. major transfected cell lines expressing CYCA-HA, Lane 3: Elution of L. major 
transfected cell lines expressing HA-CYCA. 
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Figure 5.7 Immunofluorescence of L. major procyclic promastigotes transfected with HA-
CYCA. On the left, α-HA, DAPI and greyscale can be seen. On the right, merged α-HA and 
DAPI are shown. The primary antibody was diluted at 1 in 500 and incubated for 1 hour at 
room temperature. The cells were then washed 3 times with 1 ml of PBS. The secondary 
antibody (α-Mouse FITC conjugated antibody) was diluted at 1 in 1,000 and incubated in the 
dark for 1 hour at room temperature. 
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The CRK3 antibody detected CRK3 in the N-terminal CYCA HA purification but not in 
the C-terminal tagged protein or in the WT cells. This provides evidence that other kinases 
might be binding CYCA and being activated thus generating kinase activity. Previous in 
vitro and in vivo studies have shown that CYCA binds and activates CRK3 in L. donovani 
cells and CYCA is expressed in the S phase suggesting a potential role of CYCA in G1 or 
S phase of the cell cycle (Banerjee et al., 2006). Given that CYCA might be one of the 
activating cyclins of CRK3 in all Leishmania species, it could be recognized as a potential 
drug  target.  CRK3  itself  has  a lready  been  established  as  a  d rug  target,  since  it  is  an 
essential  gene  of  kinase  cyclin  dependent  that  regulates  the  cell  cycle  of L.  mexicana 
(Grant et al., 1998). However, the idea of using a cyclin inhitors to arrest the cell cycle is 
recent (Grant et al., 1998;Kozar et al., 2005). The only specific inhibitors of a cyclin is 
INK4a  that  acts  by  binding  to the  Cdk4/6,  altering  the  structure  of  the  cyclin  binding 
domain and thus preventing the activation of the kinases (Kozar et al., 2005). 
Cyclin B binds to the cyclin-dependent kinase, cdk1, to form the cyclin B/cdk1 complex, 
while cyclin A both alone and in complex with its cognate kinase, cdk2. The cyclin E/cdk2 
is  also  an  important  functional  pair.  However, not only  Cdks  are  able  to  bind  multiple 
cyclins. Cyclins also are able to bind multiple Crks in yeast, mammals and kinetoplastids 
as well (Gourguechon et al., 2007).  
Cyclin  D1  accumulates  in  the  n ucleus  during  the  G 1
  interval  and  it  relocalizes  to  the 
cytoplasm  during  S  phase.  The
  essential  functions  of  cyclin D1  require  its  nuclear 
localization,
 and thus the redistribution of cyclin D1 complexes to the cytoplasm
 following 
G1  implies  that  regulation  of  cy clin  D1  nucleocytoplasmic
 distribution  is  necessary  for 
maintaining  cellular  homeostasis (Benzeno  and  Diehl,  2004).  At  M  phase,  cyclin  B1  is 
phosphorylated in the cytoplasmic retention sequence, which is required for nuclear export. 
During  interphase,  cyclin  B1  shuttles  between  the  nucleus  and  the  cytoplasm  because 
constitutive nuclear import is counteracted by rapid nuclear export. In M phase, cyclin B       178 
moves rapidly into the nucleus coincident with its phosphorylation, an overall movement 
that might be caused simply by a decrease in its nuclear export (Hagting et al., 1999).  
The  localization  of  individual  cyclins  to  different  subcellular  compartments  has  been 
established, G1 cyclin is primarily nuclear, whereas mitotic cyclins are cytoplasmic and 
can localize to sites of polarized growth (Miller and Cross, 2000;Bloom et al., 2007). This 
localization pattern contributes to the abilities of cyclins to regulate different substrates 
(Bloom et al., 2007). Nuclear export signals are present in mitotic cyclins but they also 
have  a  role  in  the  nucleus  despite  being  mainly  cytoplasmic (Bloom et  al.,  2007). The 
localization of LmCYCA in the cytoplasm does not prevent a role in the nucleus as well 
since  it  appears  to  be  distrib uted  all  over  the  cell  including  nucleus  although  in  small 
amounts (Figure 5.7). An interesting experiment can be done to determine if CYCA would 
be  transported to the  nucleus during  the  cell  cycle  progression.  Tranfected L.  donovani 
could be used to overexpress tagged CYCA in a synchronized cell culture and establish the 
localization of this protein in 2N2K cells.  
When CYCA-HA tagged was probed in immunofluorescense experiments with fixed cells 
to localize the protein, CYCA was found to be distributed throughout the cell including the 
flagellum, although there appeared to be a more concentrated signal in the flagellar pocket 
area  of Leishmania.  As  mentioned,  CYCA  was  associ ated  to  activities  in  the  S -phase 
(Banerjee et al., 2006) in L. donovani. The presence of CYCA in the flagella pocket may 
be associated with S-phase events in the cell cycle, since it is known that this organelle is 
one of the first cellular structures to duplicate (Hammarton et al., 2005). However, CYCA 
is being over-expressed, so the location may be an artefact of the expression system. To 
avoid  this  artefact  possibility  an  endogenous  tagged  CYCA  can  be  used  together  with 
synchronized cell cultures to analyse the cell cycle progression and CYCA localization.       179 
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Leishmaniasis is a disease with multiple clinical manifestations, multiple endemic regions 
around the world and  is caused  by  multiple Leishmania species (Murray et al., 2005a). 
Around 2 million new cases are considered to occur annually, with an estimated 12 million 
people presently infected worldwide and an effective vaccine against leishmaniasis being 
still unavailable (WHO-http://www.who.int/). The results obtained from the experiments 
presented in this study aimed to further explore the role of cyclin dependent kinases and 
cyclins in the protozoan parasite Leishmania major. Cdks in kinetoplastids, CRKs, are the 
key regulators that allow cells to progress through different cell cycle phases and promote 
parasite proliferation during infection. Previous studies have identified CRK3 as the CDK1 
orthologue,  the  cyclin  dependent  kinase  that  controls  entry  into  mitosis (Grant  et  al., 
1998;Hassan et al., 2001). However, these studies failed to identify CRK3 cyclin binding 
partners in vivo or in vitro and as such studying the biochemistry of the cyclin dependent 
kinases involved in the regulation of the cell cycle progression in these parasites becomes 
essential. In chapter 3 of this study, the results presented showed that L. major CYCA is 
capable of activating CRK3 in an in vitro kinase assay using histone H1 as substrate. The 
association  of  the  cyclin  subu nit  to  the  Cdk  not  only  activa tes  the  kinase  but  also 
determines  the  specificity  to the  substrates.  The  differences  in  substrate  specificity 
displayed  by  the  same  kinase  w hen  bound  to  different  cyclins   is  determined  by 
electrostatic properties at the substrate-binding pocket known as the cyclin groove (Lee et 
al.,  2007).  In  this  way L.  major CYCA  was  responsible  for  CRK3 specificity  towards 
histone H1 substrate in the in vitro kinase assays performed. 
The  CRK3/CYCA  active  complex  w as  then  used  to  analyse  the  ef fect  of  the 
phosphorylation at the CRK3 activation threonine using a kinase activating kinase (yeast 
CAK  or  Civ-1).  Phosphorylated  CRK3  activi ty  was  compared  to  non -phosphorylated 
CRK3  and  it  was  found  that  the   phosphorylation  promotes  a  5-fold  increase  in  kinase 
activity of the complex. The accessory protein Cks1 was assayed in vitro with the active 
CRK3/CYCA complex and it was shown that Cks1 might have an inhibitory effect when       181 
histone  H1  substrate  is  used. Finally,  the  IC 50  for  two  different  kinase  inhi bitors 
(Flavopiridol and Indirubin) was determined for the in vitro CRK3/CYCA complex and 
compared  with  the  values  found  for  the in  vivo  purified  CRK3.  Similar  values   were 
obtained  suggesting  that  the in  vivo  complex  is  indeed  represented  by  the  recombinant 
complex.  The  development  of  recom binant  active  cyclin  dependent   kinases  from 
Leishmania is important not only for studying the biochemistry of the complex in vitro but 
also may be useful for the screening of large kinase inhibitor libraries. The high throughput 
screening of a large number of molecules aims to identify inhibitors that would structurally 
be able to inhibit the kinase activity of a leishmanial CRK, while not interfering with most 
host kinases. Kinase inhibitors were first thought to be useful for cancer therapy to prevent 
uncontrolled cell proliferation. In a similar manner, parasite infection may be prevented 
using  kinase  inhibitors  specific  for  essential  CRK  proteins like  CRK3.  An  increasing 
number of protein kinases of parasitic protozoa are being evaluated as drug targets, just as 
they  had  been  in  trials  to tre at  a  wide  range  of  other  diseases  and  syndromes,  such  as 
cancer, cardiovascular disease and Alzheimer’s disease (Johnson, 2007). In recent years, 
pharmaceutical companies have invested heavily in the development of new compounds 
directed against specific protein kinase targets, and there are a wide range of protein kinase 
inhibitors that have entered clinical trials (Naula et al., 2005;Johnson, 2007). Finally, it has 
been shown that inhibition of kinases using specific compounds is possible. In this way, 
differences  in  the  biochemistry  of  different  kinase  complexes  would  result  in  different 
sensitivities to different inhibitors (Thaimattam et al., 2007). This has made possible the 
development of kinase specific compounds able to block the activity of individual kinases 
of interest. Human Cdk1 and Leishmanial CRK3 may be responsible for entry into mitosis 
in both organisms, however, they are very different kinases as our sequence analysis and 
biochemistry experiments have shown. CRK3 possess only 34% identity with human Cdk1 
and phosphorylation of the activation loop does not generate a similar stimulatory effect in 
the  parasite  enzyme.  Furthermore,  the  activating  subunity  of   these  kinases,  the  cyclin       182 
partner,  is  even  less  conserved.  The  structure  at  the  ATP  bi nding  site  contained  in  the 
kinase is the major determinant in the inhibitors compounds mode of action. The cyclin 
have not been implicated in the selection of specific inhibitors but it certainly has an effect 
in  determining  the  substrate  specificity  and  therefore  should  have  an  effect  in  the  final 
structure of substrate recognition near site and ATP binding pocket. 
 In  the  following  chapter  4,  y east  Civ-1  purified  from  E.  coli,  was  used  to  try  to 
phosphorylate, in a similar manner, the activation of threonine/serine residues from other 
L. major CRKs. The kinases assessed were CRK1, CRK2, CRK4, CRK6 and CRK7. None 
of these were phosphorylated by Civ-1 suggesting that the only CRK under this type of 
regulation is CRK3. A trypanosomatid homologue to Civ-1 or Cdk7 could not be identified 
by blast analysis using geneDB standard settings. This may be because this corresponding 
kinase  in  trypanosomatids  have  diverged  into  or  is  not  prese nt  and  organisms  like 
Leishmania do not need to phosphorylate and activate the T-loop. The evidence to support 
this hypothesis is on the fact that there is already a strong kinase activity detected from 
CRK3 caused by CYCA binding itself. The increase in kinase activity when Civ-1 is added 
to the system is only a 5-fold increase. 
L. major CRK1-4 and CRK6-8 were tested in kinase assays  by  mixing under described 
conditions  with L.  major CYC9  and  kinase  activities  towards  three  different  substrates 
were assessed. L. major CYC9 was not able to activate the above kinases and the kinase 
subunit that interacts with this cyclin could  not be  identified. Following the  inability of 
CYC9 to activate the aforementioned kinases, we tested  if CYC9 was expressed  in the 
parasite. It was also tested if the expression of cyclins CYCA, CYC2, CYC7, CYC9 and 
CYC10  was  also  present.  The  mRNA  for  synthesis  of  all  these  c yclins  was  detected, 
confirming  expression  of  the  cyclins  in  the  parasite.  However,  the  binding  partner  of 
CYC9  remains  unknown.  The  identification  of  a  cyclin  dependent  kinase  that  controls 
transitions at the S-phase can provide an important drug target since DNA replications is       183 
an essential process for parasite proliferation. In the protein sequence alignments shown in 
Figure 4.2, CYC9 is the most similar Leishmania cyclin to human transcriptional cyclin C 
and  H  and  although  CYCA  has  been  suggested  to  be involved  in  S-phase  processes 
(Banerjee et al., 2006), no conclusive evidence for the presence of a transcriptional cyclin 
in  kinetoplastids  is  available.  It  is  known  that  some  cyclins  have  the  hability  to  bind 
multiple Cdks. For instance cyclin A can bind both Cdk1 and Cdk2 to promote mitosis and 
S-phase respectively (Walker and Maller, 1991). T. brucei CYC2 (also named cyclin E1) 
was shown to interact with several Cdks using yeast two hybrid system (Gourguechon et 
al., 2007). T. brucei CYC6 (also named cyclin B2) has also been shown to interact with 
CRK3  and  control  entry  into  mi tosis  (Hammarton  et  al.,  2003a).  However,  it  was 
suggested that CRK1 is the major cyclin dependent kinase regulating transition from G1 to 
S-phase (Gourguechon et al., 2007). The previous results obtained in this study with CRK3 
and CYCA have successfully produced cyclin activated kinase. Although the expression of 
the  mRNA  of  CYC9  was  confirmed  (Figure  4.8)  and  the  same  methods  of  expression, 
purification  and  kinase  assay  applied,  no  active  kinase  was  observed  when  CYC9  was 
used. 
In chapter 5, the L. major CYCA was used to elucidate the characteristics of this cyclin in 
vivo. A gene disruption strategy aimed to replace the two genomic alleles of this protein 
gene by homologous recombination. Plasmids were developed with flanking regions of this 
gene placed in association with two different drug resistance genes, one for each of the 
allele’s  disruption.  These  constructs  were  not  able  to  produce the  first  allele  knock  out 
suggesting that not only this gene might be essential but the levels of expression may also 
be important. To explain why some resistant cell lines, but no disruption, were obtained in 
transfections  performed  with  these  plasmids,  specific  PCR  for  the  CYCA  locus  was 
performed with genomic DNA extracted from these cells. These PCR reactions showed 
that the plasmids might be functioning as episomes conferring resistance to the cells but 
leaving the locus intact. Tagging L. major CYCA was also attempted in vivo using two       184 
different  strategies  (i.e.  two  different tagging  systems).  The  first  tag  employed  was  the 
TAP  tag  system (Puig et  al.,  2001).  Although  drug  resistant transfected  cell  lines  were 
obtained, no tag detection could be observed by western blot using different tag-specific 
antibodies (α-protein-A and α-calmodulin antibodies).  The second tag employed was HA, 
the  9-amino  acid  sequence  YPYDVPDYA,  der ived  from  the  human  influenza 
hemagglutinin  (HA)  protein.  Plasmids  that  contained  C  and  N -terminal  HA  tagged L. 
major  CYCA  were  used  to  transfect  W T  cells  and  cells  extracts  of resistant  cell  lines 
analysed by western blot. Both C and N-terminal HA tagged CYCA were detected by the 
α-HA antibody. Following the confirmation of the presence of the tagged CYCA in the cell 
extracts an affinity purification using an HA affinity matrix was attempted and the matrix 
binding material was used in in vitro kinase assays (Figure 5.6). The presence of kinase 
activity  towards  Histone  H1  co nfirmed  that  CYCA  was  being  su ccessfully 
immunoprecipitated in complex with a kinase partner. The identity of the co-eluted CRK 
could  be  confirmed  using  specific  α-CRK3  antibody  that  detected  CRK3  in  th e  eluted 
material. However, CRK3 is only observed for the N-terminal CYCA tagged and not at the 
C-terminal. This suggests that more than one CRK can be activated by CYCA and not only 
CRK3,  since  kinase  activity  is  detected  for  both  cell  lines  expressing  the  differentially 
positioned tags.  
The L.  major  protein  kinase  CRK6  is  a  cycl in  dependent  kinase  that  has  not  yet  been 
studied in detail. In the present study, LmCRK6 was HA tagged, immunopreciptated and 
tested for kinase activity. LmCRK6 has in vitro kinase activity towards Histone H1 when 
imunoprecipitated from live parasites. This finding confirms that CRK6 is indeed active in 
the L. major procyclic form. In T. brucei (Tu et al., 2005), RNAi experiments have shown 
that CRK6 plays a minor or no role in the cell cycle of these parasites. A cyclin binding 
partner for CRK6, if any, remains unknown. However, the data presented in the chapter 4 
of  this  study  suggests  that there  might  be  at  least one  activation  requirement,  since  no 
kinase  activity  was  observed  u sing  monomeric  CRK6.  Furthermore,  CRK6  threonine       185 
residue could not be phosphorylated by Civ-1. This suggests that the phosphorylation by a 
CAK  like  protein  might  not  be required  for  activity of  these  CRKs  that  the  enzyme is 
capable of recognizing this residue is still unknown.  
Future plans 
Recombinant CRK3:CYCA complex can be used in high throughput screening of kinase 
inhibitors that  are  specific  for  the  parasite  kinase.  This  would  be  important to  generate 
more  efficient  drugs  for  the  treatment  of  Leishmanisis.  The identification  of  a  kinase 
activating kinase similar to Civ-1 or Cdk7 was not possible using sequence comparisons, 
however, cloning and expressing a tagged truncated T-loop region from CRK3 can be used 
to  affinity  purify  interacting  proteins  from  cell  extracts. Another  strategy  to  identify  a 
Leishmanial Civ-1 would  be to fuse  CRKs T-loop region to GST and also use  it  in an 
affinity column against cell extracts. Overexpressing the same truncated T-loop region HA 
tagged in vivo can also be attempted with the epissomal system tested in this study. 
To identify L. major CYC9 kinase counterpart an affinity column can be made with his-
tagged  recombinant  CYC9  to  aff inity  purify  binding  proteins  from  cell  extracts  since 
activation  of  tested  kinases  was  not  successful.  The  same  strategy  can  be  used  for  the 
kinase with unknown cyclin partner like CRK1, CRK2, CRK4, CRK6, CRK7 and CRK8.  
Cell lines of L. major expressing HA tagged CRK6 are already made and can be used to 
search  for a cyclin partner as well  as a kinase activating kinase  in Leishmania through 
affinity purification  in an  immobilized column.  The HA tagged CYCA cell  line  can  be 
used to better study the localization of this protein in the cells in vivo. It is important that 
immunofluorescence experiments with a second antibody that targets the flagellar pocket 
proteins are used to co-localize CYCA with this important organelle. It is also possible that 
the same constructs are used to transfect L. donovani and cell cultures of this Leishmania       186 
species  are  synchronized  by  Hydroxy  Urea  and  the  cell  cycle stages  where  CYCA  is 
active, as well as where in these cells it is detected can be better studied.  
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Appendix 
List of buffers and reagents 
Aminolink Quenching Buffer: 1M Tris•HCl, pH 7.4 
Aminolink Reduction solution: 50mM Sodium cyanoborohydride (NaCNBH3)  
Aminolink wash solution: 1M Nacl 
Aminolink Coupling Buffer: 0.1M sodium phosphate, 0.15M NaCl, pH 7.2 
Ampicillin: 100mgml
-1 stock in 50% ethanol. Stored at -20
oC. 
Blocking solution for Western blots: 5% non-fat dried milk in PBS/0.01% tween 20.  
Blocking solution for immunofluorescense slides: 0.1% Triton X-100, 0.1 % BSA.  
Chloramphenicol: Stock solution at 34 mgml
-1 in ethanol. Used at 170 µgml
-1. 
Coomassie  staining  solution:  0.25  g  of  Coomassie  Brilliant  Blue  R-250  in  90  ml  of 
methanol: H2O (1:1.v/v). 
Coomassie destaining solution: 20% Methanol, 5% Acetic Acid in H2O. 
DNA loading buffer: 0.025% bromophenol blue, 0.25% xylene cyanol, 40% sucrose in 
distilled H2O. Stored at 4
oC. Alternatively: 0.25% bromophenol blue, 0.25% xylene cyanol 
FF, 15% Ficoll (Type 400; Pharmacia) in H2O. Stored at room temperature. 
DNase I dilution buffer: 10mM Tris-Cl (pH 7.5), 150mM NaCl, 1mM MgCl2       188 
Eletroporation Buffer (transfection buffer): 21mM HEPES pH 7.5, 137mM NaCl, 5mM 
KCl, 0.7mM phosphate buffer, 5mM glucose. Stored at 4
oC. Alternatively: 120mM KCl, 
0.15mM CaCl2, 10mM K2HPO4, 25mM HEPES, 2mM EDTA and 2mM MgCl2; pH 7.6. 
Ethidium Bromide: 10mgml
-1 stock in distilled H2O. Stored at room temperature. 
GST Elution Buffer: 10mM glutathione, 50mM Tris-HCl, pH 8.0 
Ion Exchannge Buffer A: 50mM Tris-HCl, 5mM EDTA pH 7.0.  
Ion Exchannge Buffer B: A+ 1M NaCl. 
Kanamycin: Stock solution at 10 mgml
-1 in H2O. Used at 50 µgml
-1. 
Kinase assay buffer: 50mM MOPS pH 7.2, 20mM  MgCl 2, 2mM DTT, 10mM EGTA. 
Stored at 4
oC. 
Kinase assay mix: 5 µl histone H1 (10mgml
-1 stock), 8 µl ATP (100µM stock), 186 µl 
kinase assay buffer, 1 μl γ-
32P-ATP (50µCi).  
Kinase storage buffer: 20mM HEPES, pH7.4, 50mM NaCl, 2mM EGTA, 2mM DTT, 
0.02% Bry-35/NP-40 + 10% final glycerol and PI cocktail. 
LB Medium (Luria-Bertani Medium): Per litre: 950 ml of deionized H2O, 10 g tryptone, 
5 g yeast extract, 10 g NaCl, pH 7.0. Autoclaved and stored at room temperature. 
Lysis buffer / Sonication buffer (E. coli): 50mM Na2HPO4, 300mM NaCl pH 8.0. 
Lysis  Buffer  (Leishmania): 10%  glycerol,  50mM  MOPS  pH  7.2,  100mM  NaCl,  1mM 
EDTA, 1mM EGTA, 1% Triton X-100.       189 
Lysis Buffer (Leishmania) for HA purification: 50 mM Tris, pH 7.5; 150 mM NaCl; 
0.1% Nonidet P40. 
Lysozyme: 5 mgml
-1 stock in 50mM Tris-HCl pH 7.4. Stored at -20
oC. 
Mounting  Solution  (For  imunofl uorescense  slides):  50%  glycerol,  2.5%  DABCO, 
1µgml
-1 DAPI. 
PBS: 10mM phosphate buffer, 2.7mM KCl, 137mM NaCl, pH 7.4. Autoclaved and stored 
at room temperature. 
PCR mix (11.1x): 45mM Tris-HCl (pH 8.8), 11mM ammonium sulphate, 4.5mM MgCl2, 
6.7mM β-mercaptoethanol, 4.4mM EDTA pH 8, 1mM dATP, 1mM dCTP, 1mM dGTP, 
1mM dTTP and 113 µg ml
-1 BSA. Stored at -20
oC. 
RNAse A: 10mg ml
-1 stock in sterile water. Stored at -20
oC. 
SDS-PAGE 4x Tris-Cl/SDS, pH 6.8: 0.5M Tris-Cl pH 6.8, 0.4% SDS. 
SDS-PAGE 4x Tris-Cl/SDS, pH 8.8: 1.5M Tris-Cl pH 8.8, 0.4% SDS. 
SDS-PAGE electrophoresis buffer:  
SDS-PAGE  sample  loading  buffer:   (4x)  200mM  Tris -HCl  pH  6.8,  400 μM  β-
mercaptoethanol, 8% SDS, 40% glycerol, a few crystals of bromophenol blue. Stored at 
room  temperature.  Alternatively,  (6x)  300mM  Tris -HCl  pH  6.8,  8%  SDS,  0.2% 
bromophenol blue, 60% glycerol, 600mM DTT. Stored at -20
oC. 
TE Buffer: 10mM Tris-HCl pH 7.4, 1mM EDTA pH 8. Stored at room temperature. 
Western blot transfer buffer: 5mM Tris, 2mM Glycine, 20% methanol in distilled water.       190 
Washing buffer for his tag purification: Sonication (Lysis) buffer + 50mM Imidazole. 
Alternatively, 20mM or 10mM Imidazole. 
X-gal solution: Stock solution in dimethylformamide (dangerous!) at 20mgml
-1. Stored at 
20
oC and away from light. 
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